CBM 94-2

OVARIAN CANCER

January 1990 through January 1994, plus selected earlier references

1908 Citations

Prepared by

Mary E. Conway, M.L.S., National Library of Medicine
Edward L. Trimble, M.D., M.P.H., National Cancer Institute

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

National Library of Medicine
Reference Section
8600 Rockville Pike
Bethesda, Maryland 20894

1994

National Library of Medicine Cataloging in Publication

SERIES NOTE

Current Bibliographies in Medicine (CBM) is a continuation in part of the National Library of Medicine's Literature Search Series, which ceased in 1987 with No. 87-15. In 1989 it also subsumed the *Specialized Bibliography Series*. Each bibliography in the new series covers a distinct subject area of biomedicine and is intended to fulfill a current awareness function. Citations are usually derived from searching a variety of online databases. NLM databases utilized include MEDLINE®, AVLINE®, BIOETHICSLINE®, CANCERLIT®, CATLINE®, HEALTH, POPLINE™ and TOXLINE®. The only criterion for the inclusion of a particular published work is its relevance to the topic being presented; the format, ownership, or location of the material is not considered.

Comments and suggestions on this series may be addressed to:

Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD 20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: patrias@nlm.nih.gov

Ordering Information:

Current Bibliographies in Medicine is sold by the Superintendent of Documents, U.S. Government Printing Office, P.O. 371954, Pittsburgh, PA 15250-7954. To order the entire CBM series for calendar year 1994 (approximately 10 bibliographies), send $60.00 ($75.00 foreign) to the Superintendent of Documents citing GPO List ID: CBM94. For your convenience an order blank is given inside the back cover. Orders for individual bibliographies in the series ($8.50, $10.63 foreign) should be sent to the Superintendent of Documents citing <u>the title, CBM number, and the GPO List ID</u> given above.

Internet Access:

The *Current Bibliographies in Medicine* series is also available at no cost to anyone with Internet access through FTP (File Transfer Protocol). FTP to nlmpubs.nlm.nih.gov and login: as nlmpubs. The index file in the "bibs" directory provides information on the bibliographies available.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1994.

OVARIAN CANCER

Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. In 1994, approximately 24,000 new cases of ovarian cancer will be diagnosed, and 13,600 women will die of ovarian cancer. Over the past several years much attention has been paid to the epidemiology, biology, screening, treatment, and follow-up of ovarian cancer.

This bibliography was prepared in support of the National Institutes of Health Consensus Development Conference titled "Ovarian Cancer: Screening, Treatment and Follow-up" convened in Bethesda, Maryland on April 5-7, 1994. The purpose of the conference was to examine the relevant data concerning the following questions:

1. What is the current status of screening for ovarian cancer?
2. What is the appropriate management of early ovarian cancer?
3. What is the appropriate management of advanced epithelial ovarian cancer?
4. What is appropriate follow-up after primary therapy for ovarian cancer?
5. What are directions for future research?

The organization of the bibliography reflects the focus of these five questions. The main subject categories are General Articles; Screening and Prevention; Management of Early Stage Ovarian Cancer; Management of Advanced Epithelial Ovarian Cancer; Follow-Up after Primary Therapy; and New Directions for Research. Separate sections for monographs and audiovisuals appear at the end. The 1908 citations include English language journal articles, monographs, book chapters, dissertations, conference proceedings, and audiovisuals covering the period January 1990 through January 1994 with some selected earlier references. Citations under the subject "New Directions for Research" cover the period January 1992 through January 1994. In general, letters, case reports, and editorials have been omitted. Audiovisuals are arranged alphabetically by title; all other sections are arranged alphabetically by author. A citation may appear in more than one category.

SEARCH STRATEGY

A variety of online databases are usually searched in preparing bibliographies in the CBM series. To assist you in updating or otherwise manipulating the material in this search, the strategy used for the NLM's MEDLINE database is given below. Please note that the search strategies presented here differ from individual demand searches in that they are generally broadly formulated and irrelevant citations edited out prior to printing.

SS 1 = EXP OVARIAN NEOPLASMS
SS 2 = EXP OVARIAN DISEASES AND NEOPLASMS (PX)
SS 3 = EXP ENDOCRINE GLAND NEOPLASMS OR EXP GENITAL NEOPLASMS, FEMALE
SS 4 = (TW) OVARY OR OVARIES OR OVARIAN OR ALL OOPHORECTOM: OR ADNEXAL
SS 5 = EXP ADNEXAL DISEASES OR ADNEXA UTERI OR OVARIECTOMY
SS 6 = 3 AND 4 OR 3 AND 5
SS 7 = EXP CYSTADENOMA OR EXP NEOPLASMS, GERM CELL A#D EMBRYONAL
SS 8 = 7 AND 4 OR 7 AND 5
SS 9 = 2 OR 6 OR 8
SS 10 = ALL TAXOL OR ALL TAXANE# (TW) OR ALL TAXOID# (TW)
SS 11 = 1 AND 10 OR 9 AND 10
SS 12 = 9 AND TH& (PX) OR 9 AND DI& (PX) OR 9 AND SN& (PX)
SS 13 = 9 AND EXP ULTRASONOGRAPHY OR 9 AND EXP ULTRASONICS
SS 14 = ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE OR
EXP TUMOR MARKERS, BIOLOGICAL OR GENETIC MARKERS
SS 15 = QUALITY OF LIFE OR EXP ADAPTATION, PSYCHOLOGICAL
SS 16 = 9 AND 14 OR 9 AND 15 OR 9 AND PX (SH)
SS 17 = EXP SURGERY, LAPAROSCOPIC OR EXP LAPAROSCOPY OR EXP LAPAROTOMY SS 18 = 9 AND 17
SS 19 = 1 OR 11 OR 12 OR 13 OR 16 OR 18

GRATEFUL MED®

To make online searching easier and more efficient, the Library offers GRATEFUL MED, microcomputer-based software that provides a user-friendly interface to most NLM databases. This software was specifically developed for health professionals and features multiple choice menus and "fill in the blank" screens for easy search preparation. GRATEFUL MED runs on an IBM PC (or IBM-compatible) with DOS 2.0 or a Macintosh, and requires a Hayes (or Hayes-compatible) modem. It may be purchased from the National Technical Information Service in Springfield, Virginia, for $29.95 (plus $3.00 per order for shipping). For your convenience, an order blank has been enclosed at the back of this bibliography.

SAMPLE CITATIONS

Citations in this bibliographic series are formatted according to the rules established for *Index Medicus*®*. Sample journal, monograph, and audiovisual citations appear below. Note also that a colon (:) may appear within an author's name or article title. The NLM computer system automatically inserts this symbol in the place of a diacritical mark.

Journal Article:

Authors *Article Title*

Deppe G, Malviya VK. Ovarian cancer. Advances in management.
Surg Clin North Am 1991 Oct;71(5):1023-39.

Abbreviated Journal Title *Date* *Volume* *Issue* *Pages*

Monograph:

Authors/Editors *Title*

Markman, Maurie; Hoskins, William J., eds. Cancer of the ovary.
New York: Raven Press; 1993. 442 p.

Place of Publication *Publisher* *Date* *Total No. of Pages*

Audiovisual:

Title *Media Type* *Place of Publication* *Publisher* *Date*

Cancers that threaten women [videorecording]. Princeton (NJ): Films for the Humanities; c1992.
1 videocassette: 19 min., sound, color, 1/2 in. Credits: Herbert Hyman.

Physical Description *Note*

---

*For details of the formats used for references, *see* the following publication:

Patrias, Karen. *National Library of Medicine recommended formats for bibliographic citation.* Bethesda (MD): The Library; 1991 Apr. Available from: NTIS, Springfield, VA; PB91-182030.

TABLE OF CONTENTS

GENERAL ARTICLES

Alberts DS. Best papers on ovarian cancer. Cancer Invest 1992;10(6):603-4.

Andersen BL, Anderson B. Psychosomatic aspects of gynecologic oncology: Present status and future directions. Special Issue: Gynecologic oncology. J Psychosom Obstet Gynaecol 1986 Dec;5(4): 233-244.

Averette HE, Donato DM. Ovarian carcinoma. Advances in diagnosis, staging, and treatment. Cancer 1990 Feb 1;65(3 Suppl):703-8.

Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann HA, Crommelin M, van Wijck DJ, Verhagen-Teulings MT. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991 Jul; 42(1):3-8.

Barakat RR, Benjamin I. Surgery for malignant gynecologic disease. Curr Opin Obstet Gynecol 1993 Jun;5(3):311-7.

Barber HR. New frontiers in ovarian cancer diagnosis and management. Yale J Biol Med 1991 Mar-Apr; 64(2):127-41.

Barker GH. Recent advances in the treatment of carcinoma of the ovary. Br J Obstet Gynaecol 1993 Sep;100(9):803-5.

Brown MF, Hebra A, McGeehin K, Ross AJ 3d. Ovarian masses in children: a review of 91 cases of malignant and benign masses. J Pediatr Surg 1993 Jul;28(7):930-3.

Cancer of the ovary. ACOG technical bulletin number 141--May 1990 (replaces #73, October 1983). Int J Gynaecol Obstet 1991 Aug;35(4):359-66.

Cannistra SA. Cancer of the ovary. N Engl J Med 1993 Nov 18;329(21):1550-9.

de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):761-82.

Deppe G, Malviya VK. Ovarian cancer. Advances in management. Surg Clin North Am 1991 Oct; 71(5):1023-39.

Eriksson JH, Walczak JR. Ovarian cancer. Semin Oncol Nurs 1990 Aug;6(3):214-27.

Ferrier A. Ovarian carcinoma: a continuing challenge. Med J Aust 1993 May 3;158(9):584-6.

Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991 Jun;18(3): 205-12.

Gargano G, Catino A, Correale M, Lorusso V, Abbate I, Izzi G, Cramarossa A, Picciariello M, Paradiso A, De Leonardis A, et al. Prognostic factors in epithelial ovarian cancer. Eur J Gynaecol Oncol 1992;13(1 Suppl):45-55.

Gitsch E, Salzer H. The management in ovarian cancer at the First Dept. of Obstetrics and Gynecology, University of Vienna. Eur J Gynaecol Oncol 1992; 13(1):61-4.

Gitsch E, Salzer H, Sevelda P. Ovarian cancer: introduction and development in the treatment. Eur J Obstet Gynecol Reprod Biol 1991 Aug 20; 41(1):43-6.

Hamilton TC. Ovarian cancer, Part I: Biology. Curr Probl Cancer 1992 Jan-Feb;16(1):1-57.

Hanai A. Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS Suppl 1990;12:1-20.

Hole DJ, Gillis CR. Use of cancer registry data to evaluate the treatment of ovarian cancer on a hospital basis. Health Rep 1993;5(1):117-9.

Kennedy AW, Biscotti CV, Hart WR, Tuason LJ. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993 Sep;50(3):334-8.

Khoo SK, Battistutta D, Hurst T, Sanderson B, Ward BG, Free K. The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer 1993 Jul 15;72(2):531-7.

Kjaer SK, Storm HH. Survival of Danish cancer patients 1943-1987. Female genital organs. APMIS Suppl 1993;33:107-21.

Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM, Edwards CL. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol 1990 Dec;39(3):337-46.

Knobf MT, Morra ME. Women and cancer. NAACOGS Clin Issu Perinat Womens Health Nurs 1993;4(2):287-301.

Lack EE, Young RH, Scully RE. Pathology of ovarian neoplasms in childhood and adolescence. Pathol Annu 1992;27(Pt 2):281-356.

Leung Y, DePetrillo AD. Etiology, epidemiology, risk and prognostic factors, screening, and imaging of gynecologic cancers. Curr Opin Oncol 1993 Sep; 5(5):869-76.

Lowry S. Molecular basis for hormone-related cancer. Lancet 1993 Jun 26;341(8861):1630.

Lowry WS, Atkinson RJ. Tumour suppressor genes and risk of metastasis in ovarian cancer. BMJ 1993 Aug 28;307(6903):542.

Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS 1991 Apr; 99(4):353-8.

Lund B, Williamson P, van Houwelingen HC, Neijt JP. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 1990 Aug 1;50(15):4626-9.

Markman M, Lewis JL Jr, Saigo P, Hakes T, Rubin S, Jones W, Reichman B, Curtin J, Barakat R, Almadrones L, et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol 1993 May;49(2):236-9.

Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G, et al. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer 1990 Sep;62(3):444-50.

Marsoni S, Torri W, Taiana A, Gambino A, Grilli R, Liati P, Franzosi MG, Pistotti V, Parazzini F, Focarile F, et al. Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer. Ann Oncol 1990 Sep; 1(5):343-50.

McGowan L. Pathology of the ovary. Curr Opin Obstet Gynecol 1991 Aug;3(4):580-6.

Merino MJ, Jaffe G. Age contrast in ovarian pathology. Cancer 1993 Jan 15;71(2 Suppl):537-44.

Montella M, De Marco MR, Romeo F, Ventura R. Survival in ovarian cancers treated at National Cancer Institute in Naples Italy 1985-1990. Eur J Gynaecol Oncol 1993;14(3):249-54.

Nakashima N, Nagasaka T, Fukata S, Oiwa N, Nara Y, Fukatsu T, Takeuchi J. Study of ovarian tumors treated at Nagoya University Hospital, 1965-1988. Gynecol Oncol 1990 Apr;37(1):103-11.

Nash JD, Young RC. Gynecological malignancies. Cancer Chemother Biol Response Modif 1990; 11:484-509.

Niloff JM. Ovarian malignancy. Curr Opin Obstet Gynecol 1991 Feb;3(1):66-72.

Onwude JL, Holohan MB, Codd MB, Coughlan BM. Prognosis of ovarian cancer. Ir Med J 1990 Mar; 83(1):14-6.

Ozols RF, Hamilton TC, Hoskins WJ, Bast RC Jr, Young RC. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol 1991 Jun; 18(3):297-306.

Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer biology. Semin Oncol 1991 Jun;18(3):186-204.

Perspectives on Ovarian Cancer in Older-Aged Women. Current Knowledge and Recommendations for Research. Working conference. Bethesda, Maryland, November 20-21, 1991. Cancer 1993 Jan 15;71(2 Suppl):513-659.

Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993 May;81(5 Pt 1):651-4.

Protopapa E, Miaoulis G, Ferreiro M, Panayiotides J, Katsikas SK, Delides G. A new expert system for histopathological diagnosis of human ovarian epithelial cancer. In Vivo 1993 Jul-Aug; 7(4): 369-72.

Saeed M, Khawaja K, Rizwana I, Malik I, Rizvi J, Khan A. A clinicopathological analysis of ovarian tumours. JPMA J Pak Med Assoc 1991 Jul; 41(7): 161-4.

Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990 Mar;3(2):120-8.

Silva EG, Tornos C, Bailey MA, Morris M. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med 1991 Apr;115(4):377-81.

Singh P, Arunachalam I, Singh P, Tan BY, Tock EP, Ratnam SS. Ovarian cancer in Oriental women from Singapore: disease pattern and survival. Int Surg 1990 Apr-Jun;75(2):115-22.

Swenerton KD. Prognostic indices in ovarian cancer. Their significance in treatment planning. Acta Obstet Gynecol Scand Suppl 1992;155:67-74.

Talerman A. Ovarian pathology. Curr Opin Obstet Gynecol 1992 Aug;4(4):608-15.

Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993 Jan 15;71(2 Suppl):606-14.

Tintara H, Mitarnun W. Ovarian neoplasms in childhood and adolescents in Songklanagarind Hospital, February 1983-March 1989. J Med Assoc Thai 1990 Jul;73(7):375-80.

Trope C, Makar A. Unsettled questions regarding ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:7-18.

Tyler CW Jr, Lee NC, Robboy SJ, Kurman RJ, Paris AL, Wingo PA, Williamson GD. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 1991 Jan;164(1 Pt 1):65-70.

Vani R, Kuntal R, Rao PL. Ovarian tumors in the second decade of life. Asia Oceania J Obstet Gynaecol 1991 Sep;17(3):231-5.

Watkin W, Silva EG, Gershenson DM. Mucinous carcinoma of the ovary. Pathologic prognostic factors. Cancer 1992 Jan 1;69(1):208-12.

Williams C. Ovarian and cervical cancer. BMJ 1992 Jun 6;304(6840):1501-4.

Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993 Jan 15;71(2 Suppl):517-23.

Yancik R, Moore TD, Martin G, Obrams GI, Reed E. Older women as the focus for research and treatment of ovarian cancer. An overview for the National Institute on Aging, National Cancer Institute, and American Cancer Society Multidisciplinary Working Conference. Cancer 1993 Jan 15;71(2 Suppl):514-6.

SCREENING AND PREVENTION

Epidemiology

Adami HO, Bergstrom R, Persson I, Sparen P. The incidence of ovarian cancer in Sweden, 1960-1984. Am J Epidemiol 1990 Sep;132(3):446-52.

Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial epithelial ovarian cancer. JAMA 1992 Oct 14;268(14):1896-9.

Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993 Jan 15; 71(2 Suppl):566-72.

Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer 1993 Jul 1;72(1):114-9.

Augustin J, Wotke R. Ovarian malignancies in the Czech Cancer Registry. Neoplasma 1990;37(2): 213-7.

Ayhan A, Yalcin OT, Tuncer ZS, Gurgan T, Kucukali T. Synchronous primary malignancies of the female genital tract. Eur J Obstet Gynecol Reprod Biol 1992 Jun 16;45(1):63-6.

Badawy YA, Bayoumi DM. An epidemiologic study of ovarian cancer. Part 1: Reproductive and social factors. J Egypt Public Health Assoc 1992; 67(3-4):465-77.

Badawy YA, Bayoumi DM. An epidemiologic study of ovarian cancer. Part 2: Oral contraceptive use and menstrual events. J Egypt Public Health Assoc 1992;67(5-6):579-91.

Balasch J, Barri PN. Follicular stimulation and ovarian cancer? Hum Reprod 1993 Jul;8(7):990-6.

Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 1992 Apr;48(2):345-55.

Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidemiol 1992 Oct 15;136(8): 937-48.

Bernstein L, Ross RK, Henderson BE. Relationship of hormone use to cancer risk. Monogr Natl Cancer Inst 1992;(12):137-47.

Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992 Jul;11(3):180-7.

Black DM, Solomon E. The search for the familial breast/ovarian cancer gene. Trends Genet 1993 Jan;9(1):22-6.

Bokhman JB, Maximov SJ. Relative risk of development and active detection of primary multiple endometrial, breast and ovarian cancer. Eur J Gynaecol Oncol 1993;14(2):114-8.

Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44(1):7-26.

Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary malignancies following gynecological tumours in Saarland, Germany, 1968-1987. J Cancer Res Clin Oncol 1993;119(3):179-83.

Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary neoplasms following breast cancer in Saarland, Germany, 1968-1987. Eur J Cancer 1993; 29A(10):1410-4.

Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA. Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992 Feb;21(1): 23-9.

Chi I. The safety and efficacy issues of progestin-only oral contraceptives--an epidemiologic perspective. Contraception 1993 Jan;47(1):1-21.

Cohen J, Forman R, Harlap S, Johannisson E, Lunenfeld B, de Mouzon J, Pepperell R, Tarlatzis B, Templeton A. IFFS expert group report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 1993 Jul;8(7):996-9.

Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci 1990;592: 363-75; discussion 390-4.

Daly MB. The epidemiology of ovarian cancer. Hematol Oncol Clin North Am 1992 Aug; 6(4):729-38.

Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991 Sep 9; 49(2):191-5.

DePriest PD, Banks ER, Powell DE, van Nagell JR Jr, Gallion HH, Puls LE, Hunter JE, Kryscio RJ, Royalty MB. Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol Oncol 1992 Oct;47(1):71-5.

Dietl J, Marzusch K. Ovarian surface epithelium and human ovarian cancer. Gynecol Obstet Invest 1993;35(3):129-35.

Edgren RA. Oral contraceptives and cancer. Int J Fertil 1991;36 Suppl 3:37-50.

Engle A, Muscat JE, Harris RE. Nutritional risk factors and ovarian cancer. Nutr Cancer 1991;15(3-4): 239-47.

Fertility drugs and ovarian cancer. International Federation of Fertility Societies (IFFS). Fertil Steril 1993 Sep;60(3):406-8.

Franceschi S. Female hormones: for which cancers do they matter? Dev Oncol 1991;63:89-106.

Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, Trichopoulos D, Beral V. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991 Aug 19;49(1):57-60. Comment in: Int J Cancer 1992 May 8;51(2):333-4.

Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991 Aug 19;49(1):61-5.

Freddo JL. Genetic predisposition to ovarian cancer. West J Med 1992 Jun;156(6):652.

Gast K, Snyder T. Combination oral contraceptives and cancer risk. Kans Med 1990 Jul;91(7):201-8.

Gatphoh ED, Darnal HK. Pattern of ovarian neoplasm in Manipur. J Indian Med Assoc 1990 Dec;88(12): 338-9.

Greggi S, Genuardi M, Benedetti-Panici P, Cento R, Scambia G, Neri G, Mancuso S. Analysis of 138 consecutive ovarian cancer patients: incidence and characteristics of familial cases. Gynecol Oncol 1990 Dec;39(3):300-4.

Grimes DA. Neoplastic effects of oral contraceptives. Int J Fertil 1991;36 Suppl 1:19-24.

Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC. The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 1992 Jul 1;136(1):46-53.

Grover S, Quinn MA, Weideman P. Patterns of inheritance of ovarian cancer. An analysis from an ovarian cancer screening program. Cancer 1993 Jul 15;72(2):526-30.

Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43(6):559-68.

Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992 Oct;80(4):708-14.

Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 1992 Jul;80(1):19-26.

Harlow BL, Cramer DW, Geller J, Willett WC, Bell DA, Welch WR. The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk. Am J Epidemiol 1991 Sep 1;134(5):445-53. Comment in: Am J Epidemiol

1991 Sep 1;134(5):454-6 and Am J Epidemiol 1991 Sep 1;134(5):457-9; discussion 460-1.

Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 Nov 15;136(10):1204-11.

Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993 Jan 29;259(5095):633-8.

Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO blood groups. J Epidemiol Community Health 1993 Aug;47(4):287-9.

Horn-Ross PL, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 1992 Nov;3(6):490-5.

Houlston RS, Bourne TH, Collins WP, Whitehead MI, Campbell S, Slack J. Risk of ovarian cancer and genetic relationship to other cancers in families. Hum Hered 1993 Mar-Apr;43(2):111-5.

Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 1991 Aug 15;134(4):362-9.

Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992 Dec 2; 84(23):1793-8.

Jacobsen BK, Vollset SE, Kvale G. Reproductive factors and survival from ovarian cancer. Int J Cancer 1993 Jul 30;54(6):904-6.

Jin F, Shu XO, Devesa SS, Zheng W, Blot WJ, Gao YT. Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-89. Cancer Causes Control 1993 Jul; 4(4):355-60.

John EM, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 1993 Jan 20;85(2):142-7.

Katchy KC, Briggs ND. Clinical and pathological features of ovarian tumours in Rivers state of Nigeria. East Afr Med J 1992 Aug;69(8):456-9.

Kaunitz AM. Oral contraceptives and gynecologic cancer: an update for the 1990s. Am J Obstet Gynecol 1992 Oct;167(4 Pt 2):1171-6.

Koch M, Hanson J, Raphael M. Follow-up of controls participating in case-control studies for cancer risk factors. Int J Epidemiol 1990 Dec;19(4):877-80. Comment in: Int J Epidemiol 1991 Sep;20(3):820.

Kodama M, Kodama T, Totani R, Suzuoki Y, Kodama M. Relation between the hormonal and epidemiological aspects of ovarian cancer patients in Japan. Anticancer Res 1992 Sep-Oct;12(5): 1593-602.

Koonings PP, Grimes DA, Campbell K, Sommerville M. Bilateral ovarian neoplasms and the risk of malignancy. Am J Obstet Gynecol 1990 Jan; 162(1):167-9.

Kuznesov VV. Selective screening on hormonedependent tumours of women's reproductive system organs. Eur J Gynaecol Oncol 1992;13(1 Suppl):65-8.

Kvale G, Heuch I, Nilssen S. Reproductive factors and cancers of the breast and genital organs--are the different cancer sites similarly affected? Cancer Detect Prev 1991;15(5):369-77.

La Vecchia C, Levi F, Lucchini F, Negri E, Franceschi S. Descriptive epidemiology of ovarian cancer in Europe. Gynecol Oncol 1992 Aug;46(2):208-15.

La Vecchia C, Negri E, Franceschi S, Parazzini F, Gentile A, Fasoli M. Alcohol and epithelial ovarian cancer. J Clin Epidemiol 1992 Sep;45(9):1025-30.

Land JA. Ovulation, ovulation induction and ovarian carcinoma. Baillieres Clin Obstet Gynaecol 1993 Jun;7(2):455-72.

Lanza E, Shankar S, Trock B. Dietary fiber. In: Micozzi MS, Moon TE, eds. Macronutrients: investigating their role in cancer. New York: Marcel Dekker; 1992. p. 293-319.

Lauchlan SC. Non-invasive ovarian carcinoma. Int J Gynecol Pathol 1990;9(2):158-69.

Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993 Apr;4(4):289-94.

Leviton A. Methylxanthine consumption and the risk of ovarian malignancy. Cancer Lett 1990 May 30; 51(2):91-101.

Lund E. Mortality from ovarian cancer among women with many children. Int J Epidemiol 1992 Oct; 21(5):872-6.

Lund E. Number of children and death from hormone-dependent cancers. Int J Cancer 1990 Dec 15; 46(6):998-1000.

Lynch HT, Conway T, Lynch J. Hereditary ovarian cancer. Pedigree studies, Part II. Cancer Genet Cytogenet 1991 Jun;53(2):161-83.

Lynch HT, Fitzsimmons ML, Conway TA, Bewtra C, Lynch J. Hereditary carcinoma of the ovary and associated cancers: a study of two families. Gynecol Oncol 1990 Jan;36(1):48-55.

Lynch HT, Lynch JF. Hereditary ovarian carcinoma. Hematol Oncol Clin North Am 1992 Aug;6(4): 783-811.

Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P, Lynch JF, Ponder BA. Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 1991 Mar 1;67(5):1460-6.

Lynch HT, Watson P, Conway TA, Lynch JF, Slominski-Caster SM, Narod SA, Feunteun J, Lenoir G. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med 1993 Sep 13;153(17): 1979-87.

Lynch HT, Watson P, Lynch JF, Conway TA, Fili M. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer 1993 Jan 15;71(2 Suppl):573-81.

Mahoney MC, Youngblood LG, Weinstein AL, Burnett WS. Evidence for a spatiotemporal cluster of ovarian cancer cases. Gynecol Oncol 1991 Jun; 41(3):234-8.

Makar AP, Trope CG. Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors. Acta Obstet Gynecol Scand 1992 Jul;71(5):331-6.

Maximov SJ, Bokhman JB. Syndrome of primary multiple endometrial, breast, ovarian and colon adenocarcinoma. Eur J Gynaecol Oncol 1993; 14(2):109-13.

Menczer J, Ben-Baruch G. Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol 1991 Feb; 77(2):276-7.

Mettlin CJ. Invited commentary: progress in the nutritional epidemiology of ovary cancer. Am J Epidemiol 1991 Sep 1;134(5):457-9; discussion 460-1. Comment on: Am J Epidemiol 1991 Sep 1; 134(5):445-53 ; Comment on: Am J Epidemiol 1991 Sep 1;134(5):454-6.

Mettlin CJ, Piver MS. A case-control study of milk-drinking and ovarian cancer risk. Am J Epidemiol 1990 Nov;132(5):871-6. Comment in: Am J Epidemiol 1991 Sep 1;134(5):454-6.

Miller WR, Fraser HM. Is cancer in women preventable by hormone manipulation? J Endocrinol 1991 Aug;130(2):165-8.

Mukherjee AK, Leck I, Langley FA, Ashcroft C. The completeness and accuracy of health authority and cancer registry records according to a study of ovarian neoplasms. Public Health 1991 Jan; 105(1):69-78.

Negri E, Franceschi S, La Vecchia C, Parazzini F. Incomplete pregnancies and ovarian cancer risk. Gynecol Oncol 1992 Nov;47(2):234-8.

Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, Beral V, Boyle P, Trichopoulos D. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991 Aug 19;49(1):50-6.

Olsson H, Andersson H, Johansson O, Moller TR, Kristoffersson U, Wenngren E. Population-based cohort investigations of the risk for malignant tumors in first-degree relatives and wives of men with breast cancer. Cancer 1993 Feb 15;71(4): 1273-8.

Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991 Oct;43(1):9-23.

Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L, Franceschi S. Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 1991;27(5):594-8.

Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L. Family history of breast, ovarian and endometrial cancer and risk of breast cancer. Int J Epidemiol 1993 Aug;22(4):614-8.

Parazzini F, Negri E, La Vecchia C, Restelli C, Franceschi S. Family history of reproductive cancers and ovarian cancer risk: an Italian case-control study. Am J Epidemiol 1992 Jan 1;135(1): 35-40.

Patel AR, Obrams GI. Epidemiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev 1993 Jan-Feb; 2(1):79-83.

Pearl ML, Johnston CM, Frank TS, Roberts JA. Synchronous dual primary ovarian and endometrial carcinomas. Int J Gynecol Obstet 1993;43(3): 305-12.

Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S, Floderus UM, Helm G, Willen H, Mitelman F. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 1991 Feb 1;47(3): 358-61.

Petitti DB, Porterfield D. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use. Contraception 1992 Feb;45(2): 93-104.

Pike M. We are on the threshold of an era when breast cancer ... can be prevented [interview]. Oncology (Huntingt) 1991 May;5(5):14, 16, 21-2.

Pike MC. Reducing cancer risk in women through lifestyle-mediated changes in hormone levels. Cancer Detect Prev 1990;14(6):595-607.

Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993 Jan 15;71(2 Suppl):582-8.

Piver MS, Baker TR, Piedmonte M, Sandecki AM. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991 Jun;18(3):177-85.

Polychronopoulou A, Tzonou A, Hsieh CC, Kaprinis G, Rebelakos A, Toupadaki N, Trichopoulos D. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993 Sep 30;55(3):402-7.

Ponder MA. Can cancers be inherited? Prof Nurse 1991 Jul;6(10):593-7.

Prat J, Matias-Guiu X, Barreto J. Simultaneous carcinoma involving the endometrium and the ovary. A clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases. Cancer 1991 Dec 1;68(11):2455-9.

Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990 Jul;1(1):81-97; discussion 99-109. Published erratum appears in Cancer Causes Control 1990 Nov;1(3):253.

Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Prog Clin Biol Res 1991;369:21-34.

Pukkala E, Poskiparta M, Apter D, Vihko V. Life-long physical activity and cancer risk among Finnish female teachers. Eur J Cancer Prev 1993 Sep; 2(5):369-76.

Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ, van Nagell JR Jr. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992 Oct;47(1):53-7.

Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991 Feb; 12(1):14-26.

Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993 Aug;82(2):181-6.

Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer 1993 Jan 15;71 (2 Suppl):524-9.

Rosenblatt KA, Szklo M, Rosenshein NB. Mineral fiber exposure and the development of ovarian cancer. Gynecol Oncol 1992 Apr;45(1):20-5.

Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1993 Apr;22(2):192-7.

Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 1992;28A(11):1872-6.

Sellers TA, Gapstur SM, Potter JD, Kushi LH, Bostick RM, Folsom AR. Association of body fat distribution and family histories of breast and ovarian cancer with risk of postmenopausal breast cancer. Am J Epidemiol 1993 Nov 15;138(10): 799-803.

Shah S, Evans DG, Blair V, Burnell LD, Birch JM. Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. Cancer 1993 Aug 1;72(3):819-27.

Smith PE. Familial breast and ovarian cancers. Semin Oncol Nurs 1992 Nov;8(4):258-64.

Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 1993;29A(9):1297-301.

Thanikasalam K, Ho CM, Adeed N, Shahidan MN, Azizah WK. Pattern of ovarian tumours among Malaysian women at General Hospital, Kuala Lumpur. Med J Malaysia 1992 Jun;47(2):139-46.

Thomas DB. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 1991 Jun;43(6):695-710.

Tomao S, Taggi F, Sberna RC, Villani C. Ovarian cancer and dietary habits. Eur J Gynaecol Oncol 1992;13(1):91-5.

Trichopoulou A, Mossialos E, Skalkides J. Mediterranean diet and cancer. Dev Oncol 1991;63:17-25.

Trope CG, Makar AP. Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer. Curr Opin Oncol 1991 Oct; 3(5):908-19.

Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992 Oct 10;305(6858):855-7.

Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis G, Toupadaki N, Trichopoulou A, Karakatsani A, Trichopoulos D. Diet and ovarian cancer: a case-control study in Greece. Int J Cancer 1993 Sep 30;55(3):411-4.

Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993 Sep 30;55(3):408-10.

Westhoff C, Murphy P, Heller D, Halim A. Is ovarian cancer associated with an increased frequency of germinal inclusion cysts? Am J Epidemiol 1993 Jul 15;138(2):90-3.

Whelan SL. Cancer Incidence in Five Continents. Coding practices. IARC Sci Publ 1992;(120):31-8.

Whittemore AS. Fertility drugs and risk of ovarian cancer. Hum Reprod 1993 Jul;8(7):999-1000.

Whittemore AS. Personal characteristics relating to risk of invasive epithelial ovarian cancer in older women in the United States. Cancer 1993 Jan 15;71 (2 Suppl):558-65.

Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 Nov 15;136(10):1212-20.

Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 Nov 15;136(10):1184-203. Comment in: Am J Epidemiol 1993 Apr 15; 137(8):928-9.

Whittemore AS, Harris R, Itnyre J, Halpern J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 Nov 15;136(10):1175-83.

Williams JK. Oral contraceptives and reproductive system cancer. Benefits and risks. J Reprod Med 1991 Mar;36(3 Suppl):247-52.

Yoder LH. The epidemiology of ovarian cancer: a review. Oncol Nurs Forum 1990 May-Jun;17(3): 411-5. Comment in: Oncol Nurs Forum 1990 Jul-Aug;17(4):483-4.

Zheng W, Shu XO, McLaughlin JK, Chow WH, Gao YT, Blot WJ. Occupational physical activity and the incidence of cancer of the breast, corpus uteri, and ovary in Shanghai. Cancer 1993 Jun 1;71(11): 3620-4.

Screening

Acar B, Posaci C, Dicle O, Topuz A, Erten O. Diagnostic value of magnetic resonance imaging in gynaecology. Aust N Z J Obstet Gynaecol 1992 Aug;32(3):252-5.

Adams CH, Smith NJ, Wilbur DC, Grady KE. The relationship of obesity to the frequency of pelvic examinations: do physician and patient attitudes make a difference? Women Health 1993;20(2): 45-57.

Andolf E. Ultrasound screening in women at risk for ovarian cancer. Clin Obstet Gynecol 1993 Jun; 36(2):423-32.

Andolf E, Jorgensen C. A prospective comparison of transabdominal and transvaginal ultrasound with surgical findings in gynecologic disease. J Ultrasound Med 1990 Feb;9(2):71-5.

Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990 Jan;75(1):106-9.

Aubel S, Wozney P, Edwards RP. MRI of female uterine and juxta-uterine masses: clinical application in 25 patients. Magn Reson Imaging 1991;9(4): 485-91.

Averette HE, Steren A, Nguyen HN. Screening in gynecologic cancers. Cancer 1993 Aug 1;72 (3 Suppl):1043-9.

Barzen G, Hierholzer J, Cordes M, Friedmann W, Felix R. Primary diagnosis and follow-up of ovarian cancer: radioimmunoscintigraphy with iodine-131 labeled OC 125 monoclonal antibodies versus computed tomography and second look. Int J Rad Appl Instrum [B] 1991;18(1):69-76.

Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp RC. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med 1990 May;35(5): 491-5.

Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC Jr. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 1990 Apr;162(4):883-8.

Berkowitz RS. CA125 measurement in epithelial ovarian cancer: A 10-year anniversary of clinical investigation. Gynecol Oncol 1993;49(1):1-2.

Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993 Apr 21; 269(15):1970-4. Published erratum appears in JAMA 1993 Aug 18;270(7):832.

Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993 Apr; 49(1-2):93-8.

Bonilla-Musoles F, Ballester MJ, Simon C, Serra V, Raga F. Is avoidance of surgery possible in patients with perimenopausal ovarian tumors using transvaginal ultrasound and duplex color Doppler sonography? J Ultrasound Med 1993 Jan;12(1): 33-9.

Bourne T, Reynolds K, Campbell S. Ovarian cancer screening. Eur J Cancer 1991;27(5):655-9.

Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, Crayford TJ, Collins WP. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993 Apr 17;306(6884):1025-9. Comment in: BMJ 1993 Apr 17;306(6884):1015-6 and BMJ 1993 Jun 19;306(6893):1685-6.

Bourne TH, Hampson J, Reynolds K, Collins WP, Campbell S. Screening for early ovarian cancer. Br J Hosp Med 1992 Oct 21-Nov 3;48(8):454-9.

Bourne TH, Reynolds K, Campbell S. Ovarian cancer screening. Curr Opin Radiol 1991 Apr;3(2):216-24.

Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991 Nov;43(2):92-7. Comment in: Gynecol Oncol 1991 Nov;43(2):89-91 and Gynecol Oncol 1992 Dec;47(3):404.

Bronshtein M, Yoffe N, Brandes JM, Blumenfeld Z. Hair as a sonographic marker of ovarian teratomas: improved identification using transvaginal sonography and simulation model. J Clin Ultrasound 1991 Jul-Aug;19(6):351-5.

Brucks JA. Ovarian cancer. The most lethal gynecologic malignancy. Nurs Clin North Am 1992 Dec;27(4):835-45.

Buamah PK, Rake MO, Drake SR, Skillen AW. Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer. J Surg Oncol 1990 Jun;44(2):97-9.

Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C, Prevot S, Hugol D, Laromiguiere M, Truc JB, Poitout P, et al. Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 1991 Mar;178(3):811-8.

Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989 Dec 2; 299(6712):1363-7. Comment in: BMJ 1990 Jan 20; 300(6718):193-5 and BMJ 1990 Feb 3; 300(6720):330.

Campbell S, Bourne T, Bradley E. Screening for ovarian cancer by transvaginal sonography and colour

Doppler. Eur J Obstet Gynecol Reprod Biol 1993 Apr;49(1-2):33-4.

Campbell S, Royston P, Bhan V, Whitehead MI, Collins WP. Novel screening strategies for early ovarian cancer by transabdominal ultrasonography. Br J Obstet Gynaecol 1990 Apr;97(4):304-11.

Campion MJ, Reid R. Screening for gynecologic cancer. Obstet Gynecol Clin North Am 1990 Dec;17(4):695-727.

Capstick V, Maclean GD, Suresh MR, Bodnar D, Lloyd S, Shepert L, Longenecker BM, Krantz M. Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers 1991 Apr-Jun; 6(2):129-35.

Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990 Apr;75(4):701-4.

Chenevix-Trench G, Leary J, Kerr J, Michel J, Kefford R, Hurst T, Parsons PG, Friedlander M, Khoo SK. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene 1992 Jun;7(6): 1059-65.

Ciotti MC. Screening for gynecologic and colorectal cancer: is it adequate? Womens Health Issues 1992 Summer;2(2):83-92; discussion 92-3.

Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB. Human epithelial ovarian cancer allelotype. Cancer Res 1993 May 15;53(10 Suppl):2393-8.

Cliby W, Sarkar G, Ritland SR, Hartmann L, Podratz KC, Jenkins RB. Absence of prohibitin gene mutations in human epithelial ovarian tumors. Gynecol Oncol 1993 Jul;50(1):34-7.

Cole LA, Nam JH, Chambers JT, Schwartz PE. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass. Gynecol Oncol 1990 Mar;36(3):391-4.

Conte M, Guariglia L, Benedetti Panici PL, Scambia G, Cento R, Laurelli G, Mancuso S. Ovarian carcinoma: an ultrasound study. Eur J Gynaecol Oncol 1990;11(1):33-6.

Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol 1991 Jul;165(1):7-10. Comment in: Am J Obstet Gynecol 1992 May; 166(5):1591-3.

de Bruijn HW, ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders JG. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. Tumour Biol 1993;14(2):105-15.

de los Frailes MT, Stark S, Jaeger W, Hoerauf A, Wildt L. Purification and characterization of the CA 125 tumor-associated antigen from human ascites. Tumour Biol 1993;14(1):18-29.

Demaerel P, Baert AL, Ide P, Obletter N, Marchal G, Van Hecke P, Bonte J. Magnetic resonance imaging of the pathological female pelvis: assessment of 24 patients with high-field magnetic resonance imaging. In: Breit A, ed. Magnetic resonance in oncology. New York: Springer-Verlag; 1990. p. 117-24.

DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993 Oct;51(1):7-11. Comment in: Gynecol Oncol 1993 Oct;51(1):4-6.

DePriest PD, van Nagell JR Jr. Transvaginal ultrasound screening for ovarian cancer. Clin Obstet Gynecol 1992 Mar;35(1):40-4.

DePriest PD, van Nagell JR Jr, Gallion HH, Shenson D, Hunter JE, Andrews SJ, Powell DE, Pavlik EJ. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993 Nov; 51(2):205-9.

Dgani R, Shani A, Elchalal U, Harpaz N, Bentwich Z, Fink A. The leukocyte adherence inhibition test (LAI) in preoperative diagnosis of epithelial ovarian cancer. Gynecol Oncol 1993 Jun;49(3):349-53.

DiCioccio RA, Piver MS. The genetics of ovarian cancer. Cancer Invest 1992;10(2):135-41.

DiSantis DJ, Scatarige JC, Kemp G, Given FT, Hsiu JG, Cramer MS. A prospective evaluation of transvaginal sonography for detection of ovarian disease. AJR Am J Roentgenol 1993 Jul;161(1): 91-4. Comment in: AJR Am J Roentgenol 1993 Jul;161(1):95-6.

Dodson MK, Hartmann LC, Cliby WA, DeLacey KA, Keeney GL, Ritland SR, Su JQ, Podratz KC, Jenkins RB. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 1993 Oct 1;53(19):4456-60.

Dudzinski MR. Tumor markers in ovarian carcinoma. Curr Opin Obstet Gynecol 1990 Feb;2(1):52-6.

Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993 Apr;52(4):678-701.

Eccles DM, Cranston G, Steel CM, Nakamura Y, Leonard RC. Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 1990 Oct;5(10):1599-601.

Eccles DM, Gruber L, Stewart M, Steel CM, Leonard RC. Allele loss on chromosome 11p is associated with poor survival in ovarian cancer. Dis Markers 1992 Mar-Apr;10(2):95-9.

Eccles DM, Russell SE, Haites NE, Atkinson R, Bell DW, Gruber L, Hickey I, Kelly K, Kitchener H, Leonard R, et al. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene 1992 Oct;7(10):2069-72.

Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 1990 Feb;5(2): 219-23.

Einhorn N. Ovarian cancer. Early diagnosis and screening. Hematol Oncol Clin North Am 1992 Aug;6(4):843-50.

Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992 Jul;80(1): 14-8.

Ferdeghini M, Gadducci A, dell'Hoste M, Prontera C, Ceccarini T, Rispoli G, Bianchi R, Fioretti P. CAM26, CAM29 and mucin-like carcinoma associated antigen in epithelial ovarian cancer. Eur J Gynaecol Oncol 1990;11(5):395-401.

Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Annicchiarico C, Prato B, Bianchi R, Fioretti P. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer. Tumour Biol 1992;13(5-6):287-93.

Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Fanucchi A, Annicchiarico C, Facchini V, Bianchi R. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol 1993; 14(5):303-9.

Feunteun J, Narod SA, Lynch HT, Watson P, Conway T, Lynch J, Parboosingh J, O'Connell P, White R, Lenoir GM. A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet 1993 Apr;52(4):736-42.

Finkler NJ. Clinical utility of CA 125 in preoperative diagnosis of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 1993 Apr;49(1-2): 105-7.

Fleischer AC. New applications of pelvic sonography. Urol Radiol 1991;13(1):9-15.

Fleischer AC. Transabdominal and transvaginal sonography of ovarian masses. Clin Obstet Gynecol 1991 Jun;34(2):433-42.

Fleischer AC, McKee MS, Gordon AN, Page DL, Kepple DM, Worrell JA, Jones HW 3d, Burnett LS, James AE Jr. Transvaginal sonography of postmenopausal ovaries with pathologic correlation. J Ultrasound Med 1990 Nov;9(11):637-44.

Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3d. Color Doppler sonography of ovarian masses: a multiparameter analysis. J Ultrasound Med 1993 Jan;12(1):41-8.

Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3d, Gross PR. Color Doppler sonography of benign and malignant ovarian masses. Radiographics 1992 Sep;12(5):879-85.

Fleischer AC, Rodgers WH, Rao BK, Kepple DM, Worrell JA, Williams L, Jones HW 3d. Assessment of ovarian tumor vascularity with transvaginal color Doppler sonography. J Ultrasound Med 1991 Oct; 10(10):563-8. Comment in: J Ultrasound Med 1993 Jan;12(1):10, 16.

Foglia M, Verri PG, Calabrese A, Corongiu F, Tarani A, Margiaria ML, De Pascale A, Tagliati D. Echography and CA 125 in ovarian pathology. Preliminary data of a new score. J Nucl Med Allied Sci 1990 Oct-Dec;34(4 Suppl):67-70.

Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993 May 8;54(2):220-5.

Foulkes WD, Campbell IG, Stamp GW, Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 1993 Feb;67(2):268-73.

Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993 Mar;67(3):551-9.

Freimanis MG, Jones AF. Transvaginal ultrasonography. Radiol Clin North Am 1992 Sep; 30(5):955-76.

Fuith LC, Marth C, Muller-Holzner E, Zechmann W, Daxenbichler G. Enhancement of CA 125 expression by interferon-gamma in ovarian carcinoma xenographs. J Tumor Marker Oncol 1991;6(2):85-9.

Gadducci A, Ciancia EM, Malagnino G, De Luca F, Campani D, Ferdeghini M, Facchini V, Pingitore R, Fioretti P. Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors. Eur J Gynaecol Oncol 1992; 13(4):346-54.

Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Fioretti P. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992 Feb;44(2):147-54.

Gadducci A, Ferdeghini M, Prontera C, Moretti L, Pellagatta L, Bianchi R, Fioretti P. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer. J Nucl Biol Med 1991 Jan-Mar; 35(1):33-7.

Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207:19-24.

Gallion HH, Bast RC Jr. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res 1993 Aug 15;53(16):3839-42.

Gallion HH, Powell DE, Morrow JK, Pieretti M, Case E, Turker MS, DePriest PD, Hunter JE, van Nagell JR Jr. Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 1992 Nov;47(2):137-42. Comment in: Gynecol Oncol 1992 Nov;47(2):135-6.

Gallion HH, Powell DE, Smith LW, Morrow JK, Martin AW, van Nagell JR, Donaldson ES. Chromosome abnormalities in human epithelial ovarian malignancies. Gynecol Oncol 1990 Sep; 38(3):473-7.

Gargano G, Correale M, Abbate I, Falco G, De Frenza N, Lorusso V, De Lena M, De Leonardis A. The role of tumour markers in ovarian cancer. Clin Exp Obstet Gynecol 1990;17(1):23-9.

Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117--December 1992. Int J Gynaecol Obstet 1993 Jun; 41(3):321-3.

Ghazizadeh M, Sasaki Y, Oguro T, Aihara K, Tenjin H, Araki T. Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours. Histopathology 1990 Aug;17(2):123-8.

Ghossain MA, Buy JN, Ligneres C, Bazot M, Hassen K, Malbec L, Hugol D, Truc JB, Decroix Y, Poitout P, et al. Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 1991 Dec;181(3):863-70.

Granberg S. Ultrasound in the diagnosis and treatment of ovarian tumors. Acta Obstet Gynecol Scand 1991;70(4-5):385-6.

Granberg S, Norstrom A, Wikland M. Comparison of endovaginal ultrasound and cytological evaluation of cystic ovarian tumors. J Ultrasound Med 1991 Jan; 10(1):9-14.

Granberg S, Wikland M. Ultrasound in the diagnosis and treatment of ovarian cystic tumours. Hum Reprod 1991 Feb;6(2):177-85.

Granberg S, Wikland M, Friberg LG. Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. Int J Gynaecol Obstet 1990 Oct;33(2):149-52.

Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989 Nov; 35(2):139-44.

Green J, Murton F, Statham H. Psychosocial issues raised by a familial ovarian cancer register. J Med Genet 1993 Jul;30(7):575-9.

Grover S, Quinn MA, Weideman P, Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 1992 Apr;79(4):511-4.

Guinet C, Buy JN, Ghossain MA, Malbec L, Hugol D, Truc JB, Poitout P, Vadrot D. Fat suppression techniques in MR imaging of mature ovarian teratomas: comparison with CT. Eur J Radiol 1993 Sep;17(2):117-21.

Gynecologic sonography. Report of the ultrasonography task force. Council on Scientific Affairs, American Medical Association. JAMA 1991 Jun 5;265(21): 2851-5.

Hall JM, Friedman L, Guenther C, Lee MK, Weber JL, Black DM, King MC. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet 1992 Jun;50(6):1235-42.

Hall KL, Dewar MA, Perchalski J. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms. Prim Care 1992 Sep; 19(3):607-20.

Hamper UM, Sheth S, Abbas FM, Rosenshein NB, Aronson D, Kurman RJ. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol 1993 Jun;160(6): 1225-8.

Harlozinska A, Bar JK, Gawlikowski W, Richter R, Cislo M. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms. Ann Chir Gynaecol 1991; 80(4):368-75.

Hata K, Hata T, Manabe A, Sugimura K, Kitao M. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 1992 Dec;80(6):922-6.

Hata K, Makihara K, Hata T, Takahashi K, Kitao M. Transvaginal color Doppler imaging for hemodynamic assessment of reproductive tract tumors. Int J Gynaecol Obstet 1991 Dec; 36(4):301-8.

Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993 Mar 3;269(9):1123-6. Comment in: JAMA 1993 Mar 3;269(9):1163 and JAMA 1993 Jun 23-30;269(24):3106-7.

Herrmann UJ. Sonographic patterns of ovarian tumors. Clin Obstet Gynecol 1993 Jun;36(2):375-83.

Higgins RV, van Nagell JR Jr, Woods CH, Thompson EA, Kryscio RJ. Interobserver variation in ovarian measurements using transvaginal sonography. Gynecol Oncol 1990 Oct;39(1):69-71.

Hirai T, Akamatsu N, Sekiba K, Tsubota N, Tsuru S. Qualificated discrimination of ovarian malignancy by diagnostic ultrasound. Asia Oceania J Obstet Gynaecol 1993 Jun;19(2):181-9.

Hosono MN, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T, Hosono M, Nakajima T, Onoyama Y, Konishi J. Different antigenic nature in apparently healthy women with high serum CA 125 levels compared with typical patients with ovarian cancer. Cancer 1992 Dec 15;70(12):2851-6.

Houlston R, Bourne TH, Davies A, Whitehead MI, Campbell S, Collins WP, Slack J. Use of family history in a screening clinic for familial ovarian cancer. Gynecol Oncol 1992 Nov;47(2):247-52.

Houlston RS, Collins A, Slack J, Campbell S, Collins WP, Whitehead MI, Morton NE. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991 Oct;55(Pt 4):291-9.

Houvenaeghel G, Delpero JR, Rosello R, Resbeut M, Viens P, Jacquemier J, Noirclerc M, Guerinel G. Results of a prospective study with comparison of clinical, endosonographic, computed tomography, magnetic resonance imaging and pathologic staging of advanced gynecologic carcinoma and recurrence. Surg Gynecol Obstet 1993 Sep;177(3):231-6.

Hricak H. Carcinoma of the female reproductive organs. Value of cross-sectional imaging. Cancer 1991 Feb 15;67(4 Suppl):1209-18.

Huengsberg M, MacDonald LM, Bradbeer CS. The use of pelvic ultrasound in female patients attending a GUM clinic. Int J STD AIDS 1993 Jul-Aug;4(4): 190-3.

Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 1990 Feb;36(2):161-5.

Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992 Mar;79(3): 434-40.

Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M, Karino K, Endoh J, Kitao M. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest 1990;29(3):214-8.

Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M, Takahashi K, Yoshino N, Karino K, Endoh J, et al. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels. Gynecol Obstet Invest 1990; 29(1):71-4.

Jacobs I, Bast RC Jr. Immunodiagnosis of ovarian tumors. Immunol Ser 1990;53:323-38.

Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993 Apr 17;306(6884): 1030-4. Comment in: BMJ 1993 Apr 17;306(6884): 1015-6 ; BMJ 1993 Jun 19;306(6893): 1684; discussion 1685-6 ; BMJ 1993 Jun 19;306(6893): 1685 ; BMJ 1993 Jun 19;306(6893):1685-6.

Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990 Oct; 97(10):922-9.

Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992 Sep;80 (3 Pt 1):396-9.

Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leech V, Molyneux A, Berchuck A, Ponder BA, et al. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 1993 Mar 15;53(6):1218-21.

Jain KA, Friedman DL, Pettinger TW, Alagappan R, Jeffrey RB Jr, Sommer FG. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993 Mar;186(3): 697-704.

Jain KA, Jeffrey RB Jr. Pictorial essay: transabdominal and endovaginal sonography of adnexal masses. Clin Imaging 1991 Oct-Dec;15(4):245-52.

Jones MH, Nakamura Y. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene 1992 Aug;7(8):1631-4.

Juhasz B, Kurjak A, Lampe L, Zalud I, Crvenkovic G, Hernadi Z. Tissue characterization by transvaginal colour Doppler for the evaluation of gynaecological tumours. 2. Clinical experiences. Acta Med Hung 1990;47(3-4):149-56.

Karlan BY, Raffel LJ, Crvenkovic G, Smrt C, Chen MD, Lopez E, Walla CA, Garber C, Cane P, Sarti DA, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 1993 Sep;169(3):494-501.

Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H, Tomoda Y. Transvaginal Doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol 1992 Feb;79(2):163-7.

Kenemans P, Bon GG, Kessler AC, Verstraeten AA, van Kamp GJ. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem 1992 Aug; 38(8 Pt 1):1466-71.

Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993 Dec;39(12): 2509-13.

Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology--a review. Eur J Obstet Gynecol Reprod Biol 1993 Apr;49(1-2):115-24.

Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L, Pfleiderer A. Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation. Cancer 1993 Oct 15;72(8):2423-32.

Kier R, Smith RC, McCarthy SM. Value of lipid- and water-suppression MR images in distinguishing between blood and lipid within ovarian masses. AJR Am J Roentgenol 1992 Feb;158(2):321-5.

King MC, Rowell S, Love SM. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA 1993 Apr 21;269(15):1975-80.

Kobayashi H, Tamura M, Satoh T, Terao T. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125. Clin Biochem 1993 Jun;26(3):213-9.

Kopf I, Strid KG, Islam MQ, Granberg S, Friberg LG, Levan G, Carstensen J. Heterochromatin variants in 109 ovarian cancer patients and 192 healthy subjects. Hereditas 1990;113(1):7-16.

Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993 Jan 15;71(2 Suppl):589-93.

Kuesel AC, Kroft T, Prefontaine M, Smith IC. Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer 1992 Sep 30;52(3):341-6.

Kupfer MC, Schwimer SR, Lebovic J. Transvaginal sonographic appearance of endometriomata: spectrum of findings. J Ultrasound Med 1992 Apr; 11(4):129-33.

Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992 Dec;11(12):631-8.

Kurjak A, Predanic M, Kupesic-Urek S, Jukic S. Transvaginal color and pulsed Doppler assessment of adnexal tumor vascularity. Gynecol Oncol 1993 Jul;50(1):3-9.

Kurjak A, Salihagic A, Kupesic-Urek S, Predanic A. Clinical value of the assessment of gynaecological tumour angiogenesis by transvaginal colour Doppler. Ann Med 1992 Apr;24(2):97-103.

Kurjak A, Schulman H, Sosic A, Zalud I, Shalan H. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992 Dec;80(6):917-21.

Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991 Jun;10(6):295-7. Comment in: J Ultrasound Med 1992 Mar;11(3):80.

Laing FC. Ultrasound of gynecologic pathologies. Curr Opin Radiol 1992 Apr;4(2):78-84.

Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 1990 May 1;50(9):2724-8.

Li FP, Garber JE. Gene for familial breast and ovarian cancer. Lancet 1993 Apr 24;341(8852):1060-1. Comment on: Lancet 1993 Apr 24;341(8852): 1101-2 ; Comment in: Lancet 1993 May 29; 341(8857):1422.

Lotzniker M, Pavesi F, Scarabelli M, Vadacca G, Franchi M, Moratti R. Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer. Int J Biol Markers 1991 Apr-Jun;6(2):115-21.

Luxman D, Bergman A, Sagi J, David MP. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991 May;77(5):726-8. Comment in: Obstet Gynecol 1991 Oct;78(4):726.

Macri CI, DiSaia PJ. Ovarian cancer screening. West J Med 1992 Jun;156(6):652-3.

Mahon SM, Casperson DS. Focus on oncology: ovarian cancer screening and early detection. J Urol Nurs 1992 Apr-Jun;11(2):112-9.

Mazoyer S, Lalle P, Narod SA, Bignon YJ, Courjal F, Jamot B, Dutrillaux B, Stoppa-Lyonnett D, Sobol H. Linkage analysis of 19 French breast cancer families, with five chromosome 17q markers. Am J Hum Genet 1993 Apr;52(4):754-60.

Menczer J, Ben-Baruch G, Moran O, Lipitz S. Cyst fluid CA 125 levels in ovarian epithelial neoplasms. Obstet Gynecol 1993 Jan;81(1):25-8.

Mendelson EB, Bohm-Velez M. Transvaginal ultrasonography of pelvic neoplasms. Radiol Clin North Am 1992 Jul;30(4):703-34.

Milner BJ, Allan LA, Kelly KF, Cruickshank D, Hall M, Johnston A, Kitchener H, Parkin D, Haites N. Linkage studies with 17q and 18q markers in a breast/ovarian cancer family. Am J Hum Genet 1993 Apr;52(4):761-6.

Miyao M, Takahashi M, Sumi M, Miyazaki K, Okamura H. Correlation of CT patterns with histologic findings in parauterine masses. Radiat Med 1992 Nov-Dec;10(6):223-31.

Mogensen O, Mogensen B, Jakobsen A. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol 1990 Aug; 38(2):170-4.

Mogensen O, Mogensen B, Jakobsen A. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours. Br J Cancer 1990 Feb;61(2):327-9.

Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, Lopez JJ, Ballesta A. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol 1992; 13(5-6):278-86.

Monoclonal antibodies in breast and ovarian cancer. Proceedings of the British Association for Cancer Research Workshop, Oxford, 17-19 March, 1991. Dis Markers 1991 May-Aug;9(3-4):125-238.

Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S, Okazaki E. Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. Cancer 1990 Dec 15;66(12):2628-35.

Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H, Brucks JP, Tsao SW, Berkowitz RS. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993 Oct;51(1):12-20.

Nadji M. Tumor markers in gynecologic neoplasms. Clin Lab Med 1990 Mar;10(1):105-17.

Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991 Jul 13;338(8759):82-3. Comment in: Lancet 1991 Aug 17;338(8764):444-5.

Neal CE, Baker MR, Hilgers RD, Fanning J, Burke RC, Snodgrass J, Cull RD. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma. Clin Nucl Med 1993 Jun;18(6):472-6.

Neal CE, Swenson LC, Fanning J, Texter JH. Monoclonal antibodies in ovarian and prostate cancer. Semin Nucl Med 1993 Apr;23(2):114-26.

Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993 Feb;48(2):148-54.

Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993;10(4):235-44.

Normand T, Narod S, Labrie F, Simard J. Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet 1993 Apr;2(4):479-83.

Nozawa S, Aoki D, Yajima M, Tsukazaki K, Kobayashi T, Kimura E, Terashima Y, Inaba N, Takamizawa H, Negishi Y, et al. CA54/61 as a marker for epithelial ovarian cancer. Cancer Res 1992 Mar 1;52(5):1205-9.

Nozawa S, Yajima M, Sakuma T, Udagawa Y, Kiguchi K, Sakayori M, Narisawa S, Iizuka R, Uemura M. Cancer-associated galactosyltransferase as a new tumor marker for ovarian clear cell carcinoma. Cancer Res 1990 Feb 1;50(3):754-9.

Nozawa S, Yajima M, Sasaki H, Tsukazaki K, Aoki D, Sakayori M, Udagawa Y, Kobayashi T, Sato I, Furusako S, et al. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J Cancer Res 1991 Jul;82(7):854-61.

Occhipinti KA, Frankel SD, Hricak H. The ovary. Computed tomography and magnetic resonance imaging. Radiol Clin North Am 1993 Sep;31(5): 1115-32.

Ohkawa K, Takada K, Hatano T, Takizawa N, Tsukada Y, Yamada K, Terashima Y, Matsuda M, Machida K. An evaluation of ovarian carcinoma-associated antigen defined by murine monoclonal antibody CF511 in sera from patients with ovarian carcinoma. Br J Cancer 1991 Aug;64(2):259-62.

Ohuchi N, Gero E, Mori S, Akimoto M, Matoba N, Nishihira T, Hirayama K, Colcher D, Schlom J.

Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma. J Tumor Marker Oncol 1990;5(1):1-10.

Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991 Oct 1;51(19): 5171-6.

Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S. Clinical experience in gynecological cancer management. d). Ovarian tumors--1) Epithelial: report from the Gynaecological Institutes of Padua University (1963-1990). Eur J Gynaecol Oncol 1992;13(1):17-33.

Oram DH, Jacobs IJ, Brady JL, Prys-Davies A. Early diagnosis of ovarian cancer. Br J Hosp Med 1990 Nov;44(5):320, 322, 324.

Patsner B. Preoperative serum CA-125 levels in early stage ovarian cancer. Eur J Gynaecol Oncol 1990;11(5):319-21.

Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM, Furgyik S, Helm G, Himmelmann A, Willen H, et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosom Cancer 1992 Jan;4(1):58-68.

Perkins AC, Powell MC, Wastie ML, Scott IV, Hitchcock A, Worthington BS, Symonds EM. A prospective evaluation of OC125 and magnetic resonance imaging in patients with ovarian carcinoma. Eur J Nucl Med 1990;16(4-6):311-6.

Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, Jenkins RB. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 1993 Mar;142(3):733-41.

Phillips N, Ziegler M, Saha B, Xynos F. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 1993 Apr 22;54(1):85-91.

Piver MS, Hempling RE. Screening for gynecologic malignancies in primary care: ovarian cancer. Emerg Med 1993 Mar;25(4):141-2, 145-6, 148.

Plebani M, Faggian D, Masiero M, Giacomini A, Burlina A. CA 19-9 and CA 125 determination by immunoluminometric assay. J Clin Chem Clin Biochem 1990 Dec;28(12):919-21.

Popp LW, Gaetje R, Stoyanov M. Accuracy of bimanual palpation versus vaginosonography in determination of the measurements of pelvic tumors. Arch Gynecol Obstet 1993;252(4):197-202.

Porter DE, Cohen BB, Wallace MR, Carothers A, Steel CM. Linkage mapping in familial breast cancer: improved localisation of a susceptibility locus on chromosome 17q12-21. Int J Cancer 1993 Jan 21; 53(2):188-98.

Powell MA. Screening for ovarian cancer. J Am Acad Nurse Pract 1992 Jan-Mar;4(1):36-7.

Pyrgiotis E, Salamalekis E, Loghis C, Dima C, Zourlas PA. CA 125 in preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol 1993;14(4):279-82.

Quillin SP, Siegel MJ. CT features of benign and malignant teratomas in children. J Comput Assist Tomogr 1992 Sep-Oct;16(5):722-6.

Reinsberg J, Nocke W. Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2 fragments of the OC125 antibody. Eur J Clin Chem Clin Biochem 1993 May;31(5):323-7.

Reinsberg J, Schultes B, Wagner U, Krebs D. Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab')2 fragments of OC125 antibody. Clin Chem 1993 May;39(5):891-6.

Riccio TJ, Adams HG, Munzing DE, Mattrey RF. Magnetic resonance imaging as an adjunct to sonography in the evaluation of the female pelvis. Magn Reson Imaging 1990;8(6):699-704.

Roberts CG, Tattersall MH. Cytogenetic study of solid ovarian tumors. Cancer Genet Cytogenet 1990 Sep; 48(2):243-53.

Ronay G, Jager W, Weiss K, Feistel H, Wolf F, Tulusan AH, Lang N. Immunohistochemical identification of CA125 and the F(ab')2 fragments of the murine monoclonal antibody OC125 in ovarian cancer tissue. Br J Cancer Suppl 1990 Jul; 10:67-9.

Runowicz CD. Advances in the screening and treatment of ovarian cancer. CA Cancer J Clin 1992 Nov-Dec;42(6):327-49. Published erratum appears in CA Cancer J Clin 1993 May-Jun;43(3):191-2.

Runowicz CD, Goldberg GL, Smith HO. Cancer screening for women older than 40 years of age. Obstet Gynecol Clin North Am 1993 Jun;20(2): 391-408.

Russell SE, Hickey GI, Lowry WS, White P, Atkinson RJ. Allele loss from chromosome 17 in ovarian cancer. Oncogene 1990 Oct;5(10):1581-3.

Rustin GJ. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary. Dis Markers 1991 May-Aug;9(3-4):153-8.

Saga T, Endo K, Nakashima T, Awaji T, Koizumi M, Kawamura Y, Watanabe Y, Konishi J, Nonogaki H, Nanbu Y, et al. Construction of an immunoradiometric assay for ovarian cancer associated antigen CA125 recognizing different antigenic determinant. Acta Obstet Gynecol Scand 1990;69(2):175-81.

Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 1993 Jul 15;53(14):3382-5.

Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y. Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res 1992 Oct 15; 52(20):5815-7.

Sarti DA. Transvaginal sonography: a call for tempered enthusiasm. AJR Am J Roentgenol 1993 Jul;161(1): 95-6. Comment on: AJR Am J Roentgenol 1993 Jul;161(1):91-4.

Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991 Jul;78(1):70-6. Comment in: Obstet Gynecol 1991 Dec;78(6):1151-2.

Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991 Oct 1;51(19):5118-22.

Satoskar P, Deshpande A. The value of ultrasonography in the diagnosis of adnexal masses. J Postgrad Med 1991 Jan;37(1):35-9.

Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 1993 Jun 1;118(11):838-43. Comment in: Ann Intern Med 1993 Jun 1;118(11):901-2.

Schoenfeld A, Levavi H, Hirsch M, Pardo J, Ovadia J. Transvaginal sonography in postmenopausal women. J Clin Ultrasound 1990;18(4):350-8.

Schoenfeld A, Levavi H, Ovadia J. Surgery in postmenopausal women--the value of transvaginal sonography. Surg Endosc 1990;4(2):108-13.

Schwartz MK. Screening for cancer: is it cost effective? Clin Chem 1993 Nov;39(11 Pt 2):2397-403.

Schwartz PE. Ovarian masses: serologic markers. Clin Obstet Gynecol 1991 Jun;34(2):423-32.

Schwartz PE. The role of tumor markers in the preoperative diagnosis of ovarian cysts. Clin Obstet Gynecol 1993 Jun;36(2):384-94.

Schwartz PE, Chambers JT, Taylor KJ, Pellerito J, Hammers L, Cole LA, Yang-Feng TL, Smith P, Mayne ST, Makuch R. Early detection of ovarian cancer: background, rationale, and structure of the Yale Early Detection Program. Yale J Biol Med 1991 Nov-Dec;64(6):557-71.

Scott IV. The identification of high risk and practical strategies for a population based randomized trial of ovarian cancer screening. Dis Markers 1991 May-Aug;9(3-4):133-52.

Scoutt LM, McCarthy SM. Applications of magnetic resonance imaging to gynecology. Top Magn Reson Imaging 1990 Jun;2(3):37-49.

Scoutt LM, McCarthy SM. Imaging of ovarian masses: magnetic resonance imaging. Clin Obstet Gynecol 1991 Jun;34(2):443-51.

Semelka RC, Lawrence PH, Shoenut JP, Heywood M, Kroeker MA, Lotocki R. Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR imaging, with histologic correlation. J Magn Reson Imaging 1993 Jan-Feb;3(1):99-106.

Serreyn R, DeBoever J, Martens G, Vandekerckhove D. Quantitive assessment of CA-125 in the normal ovary and in benign and malignant ovarian tumors. J Tumor Marker Oncol 1990;5(4):341-9.

Siegel MJ, Surratt JT. Pediatric gynecologic imaging. Obstet Gynecol Clin North Am 1992 Mar;19(1): 103-27.

Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu The V, Vivier A, Lasko D, Morgan K, Rouleau GA, et al. Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. Hum Mol Genet 1993 Aug;2(8):1193-9.

Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44(4-5):365-80.

Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992 Oct;2(2):128-31.

Smith SA, Easton DF, Ford D, Peto J, Anderson K, Averill D, Stratton M, Ponder M, Pye C, Ponder BA. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet 1993 Apr;52(4): 767-76.

Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC Jr. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990 Feb;75(2):249-54.

Sparks JM, Varner RE. Ovarian cancer screening. Obstet Gynecol 1991 May;77(5):787-92.

Spreafico C, Frigerio L, Lanocita R, Spatti GB, Marchiano A, Milella M, Garbagnati F, Bohm S, Damascelli B. Color-Doppler ultrasound in ovarian masses: anatomo-pathologic correlation. Tumori 1993 Aug 31;79(4):262-7.

Spurr NK, Kelsell DP, Black DM, Murday VA, Turner G, Crockford GP, Solomon E, Cartwright RA, Bishop DT. Linkage analysis of early-onset breast and ovarian cancer families, with markers on the long arm of chromosome 17. Am J Hum Genet 1993 Apr;52(4):777-85.

Stevens SK, Hricak H, Stern JL. Ovarian lesions: detection and characterization with gadolinium-enhanced MR imaging at 1.5 T. Radiology 1991 Nov;181(2):481-8.

Stigbrand T, Riklund K, Tholander B, Hirano K, Lalos O, Stendahl U. Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours. Eur J Gynaecol Oncol 1990; 11(5):351-60.

Surratt JT, Siegel MJ. Imaging of pediatric ovarian masses. Radiographics 1991 Jul;11(4):533-48.

Sutton CL, McKinney CD, Jones JE, Gay SB. Ovarian masses revisited: radiologic and pathologic correlation. Radiographics 1992 Sep;12(5):853-77.

Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 1993 Dec;82(6):946-50.

Suzuki M, Sekiguchi I, Tamada T. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125. Obstet Gynecol 1990 Sep;76(3 Pt 1):422-7.

Taccone W, Mazzon W, Belli M. Evaluation of TATI and other markers in solid tumors. Scand J Clin Lab Invest Suppl 1991;207:25-32.

Tay SK, Tan YY. Risk factors and a risk scoring system for the prediction of malignancy in ovarian cysts. Aust N Z J Obstet Gynaecol 1992 Nov;32(4): 341-5.

Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P, et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosom Cancer 1993 Aug;7(4):219-26.

Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol 1990 Oct;39(1):16-25.

Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990 Oct;39(1):26-33.

Thorvinger B. Diagnostic and interventional radiology in gynecologic neoplasms. Acta Radiol Suppl 1992; 378(Pt 3):93-108.

Thurnher S, Hodler J, Baer S, Marincek B, von Schulthess GK. Gadolinium-DOTA enhanced MR imaging of adnexal tumors. J Comput Assist Tomogr 1990 Nov-Dec;14(6):939-49.

Timor-Tritsch LE, Lerner JP, Monteagudo A, Santos R. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993 Mar;168 (3 Pt 1):909-13.

Toftager-Larsen K, Hording U, Dreisler A, Daugaard S, Lund B, Bock J, Lundvall F, Frederiksen K, Norgaard-Pedersen B. CA-125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma. Gynecol Obstet Invest 1992;33(3):177-82.

Tomas C, Penttinen J, Risteli J, Risteli L, Kauppila A. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma. Ann Med 1990 Apr; 22(2):115-21.

Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Welch WR, Goodman HM, Sheets EE, Berkowitz RS, Lau CC. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993 Jan;48(1):5-10. Comment in: Gynecol Oncol 1993 Jan;48(1):1-3.

Tsao SW, Mok CH, Oike K, Muto M, Goodman HM, Sheets EE, Berkowitz RS, Knapp RC, Lau CC. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res 1991 Nov-Dec;11(6):1975-82.

van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992 Feb;40(1-2): 36-51.

van der Zee AG, Duk JM, Aalders JG, Boontje AH, ten Hoor KA, de Bruijn HW. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol 1990 Oct;97(10):934-8.

van Kamp GJ, Verstraeten AA, Kenemans P. Discordant serum CA 125 values in commercial immunoassays. Eur J Obstet Gynecol Reprod Biol 1993 Apr;49(1-2):99-103.

van Nagell JR Jr, DePriest PD, Gallion HH, Pavlik EJ. Ovarian cancer screening. Cancer 1993 Feb 15;71 (4 Suppl):1523-8.

van Nagell JR Jr, Higgins RV, Donaldson ES, Gallion HH, Powell DE, Pavlik EJ, Woods CH, Thompson EA. Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer 1990 Feb 1;65(3): 573-7.

Vandamme B, Lissens W, Amfo K, De Sutter P, Bourgain C, Vamos E, De Greve J. Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res 1992 Dec 1;52(23):6646-52.

Varpula M. Magnetic resonance imaging of female pelvic masses and local recurrent tumors at an ultra low (0.02 T) magnetic field: correlation with computed tomography. Magn Reson Imaging 1993; 11(1):35-46.

Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumour Biol 1992;13(3): 168-74.

Viel A, Giannini F, Tumiotto L, Sopracordevole F, Visentin MC, Boiocchi M. Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. Br J Cancer 1992 Dec;66(6):1030-6.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol 1992;13(2):205-8.

Wade RV. Gynecologic applications of real time ultrasound. Appl Radiol 1993 Feb;22(2):15-9.

Wahl RL. Radiolabeled monoclonal antibodies for the diagnosis and treatment of ovarian carcinoma. Front Radiat Ther Oncol 1990;24:228-39.

Walsh JM. Cancer screening in older adults. West J Med 1992 May;156(5):495-500. Comment in: West J Med 1992 Oct;157(4):469-70.

Wardle FJ, Collins W, Pernet AL, Whitehead MI, Bourne TH, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993 Apr 21;85(8):653-7.

Warner BW, Kuhn JC, Barr LL. Conservative management of large ovarian cysts in children: the value of serial pelvic ultrasonography. Surgery 1992 Oct;112(4):749-55.

Weiner Z, Beck D, Shteiner M, Borovik R, Ben-Shachar M, Robinzon E, Brandes JM. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 1993 Jul;12(7):387-93.

Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes JM. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992 Feb;79(2):159-62. Comment in: Obstet Gynecol 1992 Jul;80(1):156-7.

Weinreb JC, Barkoff ND, Megibow A, Demopoulos R. The value of MR imaging in distinguishing leiomyomas from other solid pelvic masses when sonography is indeterminate. AJR Am J Roentgenol 1990 Feb;154(2):295-9.

Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl 1992;155:85-93.

Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and in the United States. Br J Obstet Gynaecol 1992 Apr;99(4):329-32.

Westhoff C, Levin B, Ladd G, O'Connor J. Sources of variability in normal CA 125 levels. Cancer Epidemiol Biomarkers Prev 1992 Jul-Aug;1(5): 357-9.

Westhoff C, Randall MC. Ovarian cancer screening: potential effect on mortality. Am J Obstet Gynecol 1991 Sep;165(3):502-5.

Wikborn C, Pettersson F, Silfversward C, Moberg PJ. Symptoms and diagnostic difficulties in ovarian epithelial cancer. Int J Gynaecol Obstet 1993 Sep; 42(3):261-4.

Williams L. Ovarian cancer screening. The search for cost-effective methods. Postgrad Med 1992 Dec; 92(8):63-6, 72.

Willson JR. Ultrasonography in the diagnosis of gynecologic disorders. Am J Obstet Gynecol 1991 Apr;164(4):1064-7; discussion 1067-71. Comment in: Am J Obstet Gynecol 1992 Apr;166(4):1310-1.

Wolf SI, Gosink BB, Feldesman MR, Lin MC, Stuenkel CA, Braly PS, Pretorius DH. Prevalence of simple adnexal cysts in postmenopausal women. Radiology 1991 Jul;180(1):65-71.

Wong JG, Feussner JR. Screening for ovarian cancer: not worthwhile for most patients. N C Med J 1993 Sep;54(9):438-40.

Wu JT, Carlisle P. Low frequency and low level of elevation of serum CA 72-4 in human carcinomas in comparison with established tumor markers. J Clin Lab Anal 1992;6(1):59-64.

Yang-Feng TL, Han H, Chen KC, Li SB, Claus EB, Carcangiu ML, Chambers SK, Chambers JT, Schwartz PE. Allelic loss in ovarian cancer. Int J Cancer 1993 Jun 19;54(4):546-51.

Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 1992 Oct 21; 52(4):575-80.

Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE. Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 1991 Jul 9; 48(5):678-81.

Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, Voorhorst FJ, Verstraeten AA, van Kamp GJ, Hilgers J. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13(1-2):18-26.

Yedema KA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW, Thomas CM, Massuger LF, Schijf CP, Bon GG, Vermorken JB, et al. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Int J Cancer 1991 Jan 21; 47(2):170-9.

Yedema KA, Thomas CM, Segers MF, Doesburg WH, Kenemans P. Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. Eur J Obstet Gynecol Reprod Biol 1992 Dec 28;47(3): 245-52.

Yoder LH. The epidemiology of ovarian cancer: a review. Oncol Nurs Forum 1990 May-Jun;17(3): 411-5. Comment in: Oncol Nurs Forum 1990 Jul-Aug;17(4):483-4.

Yoffe N, Bronshtein M, Brandes J, Blumenfeld Z. Hemorrhagic ovarian cyst detection by transvaginal sonography: the great imitator. Gynecol Endocrinol 1991 Jun;5(2):123-9.

Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT, Klug TL, Zurawski VR Jr, Bast RC Jr. Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res 1991 Jan 15;51(2):468-75.

Zangwill BC, Balsara G, Dunton C, Varello M, Rebane BA, Hernandez E, Atkinson BF. Ovarian carcinoma heterogeneity as demonstrated by DNA ploidy. Cancer 1993 Apr 1;71(7):2261-7.

Zawin M, McCarthy S, Scoutt LM, Comite F. High-field MRI and US evaluation of the pelvis in women with leiomyomas. Magn Reson Imaging 1990;8(4):371-6.

Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 1993 May; 59(5):1028-35.

Zimmermann W, Bender E, Rohde K, Reis A, Wiseman R, Futreal A, Krause H, Prokoph H, Werner S, Scherneck S. Linkage analysis in German breast cancer families with early onset of the disease, using highly polymorphic markers from the chromosome 17q11-q24 region. Am J Hum Genet 1993 Apr;52(4):789-91.

Zimny ME. Ovarian cancer: a nursing overview. Oncology (Huntingt) 1991 Aug;5(8):147-53; discussion 154.

Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, Eklund G, Mattsson B, Connor RJ, Prorok PC, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990 Mar;36(3):299-305.

Prevention

Barber HR. Prophylaxis in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1529-33.

Boike G, Averette H, Hoskins W, Chmiel J, Zuber K, Karnell L, Winchester D. National survey of ovarian carcinoma. IV. Women with prior hysterectomy: a failure of prevention? [abstract]. Gynecol Oncol 1993 Apr;49(1):112-3.

Cruickshank DJ, Haites N, Anderson S, Matheson H, Hall MH, Milner B, Ah-See A, Gunn I, Eremin O, Gilbert F, et al. The multidisciplinary management of a family with epithelial ovarian cancer. Br J Obstet Gynaecol 1992 Mar;99(3):226-31.

Dicker RC, Scally MJ, Greenspan JR, Layde PM, Ory HW, Maze JM, Smith JC. Hysterectomy among women of reproductive age. Trends in the United States, 1970-1978. JAMA 1982 Jul 16;248(3): 323-7.

Estrogen use and postmenopausal women: a National Institutes of Health Consensus Development Conference. Ann Intern Med 1979 Dec;91(6): 921-2.

Fine BA, Yazigi R, Risser R. Prognosis of ovarian cancer developing in the residual ovary. Gynecol Oncol 1991 Nov;43(2):164-6.

Fogarty P. Prophylactic oophorectomy in Northern Ireland. Ulster Med J 1991 Oct;60(2):172-5.

Houlston RS, Hampson J, Collins WP, Whitehead MI, Campbell S, Slack J. Correlation in ages at death from familial ovarian cancer among sisters. Gynecol Oncol 1992 Nov;47(2):253-4.

Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992 Oct;80(4): 700-7. Comment in: Obstet Gynecol 1993 Feb; 81(2):315-6.

Klein B, Lurie H, Stein M, Kuten A, Steinherz R. Hereditary ovarian cancer: a dilemma in prognosis. Isr J Med Sci 1992 Jan;28(1):16-9.

Madsen EM, Lidegaard O, Tabor A. Oophorectomy in the prevention of ovarian cancer. Acta Obstet Gynecol Scand 1993 Nov;72(8):599-600.

Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992 Oct 23;47(1):59-65.

Parazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R. Hysterectomy, oophorectomy, and subsequent ovarian cancer risk. Obstet Gynecol 1993 Mar;81(3):363-6.

Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965-84. Am J Public Health 1988 Jul; 78(7):852-3.

Ponder BA, Easton DF, Peto J. Risk of ovarian cancer associated with a family history: preliminary report of the OPCS study. In: Sharp F, Mason WP, Leake RE, eds. Ovarian cancer: biological and therapeutic challenges. London: Chapman and Hall Medical; 1990. p. 3-6.

Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988 Sep;128(3):456-66.

Schumaker D. Preventing gynecologic cancer: every woman's guide... a risk factor checklist. Can Nurs 1991 Oct;87(9):23-4.

Schwartz PE. The role of prophylactic oophorectomy in the avoidance of ovarian cancer. Int J Gynaecol Obstet 1992 Nov;39(3):175-84.

Sheth S, Malpani A. Routine prophylactic oophorectomy at the time of vaginal hysterectomy in postmenopausal women. Arch Gynecol Obstet 1992;251(2):87-91.

Sightler SE, Boike GM, Estape RE, Averette HE. Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami. Obstet Gynecol 1991 Oct;78(4):681-4. Comment in: Obstet Gynecol 1992 Feb;79(2):317-9.

Speroff T, Dawson NV, Speroff L, Haber RJ. A risk-benefit analysis of elective bilateral oophorectomy: effect of changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol 1991 Jan;164(1 Pt 1):165-74.

MANAGEMENT OF EARLY STAGE OVARIAN CANCER

Management of the Adnexal Mass

Alvarez RD, Kilgore LC, Partridge EE, Austin JM, Shingleton HM. Staging ovarian cancer diagnosed during laparoscopy: accuracy rather than immediacy. South Med J 1993 Nov;86(11):1256-8.

Archie JT, Witt TR. Peritoneoscopy for biopsy, staging, and therapy of intra-abdominal tumors. In: Economou SG, Witt TR, Deziel DJ, et al., eds. Adjuncts to cancer surgery. Philadelphia: Lea and Febiger; 1991. p. 195-203.

Barber HRK, Creasman WT, Knapp RC. A rational approach to ovarian masses. Patient Care 1993 Jan 15;27(1):50-4, 61-2, 65-8 passim.

Bouwman DL. The management of unexpected findings at surgery. Surg Clin North Am 1993 Apr; 73(2): 203-12.

Bret PM, Atri M, Guibaud L, Gillett P, Seymour RJ, Senterman MK. Ovarian cysts in postmenopausal women: preliminary results with transvaginal alcohol sclerosis. Work in progress. Radiology 1992 Sep;184(3):661-3. Comment in: Radiology 1992 Sep;184(3):605-6.

Bret PM, Guibaud L, Atri M, Gillett P, Seymour RJ, Senterman MK. Transvaginal US-guided aspiration of ovarian cysts and solid pelvic masses. Radiology 1992 Nov;185(2):377-80. Comment in: Radiology 1993 Jun;187(3):878.

Bruhat MA, Mage G, Pouly JL, Canis M, Wattiez A, Chapron C. Advances in pelviscopic surgery. Ann N Y Acad Sci 1991;626:367-71.

Caspi B, Zalel Y, Lurie S, Elchlal U, Katz Z. Ultrasound-guided aspiration for relief of pain generated by simple ovarian cysts. Gynecol Obstet Invest 1993;35(2):121-2.

Conklin JT, Maguire RT. Monoclonal antibodies as an aid in the imaging of cancer. In: Economou SG, Witt TR, Deziel DJ, et al., eds. Adjuncts to cancer surgery. Philadelphia: Lea and Febiger; 1991. p. 219-28.

Cristalli B, Cayol A, Izard V, Levardon M. Benefit of operative laparoscopy for ovarian tumors suspected of benignity. J Laparoendosc Surg 1992 Apr;2(2): 69-73.

Curtin JP. Diagnosis and staging of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 153-62.

Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993 Oct;100(10):927-31.

Dordoni D, Zaglio S, Zucca S, Favalli G. The role of sonographically guided aspiration in the clinical management of ovarian cysts. J Ultrasound Med 1993 Jan;12(1):27-31.

el-Yahia AR, Rahman J, Rahman MS, al-Suleiman SA. Ovarian tumours in pregnancy. Aust N Z J Obstet Gynaecol 1991 Nov;31(4):327-30.

Fleischer AC, Shah DM, Entman SS. Sonographic evaluation of maternal disorders during pregnancy. Radiol Clin North Am 1990 Jan;28(1):51-8.

Grimes DA. Frontiers of operative laparoscopy: a review and critique of the evidence. Am J Obstet Gynecol 1992 Apr;166(4):1062-71. Comment in: Am J Obstet Gynecol 1993 Apr;168(4):1333-4.

Hasson HM. Laparoscopic management of ovarian cysts. J Reprod Med 1990 Sep;35(9):863-7.

Heloury Y, Guiberteau V, Sagot P, Plattner V, Baron M, Rogez JM. Laparoscopy in adnexal pathology in the child: a study of 28 cases. Eur J Pediatr Surg 1993 Apr;3(2):75-8.

Hulka JF, Parker WH, Surrey MW, Phillips JM. Management of ovarian masses. AAGL 1990 survey. J Reprod Med 1992 Jul;37(7):599-602.

Johns A. Laparoscopic oophorectomy/oophorocystectomy. Clin Obstet Gynecol 1991 Jun; 34(2):460-6.

Khanna AK, Misra MK, Khanna A, Misra VK, Khanna S. Fine-needle aspiration cytology of abdominal masses. J Surg Oncol 1990 May;44(1):15-9.

Khaw KT, Walker WJ. Ultrasound guided fine needle aspiration of ovarian cysts: diagnosis and treatment in pregnant and non-pregnant women. Clin Radiol 1990 Feb;41(2):105-8.

Kier R, McCarthy SM, Scoutt LM, Viscarello RR, Schwartz PE. Pelvic masses in pregnancy: MR imaging. Radiology 1990 Sep;176(3):709-13.

Kullendorff CM. Diagnosis and treatment of ovarian cysts in children. Ann Chir Gynaecol 1991;80(1): 65-7.

Langebrekke A, Urnes A. Laparoscopic adnexectomy. Acta Obstet Gynecol Scand 1991;70(7-8):605-9.

Larkin KR. Cancer and pregnancy. NAACOGS Clin Issu Perinat Womens Health Nurs 1990;1(2): 255-61.

Lee CL, Soong YK. Laparoscopic management of benign ovarian tumors. J Formos Med Assoc 1993 Mar;92(3):245-8.

Lee CL, Soong YK, Lai YM, Chang SY, Chang MY. Simplified instrumentation for laparoscopic ovarian cystectomy. Chang Keng I Hsueh 1992 Mar;15(1): 28-32.

Lipitz S, Seidman DS, Menczer J, Bider D, Oelsner G, Moran O, Shalev J. Recurrence rate after fluid aspiration from sonographically benign-appearing ovarian cysts. J Reprod Med 1992 Oct;37(10): 845-8.

Maiman M, Seltzer V, Boyce J. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant. Obstet Gynecol 1991 Apr;77(4):563-5. Comment in: Obstet Gynecol 1991 Aug;78(2): 319-21.

Martin DC. Laparoscopic treatment of ovarian endometriomas. Clin Obstet Gynecol 1991 Jun; 34(2):452-9.

Mettler L, Irani S, Semm K. Ovarian surgery via pelviscopy. J Reprod Med 1993 Feb;38(2):130-2.

Miller RC, Nash JD, Weiser EB, Hoskins WJ. The postmenopausal palpable ovary syndrome. A retrospective review with histopathologic correlates. J Reprod Med 1991 Aug;36(8):568-71.

Moore JL Jr, Martin JN Jr. Cancer and pregnancy. Obstet Gynecol Clin North Am 1992;19(4):815-27.

Moran O, Menczer J, Ben-Baruch G, Lipitz S, Goor E. Cytologic examination of ovarian cyst fluid for the distinction between benign and malignant tumors. Obstet Gynecol 1993 Sep;82(3):444-6.

Nezhat F, Nezhat C, Silfen SL. Videolaseroscopy for oophorectomy. Am J Obstet Gynecol 1991 Nov; 165(5 Pt 1):1323-30. Comment in: Am J Obstet Gynecol 1992 Oct;167(4 Pt 1):1150.

Obwegeser R, Deutinger J, Bernascheck G. The risk of malignancy with an apparently simple adnexal cyst on ultrasound. Arch Gynecol Obstet 1993;253(3): 117-20.

Ovadia J, Goldman GA. Ovarian masses in postmenopausal women. Int J Gynaecol Obstet 1992 Sep;39(1):35-9.

Parker WH, Berek JS. Management of the adnexal mass by operative laparoscopy. Clin Obstet Gynecol 1993 Jun;36(2):413-22.

Phipps JH, Monaghan JM. Laparoscopic hysterectomy and cancer. Surg Oncol 1993;2 Suppl 1:67-72.

Pinto MM, Bernstein LH, Brogan DA, Parikh F, Lavy G. Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: diagnostic adjunct to cytology. Diagn Cytopathol 1990;6(3):160-3.

Reich H, McGlynn F, Sekel L, Taylor P. Laparoscopic management of ovarian dermoid cysts. J Reprod Med 1992 Jul;37(7):640-4.

Ron-El R, Herman A, Weinraub Z, Golan A, Langer R, Caspi E, Bukovsky I. Clear ovarian cyst aspiration guided by vaginal ultrasonography. Eur J Obstet Gynecol Reprod Biol 1991 Nov 3;42(1): 43-7.

Rubin SC, Curtin JP. Surgery for gynecologic malignancies. Curr Opin Oncol 1992 Oct; 4(5):923-9.

Seltzer V. Laparoscopic surgery for ovarian lesions: potential pitfalls. Clin Obstet Gynecol 1993 Jun; 36(2):402-12.

Semm K, O'Neill-Freys I. Pelviscopy. Curr Opin Obstet Gynecol 1991 Jun;3(3):413-21.

Sommerville M, Grimes DA, Koonings PP, Campbell K. Ovarian neoplasms and the risk of adnexal torsion. Am J Obstet Gynecol 1991 Feb;164(2): 577-8.

Sutton C. Operative laparoscopy. Curr Opin Obstet Gynecol 1992 Jun;4(3):430-8.

Thornton KL, DeCherney AH. Laparoscopic management of ovarian cysts: an endocrinologist view. Yale J Biol Med 1991 Nov-Dec;64(6): 599-606.

Warner BW, Kuhn JC, Barr LL. Conservative management of large ovarian cysts in children: the value of serial pelvic ultrasonography. Surgery 1992 Oct;112(4):749-55.

Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and in the United States. Br J Obstet Gynaecol 1992 Apr;99(4):329-32.

Early Stage Epithelial Ovarian Cancer

Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990 Feb;75(2):263-73.

DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1990 Nov;16(11): 35-42.

Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 1991 Dec;43(3):203-5.

Finn CB, Luesley DM, Buxton EJ, Blackledge GR, Kelly K, Dunn JA, Wilson S. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992 Jan;99(1):54-8. Comment in: Br J Obstet Gynaecol 1992 Jun;99(6): 530-1.

Finn CB, Luesley DM, Buxton EJ, Blackledge GR, Kelly K, Dunn JA, Wilson S. Is stage I epithelial ovarian cancer over-treated both surgically and systematically? Results of a five-year cancer registry review. Obstet Gynecol Surv 1992; 47(7):491-3.

Fox H. Pathology of early malignant change in the ovary. Int J Gynecol Pathol 1993 Apr;12(2):153-5.

Gadducci A, Del Bravo B, Cardosi Carrara A, D'Amico M, Fioretti P. Adjuvant treatment of early stage ovarian carcinoma. Clin Exp Obstet Gynecol 1990;17(3-4):131-9.

Hudson CN, Potsides P, Curling OM. An audit of surgical treatment of ovarian cancer in a metropolitan health region. Association of Obstetricians and Gynaecologists of the North East Thames Region. J R Soc Med 1991 Apr;84(4): 206-9.

Lentz SS, Cha SS, Wieand HS, Podratz KC. Stage I ovarian epithelial carcinoma: survival analysis following definitive treatment. Gynecol Oncol 1991 Dec;43(3):198-202. Comment in: Gynecol Oncol 1991 Dec;43(3):193-4.

Linasmita V, Sakonratanakul P, Bhamarapravati Y. Survival of patients with stage I epithelial ovarian carcinoma, 1981-1985 at Ramathibodi Hospital. J Med Assoc Thai 1990 Feb;73 Suppl 1:7-10.

Malmstrom H, Larsson D, Simonsen E. Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol 1990 Dec; 39(3):289-94.

Marchetti M, Romagnolo C. Fertility after ovarian cancer treatment. Clin Exp Obstet Gynecol 1992; 19(3):199-202.

Marchetti M, Romagnolo C. Fertility after ovarian cancer treatment. Eur J Gynaecol Oncol 1992; 13(6):498-501.

Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, Pater JL. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991 Dec;43(3):195-7. Comment in: Gynecol Oncol 1991 Dec;43(3):193-4.

Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 219-39.

O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993 May;49(2):250-4.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Piver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992 Sep;46(3): 357-60.

Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 1990 Sep;38(3):367-72.

Raju KS, Wolfe CD. Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review (5). Br J Obstet Gynaecol 1992;99(6):530-1.

Rubin SC, Jones WB, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993 Jul;82(1):139-42.

Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993 Jul;82(1):143-7.

Schilder RJ, Young RC. Management of early-stage ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):867-77.

Schneider J, Centeno MM, Montoya F, Rodriguez-Escudero FJ. Negative second-look laparotomy does not preclude recurrence in stage I ovarian carcinoma of any histological variety. Eur J Gynaecol Oncol 1993;14(1):36-9.

Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, van der Burg ME, Fleuren GJ. Prognostic factors in well-differentiated early-stage epithelial ovarian cancer. Cancer 1993 Feb 1;71(3):787-95.

Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 1990 May 15;65(10):2349-52.

Soper JT, Berchuck A, Clarke-Pearson DL. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. Cancer 1991 Aug 15;68(4):725-9.

Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Obstet Gynecol 1992 Jun;79(6):993-7.

Thigpen JT, Lambuth BW, Vance RB. Management of stage I and II ovarian carcinoma. Semin Oncol 1991 Dec;18(6):596-602.

Trimbos JB, Schueler JA, van der Burg M, Hermans J, van Lent M, Heintz AP, Fleuren GJ. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991 Feb 1;67(3):597-602.

Trimbos JB, Schueler JA, van Lent M, Hermans J, Fleuren GJ. Reasons for incomplete surgical staging in early ovarian carcinoma. Gynecol Oncol 1990 Jun;37(3):374-7.

van Nagell JR Jr, DePriest PD. Early diagnosis of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 127-31.

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993 Jul;169(1):40-52.

Walton LA, Yadusky A, Rubinstein L, Roth LM, Young RC. Stage II carcinoma of the ovary: an analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 1992 Jan;44(1):55-60.

Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993 Nov 3;85(21):1748-51.

Young RC. Management of early stage ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 359-73.

Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long HJ. Localized ovarian cancer in the elderly. The Gynecologic Oncology Group experience. Cancer 1993 Jan 15;71(2 Suppl):601-5.

Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990 Apr 12; 322(15):1021-7. Comment in: N Engl J Med 1990 Apr 12;322(15):1076-8 and N Engl J Med 1991 Mar 14;324(11):775.

Ovarian Tumors of Low Malignant Potential (Borderline Tumors)

Ayhan A, Akarin R, Develioglu O, Yarali H, Kucukali T, Bilgin F. Borderline epithelial ovarian tumours. Aust N Z J Obstet Gynaecol 1991 May;31(2): 174-6.

Ball NJ, Robertson DI, Duggan MA, Snider DD. Intestinal differentiation in ovarian mucinous tumours. Virchows Arch A Pathol Anat Histopathol 1990;417(3):197-201.

Barnhill DR, O'Connor DM. Management of ovarian neoplasms of low malignant potential. Oncology (Huntingt) 1991 Apr;5(4):21-6; discussion 26, 28, 31-2.

Bell DA, Scully RE. Clinical perspective on borderline tumors of the ovary. In: Greer BE, Berek JS, eds. Gynecologic oncology: treatment rationale and techniques. New York: Elsevier; 1991. p. 119-34.

Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990 Apr;21(4):397-403.

Biscotti CV, Hart WR. Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum). A clinicopathologic study of 17 cases. Am J Surg Pathol 1992 May;16(5):467-75.

Cajigas HE, Fariza E, Scully RE, Thor AD. Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors. Cancer 1991 Jul 15; 68(2):348-54.

Carter J, Fowler J, Carlson J, Carson L, Twiggs LB. Borderline and invasive epithelial ovarian tumors in young women. Obstet Gynecol 1993 Nov;82(5): 752-6.

Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW. Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 1993 Sep;50(3):316-22.

Criscuolo M, Martinelli AM, Migaldi M, Zunarelli E, Bergamaschi M, Falchi AM, De Gaetani C. Prognostic significance of nucleolar organizer regions in ovarian epithelial tumors. Int J Gynecol Pathol 1993 Jul;12(3):259-63.

de Nictolis M, Montironi R, Tommasoni S, Carinelli S, Ojeda B, Matias-Guiu X, Prat J. Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 1992 Jul 1;70(1):152-60.

Drescher CW, Flint A, Hopkins MP, Roberts JA. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors. Gynecol Oncol 1993 Feb;48(2):242-6.

Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer KD. Dual-parameter flow cytometric analysis coupling the measurements of forward-angle light scatter and DNA content of archival ovarian carcinomas of low malignant potential. Anal Quant Cytol Histol 1991 Feb;13(1):45-53.

Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990 Feb 1;65(3):578-85.

Goldman TL, Chalas E, Chumas J, Loesch M, Mann WJ. Management of borderline tumors of the ovary. South Med J 1993 Apr;86(4):423-5.

Griffiths AP, Cross D, Kingston RE, Harkin P, Wells M, Quirke P. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary. Int J Gynecol Pathol 1993 Oct;12(4):307-14.

Hanselaar AG, Vooijs GP, Mayall B, Ras-Zeijlmans GJ, Chadha-Ajwani S. Epithelial markers to detect occult microinvasion in serous ovarian tumors. Int J Gynecol Pathol 1993 Jan;12(1):20-7.

Harlow BL, Fuhr JE, McDonald TW, Schwartz SM, Beuerlein FJ, Weiss NS. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993 Sep;50(3):305-9.

Harlow BL, Weiss NS, Holmes EH. Plasma alpha-L-fucosidase activity and the risk of borderline epithelial ovarian tumors. Cancer Res 1990 Aug 1; 50(15):4702-3.

Hata K, Hata T, Manabe A, Kitao M. Ovarian tumors of low malignant potential: transvaginal Doppler ultrasound features. Gynecol Oncol 1992 Jun; 45(3):259-64.

Heinonen PK. Androgen production by epithelial ovarian tumours in post-menopausal women. Maturitas 1991 Jun;13(2):117-22.

Hytiroglou P, Harpaz N, Heller DS, Liu ZY, Deligdisch L, Gil J. Differential diagnosis of borderline and invasive serous cystadenocarcinomas of the ovary by computerized interactive morphometric analysis of nuclear features. Cancer 1992 Feb 15;69(4):988-92.

Kaern J, Trope C, Kjorstad KE, Abeler V, Pettersen EO. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 1990 Sep;38(3):452-7.

Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993 Mar 1;71(5):1810-20.

Khattech A, Spatz A, Prade M, Duvillard P, Charpentier P, Bognel C, Michel G, Lhomme C. Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumor. Int J Gynecol Pathol 1992;11(1):11-4.

Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993 Apr;12(2): 120-7.

Leake JF. Tumors of low malignant potential. Curr Opin Obstet Gynecol 1992 Feb;4(1):81-5.

Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992 Nov; 47(2):150-8.

Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991 Aug;42(2):124-30.

Long L, Jiang P, Liu FZ, Wang XP, Zhao TJ. Treatment of ovarian malignant germ cell tumors with preservation of fertility. Chin Med J (Engl) 1993 Apr;106(4):303-6.

Manchul LA, Simm J, Levin W, Fyles AW, Dembo AJ, Pringle JF, Rawlings GA, Sturgeon JF, Thomas GM. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys 1992;22(5):867-74.

Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman WT. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol 1991 Dec; 78(6):1027-32.

McLellan R, Buscema J, Guerrero E, Shah KV, Woodruff JD, Currie JL. Investigation of ovarian neoplasia of low malignant potential for human papillomavirus. Gynecol Oncol 1990 Sep;38(3): 383-5.

Michael H, Roth LM, Kotylo PK. Recent developments in the pathology of ovarian epithelial tumors of low malignant potential and related neoplasms. Pathol Annu 1993;28(Pt 2):1-22.

Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993 Apr 1;53(7):1489-92.

Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T, Takeuchi J. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990 Jul;38(1):90-8.

Norris HJ. Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. Int J Gynecol Pathol 1993 Apr;12(2): 134-40.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Padberg BC, Arps H, Franke U, Thiedemann C, Rehpenning W, Stegner HE, Lietz H, Schroder S, Dietel M. DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy. A clinicomorphologic study of 80 cases. Cancer 1992 May 15;69(10):2510-4.

Padberg BC, Stegner HE, von Sengbusch S, Arps H, Schroder S. DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions. Virchows Arch A Pathol Anat Histopathol 1992;421(6):497-503.

Parazzini F, Restelli C, La Vecchia C, Negri E, Chiari S, Maggi R, Mangioni C. Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 1991 Dec;20(4):871-7.

Rice LW, Berkowitz RS, Mark SD, Yavner DL, Lage JM. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol 1990 Nov;39(2):195-8.

Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, Bell DA. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992 Aug;46(2):226-9.

Rutgers JL, Bell DA. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types. Mod Pathol 1992 Jul;5(4):367-71.

Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal implants. Am J Surg Pathol 1992 Jun;16(6):577-83.

Seidman JD, Norris HJ, Griffin JL, Hitchcock CL. DNA flow cytometric analysis of serous ovarian tumors of low malignant potential. Cancer 1993 Jun 15;71(12):3947-51.

Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno M. Clinicostatistical study of low potential malignancy ovarian cystadenoma (borderline cases). Asia Oceania J Obstet Gynaecol 1991 Jun;17(2): 107-12.

Snider DD, Stuart GC, Nation JG, Robertson DI. Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecol Oncol 1991 Feb;40(2):129-32.

Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 425-49.

Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991 Jun;41(3): 230-3.

Trimble EL, Trimble CL. Epithelial ovarian tumors of low malignant potential. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 415-29.

Vaccarello L, Kanbour A, Kanbour-Shakir A, Whiteside TL. Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential. Int J Gynecol Pathol 1993 Jan;12(1):41-50.

Yazigi R, Munoz AK, Sandstad J, Lifshitz S, Choi DJ. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential. Eur J Gynaecol Oncol 1991;12(6):451-5.

Germ Cell and Sex-Cord Stromal Tumors

Barrenetxea G, Schneider J, Centeno MM, Martinez AJ, Fernandez de Larrino A, Gonzales del Tanago J, Rodriguez-Escudero FJ. Pure theca cell tumors. A clinicopathologic study of 29 cases. Eur J Gynaecol Oncol 1990;11(6):429-32.

Bazot M, Ghossain MA, Buy JN, Deligne L, Hugol D, Truc JB, Poitout P, Vadrot D. Fibrothecomas of the ovary: CT and US findings. J Comput Assist Tomogr 1993 Sep-Oct;17(5):754-9.

Beamer WG, Shultz KL, Tennent BJ, Shultz LD. Granulosa cell tumorigenesis in genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors. Cancer Res 1993 Aug 15;53(16):3741-6.

Berkowitz RS. Recent advances in the biology and treatment of gestational trophoblastic diseases and germ cell tumors. Curr Opin Oncol 1990 Oct;2(5): 901-5.

Bjorkholm E, Lundell M, Gyftodimos A, Silfversward C. Dysgerminoma. The Radiumhemmet series 1927-1984. Cancer 1990 Jan 1;65(1):38-44.

Brammer HM 3d, Buck JL, Hayes WS, Sheth S, Tavassoli FA. From the archives of the AFIP. Malignant germ cell tumors of the ovary: radiologic-pathologic correlation. Radiographics 1990 Jul;10(4):715-24.

Chadha S, Cornelisse CJ, Schaberg A. Flow cytometric DNA ploidy analysis of ovarian granulosa cell tumors. Gynecol Oncol 1990 Feb;36(2):240-5.

Chang CY, Yeh WR, Chao KC, Ng HT. Granulosa cell tumor of the ovary. Chung Hua I Hsueh Tsa Chih (Taipei) 1990 Sep;46(3):172-6.

Chiara S, Merlini L, Campora E, Bruzzone M, Giudici S, Rosso R, Ragni N. Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa-cell tumor patients. Eur J Gynaecol Oncol 1993;14(4): 314-7.

Conte M, Guariglia L, Benedetti Panici P, Scambia G, Rabitti C, Capelli A, Mancuso S. Ovarian fibrothecoma: sonographic and histologic findings. Gynecol Obstet Invest 1991;32(1):51-4.

Coppes MJ, Ye Y, Rackley R, Zhao XL, Liefers GJ, Casey G, Williams BR. Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res 1993 Jun 15;53(12):2712-4.

Danhier S, Van Houtte P. Ovarian dysgerminoma: a therapeutic challenge. J Belge Radiol 1993 Mar; 76(2):102-4.

Daugaard G, Hansen HH, Rorth M. Treatment of malignant germ cell tumors. Ann Oncol 1990; 1(3):195-202.

De Jong FH, Grootenhuis AJ, Steenbergen J, van Sluijs FJ, Foekens JA, ten Kate FJ, Oosterhuis JW, Lamberts SW, Klijn JG. Inhibin immunoreactivity in gonadal and non-gonadal tumors. J Steroid Biochem Mol Biol 1990 Dec 20;37(6):863-6.

De Palo G, Zambetti M, Pilotti S, Rottoli L, Spatti G, Fontanelli R, Musumeci R, Kenda R, Bombardieri E, Stefanon B, et al. Nondysgerminomatous tumors of the ovary treated with cisplatin, vinblastine, and bleomycin: long-term results. Gynecol Oncol 1992 Nov;47(2):239-46.

Dietl J, Horny HP, Ruck P, Kaiserling E. Dysgerminoma of the ovary. An immunohistochemical study of tumor-infiltrating lymphoreticular cells and tumor cells. Cancer 1993 Apr 15;71(8):2562-8.

dos Santos Silva I, Swerdlow AJ. Ovarian germ cell malignancies in England: epidemiological parallels with testicular cancer. Br J Cancer 1991 May;63(5): 814-8.

Fletcher JA, Gibas Z, Donovan K, Perez-Atayde A, Genest D, Morton CC, Lage JM. Ovarian granulosa-stromal cell tumors are characterized by trisomy 12. Am J Pathol 1991 Mar;138(3):515-20.

Germa JR, Izquierdo MA, Segui MA, Climent MA, Ojeda B, Alonso C. Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau. Gynecol Oncol 1992 May;45(2): 153-9.

Gershenson DM. Ovarian germ cell and stromal tumors. In: Greer BE, Berek JS, eds. Gynecologic oncology: treatment rationale and techniques. New York: Elsevier; 1991. p. 167-84.

Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993 Feb 15;71(4 Suppl): 1581-90.

Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG, Wharton JT. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990 Apr;8(4):715-20.

Gitsch G, Kohlberger P, Hanzal E, Kolbl H, Breitenecker G. Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet 1991;249(4):173-7.

Gitsch G, Kohlberger P, Steiner A, Neumeister B, Breitenecker G. Expression of cytokeratins in granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet 1992;251(4):193-7.

Gorski GK, McMorrow LE, Blumstein L, Faasse D, Donaldson MH. Trisomy 14 in two cases of granulosa cell tumor of the ovary. Cancer Genet Cytogenet 1992 Jun;60(2):202-5.

Gribbon M, Ein SH, Mancer K. Pediatric malignant ovarian tumors: a 43-year review. J Pediatr Surg 1992 Apr;27(4):480-4.

Haba R, Miki H, Kobayashi S, Ohmori M. Combined analysis of flow cytometry and morphometry of ovarian granulosa cell tumor. Cancer 1993 Dec 1; 72(11):3258-62.

Hawkins EP. Pathology of germ cell tumors in children. Crit Rev Oncol Hematol 1990;10(2): 165-79.

Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993 Nov 18;329(21):1539-42.

Hicks ML, Piver MS. Conservative surgery plus adjuvant therapy for vulvovaginal rhabdomyosarcoma, diethylstilbestrol clear cell adenocarcinoma of the vagina, and unilateral germ cell tumors of the ovary. Obstet Gynecol Clin North Am 1992 Mar;19(1):219-33.

Inoue M, Fujita M, Azuma C, Saji F, Tanizawa O. Histogenetic analysis of ovarian germ cell tumors by DNA fingerprinting. Cancer Res 1992 Dec 15; 52(24):6823-6.

Jacoby AF, Young RH, Colvin RB, Flotte TJ, Preffer F, Scully RE, Swymer CM, Bell DA. DNA content in juvenile granulosa cell tumors of the ovary: a study of early- and advanced-stage disease. Gynecol Oncol 1992 Jul;46(1):97-103.

Jones WB. Sex cord-stromal tumors of the ovary. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 385-405.

Kawai M, Furuhashi Y, Kano T, Misawa T, Nakashima N, Hattori S, Okamoto Y, Kobayashi I, Ohta M, Arii Y, et al. Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 1990 Nov; 39(2):160-6.

Kawai M, Kano T, Furuhashi Y, Iwata M, Nakashima N, Imai N, Kuzuya K, Hayashi H, Ohta M, Arii Y, et al. Immature teratoma of the ovary. Gynecol Oncol 1991 Feb;40(2):133-7.

Kawai M, Kano T, Furuhashi Y, Mizuno K, Nakashima N, Hattori SE, Kazeto S, Iida S, Ohta M, Arii Y, et al. Prognostic factors in yolk sac tumors of the ovary. A clinicopathologic analysis of 29 cases. Cancer 1991 Jan 1;67(1):184-92.

Kawai M, Kano T, Kikkawa F, Morikawa Y, Oguchi H, Nakashima N, Ishizuka T, Kuzuya K, Ohta M, Arii Y, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol 1992 Jun;45(3):248-53.

Kelley JL 3d, Naus GJ, Christopherson WA. Endodermal sinus tumor of the ovary: a case series with flow cytometric DNA content analysis. Gynecol Oncol 1991 Jul;42(1):34-8.

Klemi PJ, Joensuu H, Salmi T. Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of the ovary. Cancer 1990 Mar 1;65(5): 1189-93.

Kumar L, Bhargawa VL, Kumar S. Cisplatin, vinblastine and bleomycin in advanced and relapsed germ cell tumours of ovary. Asia Oceania J Obstet Gynaecol 1993 Jun;19(2):133-40.

Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M. Inhibin as a marker for granulosa cell tumor. Acta Obstet Gynecol Scand Suppl 1992;155:61-5.

Malik ST, Slevin ML. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach? Br J Cancer 1991 Mar;63(3):410-1. Comment in: Br J Cancer 1992 Jan;65(1):140.

Motawy MS, Szymendera JJ, al-Jazzaf H, Behbehani AE, Foudeh MO, Ebraheem AK, Nasralla MY, Ali MA. Serum AFP, hCG and CEA in the management of patients with testicular, ovarian and extragonadal germ cell tumors. Int J Biol Markers 1992 Apr-Jun;7(2):80-6.

Muram D, Gale CL, Thompson E, Marina N. Ovarian cancer in children and adolescents. Adolesc Pediatr Gynecol 1992;5(1):21-6.

Murty VV, Dmitrovsky E, Bosl GJ, Chaganti RS. Nonrandom chromosome abnormalities in testicular and ovarian germ cell tumor cell lines. Cancer Genet Cytogenet 1990 Nov 1;50(1):67-73.

Onnis A, Marchetti M, Piazza M. Clinical experience in gynaecological cancer management. D) Ovarian tumors--non-epithelial: report from the Gynaecological Institute of Padua University. Eur J Gynaecol Oncol 1993;14(1):5-17.

Otis CN, Powell JL, Barbuto D, Carcangiu ML. Intermediate filamentous proteins in adult granulosa cell tumors. An immunohistochemical study of 25 cases. Am J Surg Pathol 1992 Oct;16(10):962-8.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Palmquist MB, Webb MJ, Lieber MM, Gaffey TA, Nativ O. DNA ploidy of ovarian dysgerminomas: correlation with clinical outcome. Gynecol Oncol 1992 Jan;44(1):13-6.

Pectasides D, Alevizakos N, Athanassiou AE. Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary. Ann Oncol 1992 Apr;3(4):316-8.

Pfleiderer A. Therapy of ovarian malignant germ cell tumors and granulosa tumors. Int J Gynecol Pathol 1993 Apr;12(2):162-5.

Pliskow S. Endodermal sinus tumor of the ovary: review of 10 cases. South Med J 1993 Feb;86(2): 187-9.

Porter S, Gilks CB. Genomic imprinting: a proposed explanation for the different behaviours of testicular and ovarian germ cell tumors. Med Hypotheses 1993 Jul;41(1):37-41.

Price FV, Schwartz PE. Management of ovarian stromal tumors. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 405-23.

Rajkumar T, Sagar TG, Maitreyan V, Vasanthan A, Devika A, Sastry DV, Shanta V. Germ-cell tumours of the ovary--treatment and results at Cancer Institute, Madras. Indian J Cancer 1992 Mar; 29(1):18-23.

Rogo KO, Persson H, Stendahl U. Dysgerminoma of the ovary: treatment results in northern Sweden. Eur J Gynaecol Oncol 1990;11(1):43-9.

Schwartz PE, Chambers SK, Chambers JT, Kohorn E, McIntosh S. Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol 1992 Apr;45(1):26-31.

Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno M. Clinicostatistical study of ovarian tumors of germ cell origin. Asia Oceania J Obstet Gynaecol 1991 Sep;17(3):207-15.

Sivanesaratnam V, Dutta R, Jayalakshmi P. Ovarian fibroma--clinical and histopathological characteristics. Int J Gynaecol Obstet 1990 Nov; 33(3):243-7.

Skinner MA, Schlatter MG, Heifetz SA, Grosfeld JL. Ovarian neoplasms in children. Arch Surg 1993 Aug;128(8):849-53; discussion 853-4.

Stewart CJ, Farquharson MA, Foulis AK. Characterization of the inflammatory infiltrate in ovarian dysgerminoma: an immunocytochemical study. Histopathology 1992 Jun;20(6):491-7.

Suh KS, Silverberg SG, Rhame JG, Wilkinson DS. Granulosa cell tumor of the ovary. Histopathologic and flow cytometric analysis with clinical correlation. Arch Pathol Lab Med 1990 May; 114(5):496-501.

Susnerwala SS, Pande SC, Shrivastava SK, Dinshaw KA. Dysgerminoma of the ovary: review of 27 casesa. J Surg Oncol 1991 Jan;46(1):43-7.

Swanson SA, Norris HJ, Kelsten ML, Wheeler JE. DNA content of juvenile granulosa tumors determined by flow cytometry. Int J Gynecol Pathol 1990;9(2):101-9.

Tandon R, Kumar L, Vaid A, Kochupillai V, Kumar S, Kriplani A, Bhargava VL. Management of malignant germ cell tumours of ovary. Indian J Cancer 1992 Sep;29(3):122-5.

Tennent BJ, Shultz KL, Beamer WG. Genetic susceptibility for C19 androgen induction of ovarian granulosa cell tumorigenesis in SWXJ strains of mice. Cancer Res 1993 Mar 1;53(5):1059-63.

Tennent BJ, Shultz KL, Sundberg JP, Beamer WG. Ovarian granulosa cell tumorigenesis in SWR-derived F1 hybrid mice: preneoplastic follicular abnormality and malignant disease progression. Am J Obstet Gynecol 1990 Aug;163(2):625-34.

Ulbright TM, Roth LM. A pathologic analysis of lesions following modern chemotherapy for metastatic germ-cell tumors. Pathol Annu 1990;25 (Pt 1):313-40.

van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit VT, Kuppen PJ, van Ravenswaay Claasen HH, Cornelisse CJ, Schrier PI. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 1993 Feb 20;53(4):613-20.

Vergote IB, Abeler VM, Kjorstad KE, Trope C. Management of malignant ovarian immature teratoma. Role of adriamycin. Cancer 1990 Sep 1; 66(5):882-6.

Williams SD. Chemotherapy of ovarian germ cell tumors. Hematol Oncol Clin North Am 1991 Dec; 5(6):1261-9.

Williams SD. Germ cell tumors. Hematol Oncol Clin North Am 1992 Aug;6(4):967-74.

Williams SD. Ovarian germ cell tumors. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 391-404.

Williams SD. Treatment of germ cell tumors of the ovary. Semin Oncol 1991 Jun;18(3):292-6.

Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 1991 Nov;9(11):1950-5.

Williams SD, Gershenson DM. Management of germ cell tumors of the ovary. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 375-84.

Williams SD, Gershenson DM, Horowitz CJ, Scully RE. Ovarian germ cell and stromal tumors. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott; 1992. p. 715-30.

Williams SD, Loehrer PJ, Nichols CR, Einhorn LN. Chemotherapy of male and female germ cell tumors. Semin Oncol 1992 Apr;19(2 Suppl 5): 19-23; discussion 23-4.

Wollner N, Ghavimi F, Wachtel A, Luks E, Exelby P, Woodruff J. Germ cell tumors in children: gonadal and extragonadal. Med Pediatr Oncol 1991;19(4): 228-39.

Wong LC, Collins RJ, Ngan HY, Ma HK. Etoposide combination chemotherapy in refractory ovarian malignant germ cell tumor. Gynecol Oncol 1990 Nov;39(2):123-6.

Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman SJ, Stephens RL, Natale RB, Bouroncle BA, Blumenstein BA, et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991 Jan;9(1):70-6. Comment in: J Clin Oncol 1991 Jun;9(6):1092-4.

Wu PC, Huang RL, Lang JH, Huang HF, Lian LJ, Tang MY. Treatment of malignant ovarian germ cell tumors with preservation of fertility: a report of 28 cases. Gynecol Oncol 1991 Jan;40(1):2-6.

Young RH. New and unusual aspects of ovarian germ cell tumors. Am J Surg Pathol 1993 Dec;17(12): 1210-24.

Young RH. Ovarian tumors other than those of surface epithelial-stromal type. Hum Pathol 1991 Aug; 22(8):763-75.

Zaghloul MS, Khattab TY. Dysgerminoma of the ovary: good prognosis even in advanced stages. Int J Radiat Oncol Biol Phys 1992;24(1):161-5.

Zambetti M, Escobedo A, Pilotti S, De Palo G. cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol 1990 Mar; 36(3):317-20.

Radiotherapy

Arian-Schad KS, Kapp DS, Hackl A, Juettner FM, Leitner H, Porsch G, Lahousen M, Pickel H. Radiation therapy in stage III ovarian cancer following surgery and chemotherapy: prognostic factors, patterns of relapse, and toxicity: a preliminary report. Gynecol Oncol 1990 Oct; 39(1):47-55.

Belch RZ, Coughlin CT, Cooney LC, Forcier RJ, Maurer LH. Lack of acute toxicity associated with a multimodality treatment of stage III ovarian epithelial carcinoma. Gynecol Oncol 1990 Apr; 37(1):17-20.

Bertelsen K, Jakobsen A. Radiotherapy for gynecologic cancer. Curr Opin Oncol 1993 Sep;5(5):885-90.

Bolis G, Zanaboni F, Vanoli P, Russo A, Franchi M, Scarfone G, Pecorelli S. The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy. Gynecol Oncol 1990 Nov;39(2):150-4.

Bruzzone M, Repetto L, Chiara S, Campora E, Conte PF, Orsatti M, Vitale V, Rubagotti A, Rosso R. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 1990 Sep; 38(3):392-5.

Buckman R, De Angelis C, Shaw P, Covens A, Osborne R, Kerr I, Reed R, Michaels H, Woo M, Reilly R, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992 Oct;47(1):102-9.

Calkins AR, Rosenshein NB, Fox MG, Order SE. Delayed split whole abdominal irradiation in the combined modality treatment of ovarian cancer. Int J Radiat Oncol Biol Phys 1991 Apr;20(4):661-5.

Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T, Bush RS. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer 1993;3(1):24-35.

Chiara S, Orsatti M, Franzone P, Scarpati D, Bruzzone M, Repetto L, Vitale V, Conte PF, Rosso R. Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer. Clin Oncol (R Coll Radiol) 1991 Nov;3(6):340-4.

De Pooter CM, Scalliet PG, Elst HJ, Huybrechts JJ, Gheuens EE, Van Oosterom AT, Fichtinger-Schepman AM, De Bruijn EA. Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Res 1991 Sep 1; 51(17): 4523-7.

Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1992; 22(5):835-45.

Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, Reid JG. Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 1979 Aug 1;134(7):793-800.

Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon JF. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep 1979 Feb;63(2): 249-54.

Dufour P, Bergerat JP, Liu KL, Bohbot A, Maloisel F, Duclos B, Herbrecht R, Faradji A, Jung JM, Oberling F. High dose melphalan and ABMT with or without abdominal radiotherapy as consolidation treatment for ovarian carcinoma in complete remission or with microscopic residual disease. Eur J Gynaecol Oncol 1991;12(6):457-61.

Eifel PJ, Gershenson DM, Delclos L, Wharton JT, Peters LJ. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma. Int J Radiat Oncol Biol Phys 1991 Sep; 21(4):1013-8.

Franchin G, Tumolo S, Scarabelli C, De Paoli A, Boz G, Crivellari D, Arcicasa M, Bortolus R, Gobitti C, Minatel E, et al. Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. Gynecol Oncol 1991 Jun;41(3):206-11.

Fuller DB, Sause WT, Plenk HP, Menlove RL. Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. J Clin Oncol 1987 Jun;5(6):897-905.

Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul LA, Pringle JF, Rawlings GA, Sturgeon JF, Thomas GM, Simm J. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1992;22(5):847-51.

Garton GR, Gunderson LL, Webb MJ, Wilson TO, Martenson JA Jr, Cha SS, Podratz KC. Intraoperative radiation therapy in gynecologic cancer: the Mayo Clinic experience. Gynecol Oncol 1993 Mar;48(3):328-32.

Goldberg N, Peschel RE. Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Radiat Oncol Biol Phys 1988 Mar;14(3):425-9.

Hammond R, Bull C, Houghton CR. Primary adjunctive whole abdominal radiotherapy in epithelial ovarian cancer: results of 10-years' experience. Aust N Z J Obstet Gynaecol 1992 Aug; 32(3):267-9.

Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JS, Mason P, Lambert HE, Epenetos AA. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993 Aug;68(2):403-6.

Holt JA, Scharl A, Kullander S, Beckmann MW. Intracellular actions of steroid hormones and their therapeutic value, including the potential of radiohalosteroids against ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:39-54.

Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD, Creasman WT. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol 1980 Sep 15;138(2):139-45.

Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993 Oct;82(4 Pt 1):586-93.

Jusko WJ, Kung LP, Schmelter RF. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients. Targeted Diagn Ther 1992;6:177-90.

King LA, Downey GO, Potish RA, Adcock LL, Carson LF, Twiggs LB. Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. A pilot study. Cancer 1991 Jun 1;67(11):2867-71.

Kohler MF, Soper JT, Tucker JA Jr, Clarke-Pearson DL. Isolated incisional metastases after intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma. Cancer 1991;68(6): 1380-3.

Konski AA, Neisler J, Phibbs G, Bronn DG, Dobelbower RR Jr. A pilot study investigating intraoperative electron beam irradiation in the treatment of ovarian malignancies. Gynecol Oncol 1990 Jul;38(1):121-4.

Kosmas C, Man S, Epenetos AA, Courtenay-Luck NS. The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy. Br J Cancer Suppl 1990 Jul;10:85-8.

Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992 Feb 15; 52(4):904-11.

Kucera PR, Berman ML, Treadwell P, Sheets EE, Micha JP, Rettenmaier MA, Colman M, DiSaia PJ. Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Gynecol Oncol 1990 Mar;36(3):338-42.

Lanciano RM, Randall M. Update on the role of radiotherapy in ovarian cancer. Semin Oncol 1991 Jun;18(3):233-47.

Lawton F, Luesley D, Blackledge G, Hilton C, Kelly K, Latief T, Mould J, Spooner D, Rollason T, Wade-Evans T, et al. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Clin Oncol (R Coll Radiol) 1990 Jan;2(1):4-9.

Ledermann JA, Dembo AJ, Sturgeon JF, Fine S, Bush RS, Fyles AW, Pringle JF, Rawlings GA, Thomas GM, Simm J. Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation. Gynecol Oncol 1991 Apr;41(1):30-5.

Lentz SS, Schray MF, Wilson TO. Chylous ascites after whole-abdomen irradiation for gynecologic malignancy. Int J Radiat Oncol Biol Phys 1990 Aug;19(2):435-8.

Lindner H, Willich H, Atzinger A. Primary adjuvant whole abdominal irradiation in ovarian carcinoma. Int J Radiat Oncol Biol Phys 1990 Nov;19(5): 1203-6.

Linstadt DE, Stern JL, Quivey JM, Leibel SA, Lacey CG. Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma. Gynecol Oncol 1990 Mar;36(3):327-30.

Manetta A, Lucci J, Soopikian J, Granger G, Berman ML, DiSaia PJ. In vitro cytotoxicity of human recombinant tumor necrosis factor alpha in association with radiotherapy in a human ovarian carcinoma cell line. Gynecol Oncol 1990 Aug; 38(2):200-2.

Martinez A, Schray MF, Howes AE, Bagshaw MA. Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience. J Clin Oncol 1985 Jul;3(7):901-11.

Martinez Monge R, Jurado M, Azinovic I, Aristu JJ, Tangco E, Viera JC, Berian JM, Calvo FA. Intraoperative radiotherapy in recurrent gynecological cancer. Radiother Oncol 1993 Aug; 28(2):127-33.

May LF, Belinson JL, Roland TA. Palliative benefit of radiation therapy in advanced ovarian cancer. Gynecol Oncol 1990 Jun;37(3):408-11.

Moore DH. Role of radiation therapy in ovarian cancer. Curr Opin Obstet Gynecol 1990 Feb;2(1):64-8.

Mothersill C, Seymour CB, Bonnar J. Effect of radiation and other cytotoxic agents on the growth of cells cultured from normal and tumor tissues from the female genital tract. Gynecol Oncol 1990 May;37(2):210-8.

Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR Jr, Weadock K, Tumeh SS, Lavin P, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 1992 Jun;45(3): 265-72.

Mychalczak BR, Fuks Z. The current role of radiotherapy in the management of ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4): 895-913.

Mychalczak BR, Fuks Z. The role of radiotherapy in the management of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 229-41.

Peters WA 3d, Smith MR, Cain JM, Lee RB, Yon JL Jr. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary. Gynecol Oncol 1992 Nov;47(2):146-9.

Pickel H, Petru E, Lahousen M, Stettner H, Heydarfadai M, Arian-Schad K, Hackl A. Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study. Am J Clin Oncol 1991 Jun;14(3):184-7.

Pirkowski M, Holloway R, Delgado G, Barnes W, Thomas D, Torrisi J, Popescu G, Rodgers J, Dritschilo A. Radiotherapy of malignant subdiaphragmatic implants in advanced ovarian carcinoma: a new technique. Int J Radiat Oncol Biol Phys 1992;22(5):1105-8.

Piver MS, Malfetano J, Hempling RE, Baker TR, Driscoll DL. Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a preliminary report. Gynecol Oncol 1990 Dec;39(3):249-52.

Potish RA, King LA, Downey GO, Adcock LL, Carson LF, Twiggs LB. The integration of whole abdominal radiotherapy and intraperitoneal cisplatin into the primary management of advanced ovarian carcinoma. Am J Clin Oncol 1991 Aug;14(4): 312-6.

Randall ME. Curative potential of primary whole-abdomen irradiation in ovarian carcinoma. South Med J 1991 Sep;84(9):1119-22.

Randall ME, Evans L. Issues in gynecologic radiation oncology. Curr Opin Oncol 1991 Oct;3(5):920-9.

Reddy S, Lee MS, Yordan E, Graham J, Sarin P, Hendrickson FR. Salvage whole abdomen radiation therapy: its role in ovarian cancer. Int J Radiat Oncol Biol Phys 1993 Nov 15;27(4):879-84.

Redman CW, Mould J, Warwick J, Rollason T, Luesley DM, Budden J, Lawton FG, Blackledge GR, Chan KK. The West Midlands epithelial ovarian cancer adjuvant therapy trial. Clin Oncol (R Coll Radiol) 1993;5(1):1-5.

Reid GC, Roberts JA, Hopkins MP, Schoeppel SL, Perez-Tamayo C, Drescher C, Chamberlain D, Morley GW. Primary treatment of stage III ovarian carcinoma with sequential chemotherapy and whole abdominal radiation therapy. Gynecol Oncol 1993 Jun;49(3):333-8.

Reinfuss M, Kojs Z, Skolyszewski J. External beam radiotherapy in the management of ovarian carcinoma. Radiother Oncol 1993 Jan;26(1):26-32.

Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL. Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol 1992 Oct; 10(10):1553-60.

Rogers L, Varia M, Halle J, Freddo J, Qaqish B, O'Keefe T, Fowler W. 32P following negative second-look laparotomy for epithelial ovarian cancer. Gynecol Oncol 1993 Aug;50(2):141-6. Comment in: Gynecol Oncol 1993 Aug;50(2): 139-40.

Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992 May; 10(5):727-34. Comment in: J Clin Oncol 1992 May;10(5):683-5 and J Clin Oncol 1992 Nov; 10(11):1820-1.

Rotmensch J, Roeske J, Chen G, Pelizzari C, Montag A, Weichselbaum R, Herbst AL. Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy. Gynecol Oncol 1990 Sep;38(3):478-85.

Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 1990 Jun;37(3):367-73.

Slotman BJ, Karim AB, Rao BR. Ovarian cancer: radiation sensitivity in vitro. Radiother Oncol 1990 Dec;19(4):323-7.

Sorbe B, Berglind AM, De Bruijn K. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of irradiation-induced nausea, vomiting and diarrhoea. Eur J Gynaecol Oncol 1992;13(5):382-9.

Spanos WJ Jr, Day T, Abner A, Jose B, Paris K, Pursell S. Complications in the use of intra-abdominal 32P for ovarian carcinoma. Gynecol Oncol 1992 Jun;45(3):243-7.

Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, Papadimitriou JT, Rowlinson G, Sullivan

M, Lambert HE, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990 Dec;8(12):1941-50. Comment in: J Clin Oncol 1990 Dec;8(12): 1938-40.

Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol 1993 Oct;51(1):97-103.

Thomas GM, Dembo AJ. Integrating radiation therapy into the management of ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1710-8.

Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet Gynecol Scand 1993;72(8):682-4.

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, Trope CG. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992 Feb 1;69(3):741-9.

Vergote IB, Winderen M, De Vos LN, Trope CG. Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy. Cancer 1993 Apr 1;71(7):2250-60.

Wahl RL. Radiolabeled monoclonal antibodies for the diagnosis and treatment of ovarian carcinoma. Front Radiat Ther Oncol 1990;24:228-39.

Walton LA, Yadusky A, Rubinstein L. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications. Int J Radiat Oncol Biol Phys 1991 May;20(5):939-44.

Weiser EB, Burke TW, Heller PB, Woodward J, Hoskins WJ, Park RC. Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR). Gynecol Oncol 1988 Jun;30(2):201-8.

Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S, Pringle JF, Rawlings GA, Thomas GM, Simm J. Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys 1992; 22(5):853-8.

MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN CANCER

Preoperative Evaluation and Preparation

Adelson MD. Cytoreduction of diaphragmatic metastases using the Cavitron Ultrasonic Surgical Aspirator. Gynecol Oncol 1991 Jun;41(3):220-2.

Adelson MD. Ultrasonic surgical aspirator in cytoreduction of splenic metastases to avoid splenectomy. J Reprod Med 1992 Nov;37(11): 917-20.

Barbieri RL, Niloff JM, Bast RC Jr, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 1986 May;45(5):630-4.

Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 Oct 13;309(15):883-7.

Beck DE, Fazio VW. Current preoperative bowel cleansing methods. Results of a survey. Dis Colon Rectum 1990 Jan;33(1):12-5.

Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990 Aug;38(2):203-9.

Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993 Apr;49(1):30-6.

Bostofte E, Larsen T, Torp-Pedersen S, Ottesen M. Preoperative investigations for suspected pelvic masses. Eur J Obstet Gynecol Reprod Biol 1992 Dec 28;47(3):239-43.

Bourne TH, Campbell S, Whitehead MI, Royston P, Steer CV, Collins WP. Detection of endometrial cancer in postmenopausal women by transvaginal ultrasonography and colour flow imaging. BMJ 1990 Aug 18-25;301(6748):369. Comment in: BMJ 1990 Oct 13;301(6756)873-4.

Buchsbaum HJ, Lifshitz S. Staging and surgical evaluation of ovarian cancer. Semin Oncol 1984 Sep;11(3):227-37.

Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C, Prevot S, Hugol D, Laromiguiere M, Truc JB, Poitout P, et al. Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 1991 Mar;178(3):811-8.

Corfitsen MT, Pedersen IR, Lebech AM, Kaae HH. Appendectomy and carcinoma ovarii. Cytoreduction, palliation, or simple tradition? Acta Obstet Gynecol Scand 1991;70(7-8):601-4.

Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990 Feb;75(2):287-8.

Crippa F, Presti M, Marini A, D'Onofrio B, Bolis G, Buraggi GL. Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: a prospective study. Int J Biol Markers 1990 Jul-Sep;5(3):103-8.

Deppe G, Malviya VK, Malone JM Jr, Christensen CW. Debulking of pelvic and para-aortic lymph node metastases in ovarian cancer with the cavitron ultrasonic surgical aspirator. Obstet Gynecol 1990 Dec;76(6):1140-2.

Dershaw DD, Panicek DM. Radiologic evaluation of ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 133-52.

Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986 Mar;67(3): 414-6.

Eisenkop SM, Nalick RH, Teng NN. Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991 Nov;78(5 Pt 1):879-85.

Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992 Nov;47(2):203-9.

Eisner RF, Montz FJ, Berek JS. Cytoreductive surgery for advanced ovarian cancer: cardiovascular evaluation with pulmonary artery catheters. Gynecol Oncol 1990 Jun;37(3):311-4.

Gore ME, Cooke JC, Wiltshaw E, Crow JM, Cosgrove DO, Parsons CA. The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary. Br J Cancer 1989 Nov;60(5):751-4.

Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989 Nov; 35(2):139-44.

Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni S, Nicolucci A, Torri V, Zola P, Compagnucci M, Di Mambro E, et al. The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer. Ann Oncol 1990;1(2):112-8. Comment in: Ann Oncol 1991 Mar;2(3):216.

Grilli R, Apolone G, Marsoni S, Nicolucci A, Zola P, Liberati A. The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy. Med Care 1991 Jan;29(1):50-63.

Guidozzi F, Sonnendecker EW. Evaluation of preoperative investigations in patients admitted for ovarian primary cytoreductive surgery. Gynecol Oncol 1991 Mar;40(3):244-7.

Hallenbeck P, Sanniez CK, Ryan AB, Neiley B, Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy. Treatment for peritoneal carcinomatosis. AORN J 1992 Jul; 56(1):50-7, 60-72.

Hammond RH, Houghton CR. The role of bowel surgery in the primary treatment of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 1990 May;30(2):166-9.

Hricak H. Role of imaging in the evaluation of pelvic cancer. Important Adv Oncol 1991:103-33.

Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990 Oct; 97(10):922-9.

Johnson RJ, Blackledge G, Eddleston B, Crowther D. Abdomino-pelvic computed tomography in the management of ovarian carcinoma. Radiology 1983 Feb;146(2):447-52.

Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991 Jun;10(6):295-7. Comment in: J Ultrasound Med 1992 Mar;11(3):80.

La Fianza A, Campani R, Dore R, Babilonti L, Tateo S. The clinical value of computed tomography and lymphography in detecting lymph node metastases from epithelial ovarian cancer. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992 Aug; 157(2):162-6.

Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988 Aug;159(2):341-6.

Penalver M, Averette H, Sevin BU, Lichtinger M, Girtanner R. Gastrointestinal surgery in gynecologic oncology: evaluation of surgical techniques. Gynecol Oncol 1987 Sep;28(1):74-82.

Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med

1991 Aug 22;325(8):525-32. Comment in: N Engl J Med 1991 Aug 22;325(8):573-5; Comment in: N Engl J Med 1992 Jan 23;326(4):273; discussion 274; N Engl J Med 1992 Jan 23; 326(4):273-4.

Russell AH, Anderson M, Walter J, Kinney W, Smith L, Scudder S. The integration of computed tomography and magnetic resonance imaging in treatment planning for gynecologic cancer. Clin Obstet Gynecol 1992 Mar;35(1):55-72.

Schwartz PE. An oncologic view of when to do endoscopic surgery. Clin Obstet Gynecol 1991 Jun;34(2):467-72.

Solla JA, Rothenberger DA. Preoperative bowel preparation. A survey of colon and rectal surgeons. Dis Colon Rectum 1990 Feb;33(2):154-9.

Taylor PT, consultant. Advanced ovarian cancer: principles of management. In: Wanabo HJ, ed. Common problems in cancer surgery. Chicago: Year Book; 1990. p.280-4.

Whitley N, Brenner D, Francis A, Kwon T, Villasanta U, Aisner J, Wiernik P, Whitley J. Use of the computed tomographic whole body scanner to stage and follow patients with advanced ovarian carcinoma. Invest Radiol 1981 Nov-Dec;16(6): 479-86.

Principles of Primary Surgery

Aalders JG, Neijt JP. Aspects of surgery in ovarian and endometrial carcinoma. Eur J Cancer 1993;29A(4): 624-8.

Archer JC, Soeters RP, Bloch B, Dehaeck CM, Levin W. Repeat laparotomy in ovarian carcinoma after primary surgery. S Afr Med J 1991 Sep 21; 80(6):276-7.

Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Karnell LH, Winchester DP. National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 1993 Feb 15;71 (4 Suppl):1629-38.

Brand E, Lidor Y. The decline of CA 125 level after surgery reflects the size of residual ovarian cancer. Obstet Gynecol 1993 Jan;81(1):29-32.

Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990 Nov;39(2): 115-8.

Bridges JE, Leung Y, Hammond IG, McCartney AJ. En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: The KEMH experience. Int J Gynecol Cancer 1993;3(4): 199-202.

Buchsbaum HJ, Lifshitz S. Staging and surgical evaluation of ovarian cancer. Semin Oncol 1984 Sep;11(3):227-37.

Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991 Feb;40(2):103-6.

Fioretti P, Gadducci A, Del Bravo B, Prato B. The potential of primary cytoreductive surgery in patients with FIGO stages III and IV ovarian carcinoma. Eur J Gynaecol Oncol 1990;11(3): 175-9.

Fontanelli R, Paladini D, Raspagliesi F, di Re E. The role of appendectomy in surgical procedures for ovarian cancer. Gynecol Oncol 1992 Jul;46(1):42-4.

Hacker NF. Surgery for gynaecological cancer: results since the introduction of radical operations. Aust N Z J Obstet Gynaecol 1990 Feb;30(1):24-8.

Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992 Jun;45(3):284-9.

Hand R, Fremgen A, Chmiel JS, Recant W, Berk R, Sylvester J, Sener S. Staging procedures, clinical management, and survival outcome for ovarian carcinoma. JAMA 1993 Mar 3;269(9):1119-22. Comment in: JAMA 1993 Mar 3;269(9):1163 and JAMA 1993 Sep 8;270(10):1196-7.

Heintz AP. Cytoreductive surgery for ovarian cancer. In: Greer BE, Berek JS, eds. Gynecologic oncology: treatment rationale and techniques. New York: Elsevier; 1991. p. 135-48.

Hoskins WJ. Primary cytoreduction. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 163-73.

Hoskins WJ. Primary surgical management of advanced epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 241-53.

Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993 Feb 15; 71(4 Suppl):1534-40.

Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992 Nov;47(2): 159-66.

Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.

Hudson CN, Potsides P, Curling OM. An audit of surgical treatment of ovarian cancer in a metropolitan health region. Association of Obstetricians and Gynaecologists of the North East Thames Region. J R Soc Med 1991 Apr;84(4): 206-9.

Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992 Feb;166(2):504-11. Comment in: Am J Obstet Gynecol 1993 Jul;169(1):236-7.

Jadhon ME, Morgan MA, Kelsten ML, Carlson JA Jr, Mikuta JJ. Cytologic smears of peritoneal surfaces as a sampling technique in epithelial ovarian carcinoma. Obstet Gynecol 1990 Jan;75(1):102-5.

Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol 1990 Nov; 39(2):135-8.

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Itamochi H, Terakawa N. Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer. Eur J Surg Oncol 1993 Jun;19(3):273-8.

Kirschner CV, DeSerto TM, Isaacs JH. Surgical treatment of the elderly patient with gynecologic cancer. Surg Gynecol Obstet 1990 May;170(5): 379-84.

Lawton F, Luesley D, Redman C, Chan KK, Varma R, Blackledge G. Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer. J Surg Oncol 1990 Sep; 45(1):14-9.

Luesley DM, Williams DR, Ward K, Redman CR, Lawton FG. Prospective comparative cytologic study of direct peritoneal smears and lavage fluids in patients with epithelial ovarian cancer and benign gynecologic disease. Acta Cytol 1990 Jul-Aug; 34(4):539-44.

Magli G, De Marco I, Biello A, Turtoro L, Esposito A. Regional surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1992;13(1 Suppl):97-8.

Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993 Apr; 49(1):86-91.

Markman M. Surgeon's skill key to ovarian cancer management. Cleve Clin J Med 1993 May-Jun; 60(3):183-4.

Mayer AR, Chambers SK, Graves E, Holm C, Tseng PC, Nelson BE, Schwartz PE. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992 Nov;47(2):223-7.

McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993 Jan 15;71(2 Suppl):628-33.

Menczer J. Cytoreductive surgery in the treatment of advanced ovarian carcinoma. Some controversial aspects. Eur J Gynaecol Oncol 1992;13(3):246-55.

Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993 Jan;11(1):166-72.

Nishimura H, Hamaguchi K, Miyahara K, Tazaki T, Tateno N, Yakushiji M. The current therapeutic approaches to advanced ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12): 1691-6.

Obiakor I, Maiman M, Mittal K, Awobuluyi M, DiMaio T, Demopoulos R. The accuracy of frozen section in the diagnosis of ovarian neoplasms. Gynecol Oncol 1991 Oct;43(1):61-3.

Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S. Clinical experience in gynecological cancer management. d). Ovarian tumors--1) Epithelial: report from the Gynaecological Institutes of Padua University (1963-1990). Eur J Gynaecol Oncol 1992;13(1):17-33.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Partridge EE, Gunter BC, Gelder MS, Alvarez RD, Soong SJ, Austin JM, Kilgore LC. The validity and significance of substages of advanced ovarian cancer. Gynecol Oncol 1993 Feb;48(2):236-41.

Penalver M, Averette H, Sevin BU, Lichtinger M, Girtanner R. Gastrointestinal surgery in gynecologic oncology: evaluation of surgical techniques. Gynecol Oncol 1987 Sep;28(1):74-82.

Petru E, Pickel H, Tamussino K, Lahousen M, Heydarfadai M, Posawetz W, Jakse R. Pretherapeutic scalene lymph node biopsy in ovarian cancer. Gynecol Oncol 1991 Dec; 43(3):262-4.

Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck S. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet 1991; 249(2):87-93.

Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991 Mar;40(3):195-200.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A. Prognostic factors in ovarian cancer. Eur J Gynaecol Oncol 1990;11(3):171-3.

Rose PG. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992 Mar;166(3):843-6. Comment in: Am J Obstet Gynecol 1993 Feb;168(2):736.

Rose PG, Reale FR, Fisher A, Hunter RE. Appendectomy in primary and secondary staging operations for ovarian malignancy. Obstet Gynecol 1991 Jan;77(1):116-8.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):851-65.

Scott NA, Schofield PF. Cytoreductive surgery for ovarian carcinoma. Br J Surg 1990 May;77(5): 481-2.

Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 1991 Jun;41(3):239-44. Comment in: Gynecol Oncol 1992 Jul;46(1):138.

Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992 Dec;80(6):949-53.

Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K, Saito T, Kaku T, To N, Nakano H. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer--a multivariate analysis. Gynecol Oncol 1993 Apr;49(1):51-5.

Tummarello D, Menichetti ET, Miseria S, Torresi U, Guidi F, Gramazio A, Vissani L, Cellerino R. Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy. J Chemother 1990 Aug;2(4): 260-3.

Unzelman RF. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital. Am J Obstet Gynecol 1992 Jun;166(6 Pt 1):1663-71; discussion 1671-2.

Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II. Acta Obstet Gynecol Scand 1992 Jul; 71(5):361-7.

Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992 Feb;79(2): 168-72. Comment in: Obstet Gynecol 1992 Jul; 80(1):155-6.

Vergote IB. Surgery for gynecologic malignancies. Curr Opin Oncol 1993 Sep;5(5):877-84.

Wils JA. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. Oncology 1990;47(2):115-20.

Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet 1990 Mar;170(3):276-81.

Yedema CA, Kenemans P, Thomas CM, Massuger LF, Wobbes T, Verstraeten R, van Kamp GJ, Hilgers J. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 1993;29A(7): 966-71.

Primary Adjuvant Chemotherapy

Abel U. Chemotherapy of advanced epithelial cancer - A critical review. Biomed Pharmacother 1992; 46(10):439-52.

Alberts DS, Canetta R, Mason-Liddil N. Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 1990 Feb;17(1 Suppl 2):54-60.

Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 1993 Jan 15; 71(2 Suppl):618-27.

Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992 May;10(5):706-17. Published erratum appears in J Clin Oncol 1992 Sep;10(9):1505. Comment in: J Clin Oncol 1992 May;10(5):683-5.

Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol 1993 Aug;50(2):215-20.

Araujo CE, Cervellino JC, Pirisi C, Pannunzio O, Callegari J. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer. J Surg Oncol 1991 Mar;46(3):198-202.

Barrett RJ, Muss HB. Gynecologic malignancies. In: Lokich JJ, ed. Cancer chemotherapy by infusion. 2nd ed. Chicago; Precept Press; 1990. p.463-83.

Belinson JL, Lee KR, Jarrell MA, McClure M. Management of epithelial ovarian neoplasms using a platinum-based regimen: a 10-year experience. Gynecol Oncol 1990 Apr;37(1):66-73.

Beller U, Speyer J, Colombo N, Sorich J, Wernz J, Hochster H, Zeleniuch-Jacquotte A, Porges R, Beckman EM. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. J Clin Oncol 1991 May;9(5):809-17.

Bertelsen K, Bastholt L. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study. Gynecol Oncol 1992 Jan;44(1):79-82.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993 Jan 15;71(2 Suppl): 594-600.

Bruckner HW, Cohen C, Mandeli J, Chesser MR, Kabakow B, Wallach R, Holland J. Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience. Cancer Treat Rev 1991 Mar;18 Suppl A:57-65.

Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990 Jun;37(3):327-31.

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 1991 Oct 12; 303(6807):884-93. Comment in: BMJ 1991 Nov 16; 303(6812):1269 and BMJ 1992 Jan 11; 304(6819): 119.

Cherchi PL, Bagella MP, Campiglio A, Rubattu A, Farina M, Ambrosini A. Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes. Eur J Gynaecol Oncol 1990; 11(6):453-6.

Cheson BD. Clinical trials referral resource. Ovarian cancer. Oncology (Huntingt) 1990 Aug;4(8):69-75.

Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone M, Sertoli MR, Parodi GC, Ragni N, Foglia G, Odicino F, et al. Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience. Eur J Cancer 1991;27(10): 1211-5. Comment in: Eur J Cancer 1991;27(10): 1196.

Conte PF. Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. Bull Cancer 1993;80(2):152-5.

Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V, Fioretti P, Foglia G, Gadducci A, Gallo L, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1991 Apr;9(4):658-63.

Cornelison TL, Reed E. Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer 1993 Jan 15;71(2 Suppl): 650-5.

Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RCJr, Fujii S, Long HJ 3d, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia 1992;19(3-4):131-49.

Creasman WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, Beecham J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1990 Dec;39(3):239-43.

Cruickshank DJ, Paul J, Lewis CR, McAllister EJ, Kaye SB. An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Br J Cancer 1992 Apr; 65(4):597-600.

Cruickshank DJ, Terry PB, Fullerton WT. CA125-response assessment in epithelial ovarian cancer. Int J Cancer 1992 Apr 22;51(1):58-61.

Cruickshank DJ, Terry PB, Fullerton WT. The potential value of CA125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer. Int J Biol Markers 1991 Oct-Dec;6(4): 247-52.

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991 Sep;9(9):1668-74.

Davidson NG, Khanna S, Kirwan PH, Bircumshaw D. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1991 Jan;3(1): 32-6.

Davidson NG, Khanna S, Kirwan PH, Naftalin NJ, Roy UK, Chui D, Mitchell S. Long-term survival after chemotherapy with cisplatinum, adriamycin and cyclophosphamide for carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1990 Jul;2(4):206-9.

de Oliveira CF, Lacave AJ, Villani C, Wolff JP, di Re F, Namer M, Maskens A, George M, Dalesio O, Rotmensz N, et al. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study. Eur J Gynaecol Oncol 1990;11(5):323-30.

de Vries EG, Biesma B, Willemse PH, Mulder NH, Stern AC, Aalders JG, Vellenga E. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991 Jan 1;51(1):116-22.

Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer 1993 Jan 15;71(2 Suppl):615-7.

Eiermann W, Achterrath W, Lenaz L, Hepp H. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother Pharmacol 1991;27(5):389-93.

Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992 Dec;80(6):954-60. Comment in: Obstet Gynecol 1993 Apr;81(4):641-2.

Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE. The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993 Jul;68(1):140-5.

Gadducci A, Brunetti I, Bruzzone M, Carnino F, Chiara S, Conte PF, Fioretti P, Foglia G, Ragni N. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO). Eur J Gynaecol Oncol 1992;13(1 Suppl): 36-9.

Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Facchini V, Bianchi R, Fioretti P. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma. Eur J Gynaecol Oncol 1990; 11(2):127-33.

Gadducci A, Ferdeghini M, Cristofani R, Fioretti P. Comparison of common clinico-pathological prognostic variables and serum CA 125 assay as predictors of clinical outcome in patients with advanced ovarian carcinoma. Ital J Gynaecol Obstet 1993;5(1):16-23.

Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Burke TW, Morris M, Kavanagh JJ, Warner D, Wharton JT. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer 1993 Jan 15;71(2 Suppl):638-43.

Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh JJ, Morris M, Burke TW, Warner D, Wharton JT. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: maintenance therapy reconsidered. Gynecol Oncol 1992 Oct;47(1):7-13. Comment in: Gynecol Oncol 1992 Oct;47(1):5-6.

Gershenson DM, Silva EG, Mitchell MF, Atkinson EN, Wharton JT. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 1993 Apr;168(4):1178-85; discussion 1185-7.

Goodman HM, Harlow BL, Sheets EE, Muto MG, Brooks S, Steller M, Knapp RC, Berkowitz RS. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992 Sep;46(3):367-71.

Greco FA, Johnson DH, Hainsworth JD. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. Cancer Treat Rev 1991 Mar;18 Suppl A:47-55.

Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1991 Oct;9(10):1793-800.

Hainsworth JD, Burnett LS, Jones HW 3d, Grosh WW, Johnson DH, Greco FA. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J Clin Oncol 1990 Mar;8(3):502-8. Comment in: J Clin Oncol 1990 Jul;8(7):1287-8.

Hainsworth JD, Jones HW 3d, Burnett LS, Johnson DH, Greco FA. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). Am J Clin Oncol 1990 Oct;13(5):410-5.

Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur J Gynaecol Oncol 1992;13(1):35-44.

Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 1993 Nov;50 Suppl 2:2-9.

Harding M, Milsted R, Hole D, Cordiner J, Barr W, Soukop M, Kennedy J, Soutter WP, Kaye S. Long term results of cyclophosphamide, adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer. Ann Oncol 1991 Mar;2(3):231-3.

Hardy JR, Wiltshaw E, Blake PR, Harper P, Slevin M, Perren TJ, Tan S. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol 1991 Feb;2(2):131-6.

Harvey VJ, Evans BD, Mitchell PL, Mak D, Neave LM, Langley GB, Dickson DS. Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 1991 Jun;63(6):942-4.

Heintz AP. Sequential cisplatin--doxorubicin, early debulking in advanced ovarian cancer. Eur J Cancer 1992;28A(6-7):1009-10.

Hempling RE, Piver MS, Natarajan N, Baker TR, Thompson JM, Hicks ML, Mettlin CJ. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer. J Surg Oncol 1993 Sep;54(1):38-44.

Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993 Jan;48(1):38-49.

Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69(5):423-9.

Homesley HD, Harry DS, O'Toole RV, Hoogstraten B, Franklin EW, Cavanagh D, Nahhas WA, Smith JJ, Lovelace JV. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial. Am J Clin Oncol 1992 Apr;15(2):129-34.

Hoskins PJ, O'Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992 Oct;10(10):1561-8. Comment in: J Clin Oncol 1993 Mar;11(3):587-8.

Hoskins WJ. Treatment strategies for advanced ovarian cancer. In: Greer BE, Berek JS, eds. Gynecologic oncology: treatment rationale and techniques. New York: Elsevier; 1991. p. 149-66.

Hunter RE, Griffin TW, Stevens S, Roman LD, Bokhari F, Reale FR, Tak WK, Fitzgerald TJ, Dillon MB, Rose PG. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer. Cancer 1991 Nov 1;68(9):1890-4.

Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990 Oct;163(4 Pt 1):1164-7. Comment in: Am J Obstet Gynecol 1991 Sep; 165(3):779.

Inoue M, Nakanishi K, Ueda G, Tanizawa O. Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer. Am J Clin Oncol 1992 Feb;15(1):1-6.

Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, Nakamuro K, Tani T, Okudaira Y, Karita T, et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy 1993;6(1):13-8.

Iversen OE. Modern cytostatic therapy and survival in ovarian carcinoma (1). Acta Obstet Gynecol Scand 1993;72(1):69.

Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991 Aug;42(2): 146-50.

Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992 Apr;10(4):520-8. Comment in: J Clin Oncol 1992 Apr;10(4):513-4.

Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990 Jan 4;322(1):1-6. Comment in: N Engl J Med 1990 Jan 4;322(1):52-3.

Karrer K, Salzer H, Sevelda P, Dittrich C. The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group. Cancer Chemother Pharmacol 1990; 26 Suppl:S30-2.

Kaye SB. Chemotherapy for ovarian cancer. Eur J Cancer 1993;29A(4):632-5.

Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992 Aug 8; 340(8815):329-33. Comment in: Lancet 1992 Sep 12;340(8820):678-9.

Kehoe S, Redman C, Varma R, Buxton J, Luesley D, Blackledge G, Stanley A. Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma. Br J Cancer 1992 Oct;66(4):717-9.

Kjorstad K, Harris A, Bertelsen K, Slevin M, Schultz H, Hellman K, Janssens N, Martin A, Canetta R. A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992 Mar;3(3):217-22.

Kolb BA, Buller RE, Connor JP, DiSaia PJ, Berman ML. Effects of early postoperative chemotherapy on wound healing. Obstet Gynecol 1992 Jun;79(6): 988-92. Comment in: Obstet Gynecol 1992 Oct; 80(4):730.

Krommer CF, Szalai JP. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study. Ann Oncol 1992 Jan;3(1):37-9.

Krommer CF, Szalai JP. A review of 28 years of treating advanced ovarian cancer. Anticancer Res 1993 May-Jun;13(3):817-25.

Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 1993 Mar;11(3):440-8.

Lawton F, Meanwell C, Mould J, Blackledge G. A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer. Gynecol Oncol 1990 Jan;36(1):19-22.

Lawton FG, Hilton C, Mould JJ, Chan KK, Blackledge G. Short-duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer. Gynecol Oncol 1991 Mar;40(3):225-9.

Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 1993 Nov 3;85(21):1732-42.

Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 1993;5(4):198-202.

Locatelli MC, D'Antona A, Carcione R, Cesana B, Dallavalle G, Vinci M, Clerici M, Labianca R, Pasquinucci C, Luporini G. A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results. Oncology 1993 Mar-Apr;50(2):92-9.

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy. Gynecol Oncol 1992 May; 45(2):115-7.

Lund B. Clinical and prognostic features of advanced ovarian carcinoma. Dan Med Bull 1993;40(5): 537-45.

Lund B, Hansen M, Hansen HH, Thomsen HK, Sorensen BL, Nielsen NC, Lundvall F. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma. Ann Oncol 1990;1(2):134-40.

Lund B, Hansen M, Hansen OP, Hansen HH. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990 Jul;8(7):1226-30.

Lund B, Hansen OP, Hansen HH, Hansen M. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 1):26-9.

Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991 Apr;2(4):281-7. Comment in: Ann Oncol 1991 Apr;2(4):245-7.

Makar AP, Kristensen GB, Bormer OP, Trope CG. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993 Apr;49(1):73-9.

Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992 Jun;79(6):1002-10.

Malviya VK, Deppe G, Boike G, Young J. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. Gynecol Oncol 1990 Feb;36(2):185-8.

Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993 Apr; 49(1):86-91.

Markman M, Lewis JL Jr, Saigo P, Hakes T, Jones W, Rubin S, Reichman B, Barakat R, Curtin J, Almadrones L, et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1993 Jan 15; 71(2 Suppl):634-7.

Markmann M, Rothman R, Reichman B, Hakes T, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol 1991;117(2): 89-90.

Markowska J, Kopczynski Z, Manys G, Szewierski Z. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment. Neoplasma 1990;37(6):687-92.

Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a marker of ovarian cancer. Eur J Gynaecol Oncol 1992;13(4):360-5.

Markowska J, Manys G, Szewierski Z. CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study. Eur J Gynaecol Oncol 1992;13(2):201-4.

Martoni A, Ercolino L, Bellucco A, Canova N, Lelli G, Pannuti F. Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer. J Chemother 1990 Feb;2(1):62-6.

Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. J Chemother 1993 Feb;5(1):47-51.

Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E, Rostom AY, Menday AP. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol 1990 Apr;97(4):342-51.

McGuire WP. Primary chemotherapy of epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 255-68.

McGuire WP. Primary treatment of epithelial ovarian malignancies. Cancer 1993 Feb 15;71(4 Suppl): 1541-50.

McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. Semin Oncol 1991 Jun;18(3): 255-69.

Mirshahi SS, Pujade-Lauraine E, Soria C, Mirshahi M, Fretault J, Bernadou A, Soria J. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer 1992 May 1;69(9):2289-92.

Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992 Mar;44(3): 207-12. Comment in: Gynecol Oncol 1992 Mar; 44(3):205 and Gynecol Oncol 1992 Oct;47(1): 131-2.

Mogensen O, Mogensen B, Jakobsen A. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol 1990 Apr; 37(1):44-6.

Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi H, Nakashima N, Ishizuka T, Furuhashi Y, Hattori SE, Kuzuya K, et al. Clinical remission criteria for epithelial carcinoma of the ovary. Gynecol Oncol 1993 Mar;48(3):342-8.

Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M, Patel U, Dougal M, Buckley CH, Tindall VR. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993 May;4(5):377-83.

Nash JD, Young RC. Gynecologic malignancies. Cancer Chemother Biol Response Modif 1991; 12:549-69.

Neijt JP. Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 1992 Jan; 3(1):17-27.

Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27(11):1367-72.

Ng LW, Rubin SC, Hoskins WJ, Jones WB, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL Jr. Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990 Sep;38(3):358-63.

Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993 Dec 15;72(12):3663-70.

Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993 Nov 15; 72(10):3007-11.

Nishida T, Nagasue N, Yakushiji M. Treatment of gynecological malignancies with a combination of cisplatin, Adriamycin and ifosfamide. Cancer Chemother Pharmacol 1990;26 Suppl:S39-42.

Ojeda-Gonzalez MB, Alvarez-Lopez I, Alonso-Munoz MC, Badia-Serra J, Delgado-Latre E, de Andres-Basauri L, Lopez-Lopez JJ. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look. Oncology 1991;48(1):7-12.

Omura GA, Brady MF, Fanning J, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma (1). Obstet Gynecol 1993; 81(4):641-2.

Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991 Jul; 9(7):1138-50.

Omura GA, Buyse M, Marsoni S, Bertelsen K, Conte PF, Jakobsen A, Vermorken J. Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9(9):1668-74.

Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S. Clinical experience in gynecological cancer management. d). Ovarian tumors--1) Epithelial: report from the Gynaecological Institutes of Padua University (1963-1990). Eur J Gynaecol Oncol 1992;13(1):17-33.

Ozols RF. Advances in the chemotherapy of gynecologic malignancies. Hematol Oncol 1992 Jan-Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the treatment of ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990; 6(6):328-38.

Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev 1991 Mar;18 Suppl A:77-83.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment of ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.

Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991 Jun;18(3):222-32.

Panici PB, Greggi S, Scambia G, Baiocchi G, Lomonaco M, Conti G, Mancuso S. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-Year survival analysis and neurological follow-up. Int J Gynecol Cancer 1993; 3(1):44-53.

Perren TJ, Wiltshaw E, Harper P, Slevin M, Stein R, Tan S, Gore M, Fryatt IJ, Blake PR. A randomised study of carboplatin vs sequential ifosfamide/ carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. Br J Cancer 1993; 68(6):1190-4.

Petru E, Pickel H, Heydarfadai M, Lahousen M. Remission induction with carboplatin-epirubicin-prednimustine followed by consolidation radiotherapy in advanced ovarian cancer. Int J Clin Pharmacol Res 1992;12(4):205-7.

Petru E, Pickel H, Lahousen M, Boike G, Heydarfadai M. Combination chemotherapy in radically operated advanced ovarian cancer. Cancer Treat Rev 1990 Sep;17(2-3):329-34.

Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck S. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet 1991; 249(2):87-93.

Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries F, Kains JP, Gobert P, Domange AM, Sculier JP, Gompel C. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. J Natl Cancer Inst 1990 Apr 18;82(8):703-7.

Pinto V, Marinaccio M, Miniello G, Cagnazzo G. Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer. Eur J Gynaecol Oncol 1993; 14(4):302-7.

Piura B, Glezerman M, Cohen Y. Experience in the treatment of epithelial ovarian carcinoma with cisplatinum-containing combination chemotherapy and dose intensity calculation. Eur J Gynaecol Oncol 1990;11(5):389-93.

Piver MS, Malfetano J, Hempling RE, Baker TR, Driscoll DL. Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a preliminary report. Gynecol Oncol 1990 Dec;39(3):249-52.

Plaxe SC, Dottino PR, Cohen CJ. Therapeutic and metabolic effects of high (greater than 1 g/m2) systemic cumulative doses of cis-platinum in patients with ovarian carcinoma. Gynecol Oncol 1990 May;37(2):250-3.

Poka R, Hernadi Z, Juhasz B, Lampe L. Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. Int J Gynaecol Obstet 1993 Jul;42(1):19-24.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G, Lucarelli C. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan ID, Fullerton W, et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992 Feb;65(2):275-81.

Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990;26(5):593-6.

Reed E, Jacob J, Brawley O. Measures of renal function in patients with cisplatin-related chronic renal disease. J Natl Med Assoc 1991 Jun; 83(6):522-6.

Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC, Ozols RF, VanderMolen L, Kohn E, Jacob JL, et al. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993 Nov;11(11): 2118-26.

Repetto L, Chiara S, Pace M, Guido T, Bruzzone M, Oliva C, Murolo C, Conte PF, Rosso R. Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. Tumori 1990 Jun 30; 76(3):274-7.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993;29A(2):181-4.

Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 1993 Jun; 11(6):1156-64.

River MS, Fanning J, Sprance HE. Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery. J Surg Oncol 1991 Sep;48(1):39-44.

Rosen A, Sevelda P, Klein M, Spona J, Beck A. A CA125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 1990;247(3): 125-9.

Rubin SC, Curtin JP. Surgery for gynecologic malignancies. Curr Opin Oncol 1992 Oct;4(5): 923-9.

Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F, Guarnieri G, Carollo F, Leonardi V, Meli M, Gebbia N, et al. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma. Eur J Gynaecol Oncol 1993;14(3):228-33.

Rustin GJ. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary. Dis Markers 1991 May-Aug;9(3-4):153-8.

Rustin GJ, Nelstrop A, Stilwell J, Lambert HE. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 1992;28(1):79-82.

Saksela E. Prognostic markers in epithelial ovarian cancer. Int J Gynecol Pathol 1993 Apr;12(2): 156-61.

Sawada M, Yamasaki M, Urabe T, Ozaki M, Yanagita T, Takayama K, Taki I. Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.

Asia Oceania J Obstet Gynaecol 1990 Dec;16(4): 315-21.

Schneider J, Martin M, Erasun F, Matia JC, Rodriguez-Escudero FJ. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy. Oncology 1990;47(2):109-11.

Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results. Cancer Treat Rev 1991 Mar;18 Suppl A:37-46.

Sevelda P, Dittrich C, Kurz C, Schemper M, Haider F, Denison U, Breitenecker G, Czerwenka K, Salzer H. Prospective randomized trial of sequential alternating chemotherapy in advanced ovarian carcinoma. Onkologie 1992;15(4):288-92.

Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990 Feb 15;65(4):870-3.

Shimizu Y, Hasumi K. Treatment of ovarian cancer at FIGO stage III and IV - Prognostic factors for patients receiving neoadjuvant chemotherapy. Acta Obstet Gynaecol Jpn 1993;45(7):665-72.

Smith DB, Rustin GJ, Howells N, Lambert HE, McQuade B. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group. Ann Oncol 1991 Sep;2(8): 607-8.

Smyth JF, Beattie GJ, Stewart ME, Cowie VJ, Smart GE, Livingstone JR, Leonard RC. Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer. Ann Oncol 1991 Nov-Dec;2(10):755-8.

Sorbe B, Hallen C. Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. Eur J Gynaecol Oncol 1991;12(1):31-7.

Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 1991;28(5):397-401.

Stoot J, Wils J, von Geuns H, Smeets J, Schouten L. Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands. Cancer Invest 1993;11(1):1-5.

Sweetenham JW, McKendrick JJ, Jones DH, Whitehouse JM, Williams CJ. High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study. Br J Cancer 1990 Feb;61(2):319-22.

Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992 May;10(5):718-26. Comment in: J Clin Oncol 1992 May;10(5):683-5.

Swenerton KD, Pater JL. Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. Semin Oncol 1992 Feb; 19(1 Suppl 2):114-9.

Takada M, Usui N, Yoshida K, Hirayama H, Suzuki M, Takeuchi H, Wada H, Iwasa T, Yamamoto T, Nagasawa I. Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors. Acta Obstet Gynaecol Jpn 1990;42(4): 333-8.

Tattersall MH, Swanson CE, Solomon HJ. Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. Gynecol Oncol 1992 Dec;47(3): 292-7.

Tedeschi M, De Cesare A, Oriana S, Perego P, Silva A, Venturino P, Zunino F. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Cancer Treat Rev 1991 Dec;18(4): 253-9.

Teeling M, Carney DN. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer. Eur J Gynaecol Oncol 1990;11(3):219-24.

Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2): 102-6.

ten Bokkel Huinink WW, Dalesio O, Rodenhuis S, Dubbelman R, Hilton A, Franklin H, Koier I, van Tinteren H, van der Burg ME, van Oosterom AT, et al. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. Semin Oncol 1992 Feb;19(1 Suppl 2): 99-101.

Thigpen JT. Chemotherapy in the management of celomic epithelial carcinoma of the ovary. In:

Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 277-86.

Tibben JG, Schijf CP, Beex LV. Results of cyclophosphamide and cisplatin combination chemotherapy in patients with ovarian carcinoma. Eur J Gynaecol Oncol 1992;13(4):331-9.

Torri V, Korn EL, Simon R. Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer 1993 Jan;67(1):190-7.

Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst 1992 Mar 18; 84(6):407-14. Comment in: J Natl Cancer Inst 1992 Mar 18;84(6):376-8.

Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992;28A(8-9):1358-61.

Trask C, Silverstone A, Ash CM, Earl H, Irwin C, Bakker A, Tobias JS, Souhami RL. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J Clin Oncol 1991 Jul; 9(7):1131-7.

Unzelman RF. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital. Am J Obstet Gynecol 1992 Jun;166(6 Pt 1):1663-71; discussion 1671-2.

van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990 Oct 15;66(8):1697-702.

van der Hoop RG, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FG, Gispen WH, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990 Jan 11;322(2):89-94. Comment in: N Engl J Med 1990 Jan 11;322(2): 126-7.

Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II. Acta Obstet Gynecol Scand 1992 Jul; 71(5):361-7.

Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet Gynecol Scand 1993;72(8):682-4.

Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumour Biol 1992;13(3): 168-74.

Vermorken JB. High-dose intensity regimens with epirubicin in ovarian cancer. Pathol Biol (Paris) 1992 Nov;39(9):833.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol 1992;13(2):205-8.

Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B, Tripcony L, Free KE. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays. Cancer 1993 Jan 15;71(2):430-8.

Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991 Apr;12(2):91-102.

Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl 1992;155:85-93.

Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992;10(1):1-9.

Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG. CA-125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer 1991;27(8):993-5.

Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries EG, Sleijfer DT. Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 1990 Mar; 26(3):345-52.

Williams CJ. Implications of an overview of chemotherapy in advanced ovarian carcinoma. Br J Cancer 1992;66(2):225-6.

Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992 Feb;19(1 Suppl 2):120-8.

Wils JA. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. Oncology 1990;47(2):115-20.

Wiltshaw E, Perren TJ, Fryatt ID, Blake PR, Harper P, Slevin M. Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group. Cancer Chemother Pharmacol 1990;26 Suppl:S48-50.

Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993 Jun;67(6): 1361-7.

Zambetti M, Gianni L, Di Re F, Spatti G, Fontanelli R, Escobedo A, De Palo G, Bonadonna G. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen. Am J Clin Oncol 1990 Jun;13(3):199-203.

Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D, Dormont D. Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer. Gynecol Oncol 1990 Feb;36(2): 271-6.

Taxanes

Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 1993 Aug;20(4 Suppl 3):31-9.

Bissett D, Kaye SB. Taxol and taxotere--current status and future prospects. Eur J Cancer 1993;29A(9): 1228-31.

Boven E, Venema-Gaberscek E, Erkelens CA, Bissery MC, Pinedo HM. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann Oncol 1993 Apr; 4(4):321-4.

Brown J, McDermott B, Runzer N. Taxol: women with ovarian cancer participate in a new clinical trial. Can Oncol Nurs J 1992 May;2(2):47-50.

Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991 Jul; 9(7):1261-7.

Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 May;11(5):950-8.

Caldas C, McGuire WP 3d. Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol 1993 Aug; 20(4 Suppl 3):50-5.

Cheson BD. Clinical trials referral resource. Clinical trials with taxol. Oncology (Huntingt) 1992 Mar; 6(3):67-70.

Cheson BD. Clinical trials referral resource. Update on taxol trials. Oncology (Huntingt) 1993 Jan;7(1): 63, 66-7.

Cheson BD, Arbuck SG, Phillips PH. Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere). Oncology (Huntingt) 1993 Sep;7(9): 51-2.

Chuang LT, Lotzova E, Cook KR, Cristoforoni P, Morris M, Wharton JT. Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes. Gynecol Oncol 1993 Jun;49(3):291-8.

Cornelissen G, Halberg E, Long HJ 3d, Prem K, Bakken E, Touitou Y, Elg S, Haus E, Halberg F. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background. Chronobiologia 1991 Oct-Dec;18(4):153-66.

Diergarten K, Dreps A. Taxol: A new antineoplastic agent. Onkologie 1993;16(5):329-37.

Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992 Nov; 10(11):1748-53.

Einzig AI, Wiernik PH, Schwartz EL. Taxol: a new agent active in melanoma and ovarian cancer. Cancer Treat Res 1991;58:89-100.

Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 Mar 1; 53(5):1037-42.

Granai CO. Ovarian cancer--unrealistic expectations. N Engl J Med 1992 Jul 16;327(3):197-200. Comment in: N Engl J Med 1993 Mar 4;328(9):663-4 and N Engl J Med 1993 Mar 4;328(9): 664; discussion 664-5.

Gregory RE, DeLisa AF. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 1993 Jun;12(6):401-15.

Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 1993 Nov 1;72(9): 2705-11.

Hamers FP, Pette C, Neijt JP, Gispen WH. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993 Mar 16;233(1):177-8.

Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992 Apr;3(2): 121-4.

Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993 Nov;11(11): 2127-35.

Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993 Mar 17; 85(6):478-83.

Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30(6):444-50.

Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993;24(2):129-38.

Leu JG, Chen BX, Schiff PB, Erlanger BF. Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serum. Cancer Res 1993 Mar 15;53(6):1388-91.

Lubejko BG, Sartorius SE. Nursing considerations in paclitaxel (Taxol) administration. Semin Oncol 1993 Aug;20(4 Suppl 3):26-30.

Markman M. Taxol: an important new drug in the management of epithelial ovarian cancer. Yale J Biol Med 1991 Nov-Dec;64(6):583-90.

Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 1992 Sep;10(9):1485-91.

McGuire WP. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1993 Oct;51(1): 78-85.

McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. Semin Oncol 1991 Jun;18(3): 255-69.

Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W. Design, synthesis and biological activity of protaxols. Nature 1993 Jul 29; 364(6436):464-6.

Ozols RF. Advances in the chemotherapy of gynecologic malignancies. Hematol Oncol 1992 Jan-Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990; 6(6):328-38.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of chemotherapy in the future treatment of ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.

Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993 Oct;19(4): 351-86.

Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992 Dec 2;84(23):1781-8.

Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993 May;11(5):885-90.

Pokalo CL. The promise of taxol. Todays OR Nurse 1992 Dec;14(12):31-2.

Rowinsky EK, Citardi MJ, Noe DA, Donehower RC. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993;119(12):727-33.

Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 1993 Aug;20(4 Suppl 3):16-25.

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993 Aug; 20(4 Suppl 3):1-15.

Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991 Sep;9(9):1692-703.

Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992 Apr;10(4):647-56.

Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992 Dec;19(6):646-62.

Runowicz CD, Wiernik PH, Einzig AI, Goldberg GL, Horwitz SB. Taxol in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1591-6.

Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992 Jul;10(7):1165-70.

Sarosy G, Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc 1993 Jun; 85(6):427-31.

Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol 1990 Sep;30(9):770-88.

Steren A, Sevin BU, Perras J, Angioli R, Nguyen H, Guerra L, Koechli O, Averette HE. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993 Feb;48(2):252-8.

Steren A, Sevin BU, Perras J, Ramos R, Angioli R, Nguyen H, Koechli O, Averette HE. Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol 1993 Jul;50(1):89-93.

ten Bokkel Huinink WW, Eisenhauer E, Swenerton K. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. Cancer Treat Rev 1993;19 Suppl C:79-86.

Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22(3):613-7.

Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993 Dec;11(12):2405-10.

Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 1993 Oct 20;85(20):1685-90.

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol 1990 Jul; 8(7):1263-8.

Williams S, Mutch DG, Xu L, Collins JL. Divergent effects of taxol on tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma cells. Am J Obstet Gynecol 1992 Dec;167(6):1870-6.

Workman P, Kaye SB, Schwartsmann G. Laboratory and phase I studies of new cancer drugs. Curr Opin Oncol 1992 Dec;4(6):1065-72. Published erratum appears in Curr Opin Oncol 1993 Mar;5(2):434.

Second-Look Surgery

Aravantinos D, Michalas S, Papazefkos V, Christoforaki M, Stypsaneli A, Vlachos G, Athanasiadis P. Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1990 Dec;37(3):265-70.

Ayhan A, Urman B, Yarali H, Yuce K, Ayhan A. Predictors of recurrent disease after negative second-look laparotomy for epithelial ovarian cancer. J Surg Oncol 1990 Jun;44(2):119-21.

Ayhan A, Yarali H, Develioglu O, Uren A, Ozyilmaz F. Prognosticators of second-look laparotomy findings in patients with epithelial ovarian cancer. J Surg Oncol 1991 Apr;46(4):222-5.

Bar-Am A, Kovner F, Lessing JB, Inbar M, Chaitchik S, Azem F, Brenner SH, Peyser MR. A second thought on second look laparotomy. Acta Obstet Gynecol Scand 1993 Jul;72(5):386-90.

Barakat RR, Rubin SC, Saigo PE, Lewis JL Jr, Jones WB, Curtin JP. Second-look laparotomy in carcinoma of the fallopian tube. Obstet Gynecol 1993 Nov;82(5):748-51.

Barrenetxea G, Martin-Mateos M, Barzazan MJ, Montoya F, Matia JC, Rodriguez-Escudero FJ. Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas. Eur J Gynaecol Oncol 1990;11(5):369-74.

Barter JF, Barnes WA. Second-look laparotomy. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 269-300.

Bell J, Mojzisik C, Hinkle G Jr, Derman H, Schlom J, Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma-detecting probe. Obstet Gynecol 1990 Oct;76(4):607-11.

Bokhman YaV, Vinokurov VL, Gulo EI. The controversial 'second-look' laparotomy. Acta Obstet Gynecol Scand Suppl 1992;155:79-83.

Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M. Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. Eur J Nucl Med 1991;18(4):269-73.

Carson LF, Rubin SC. Secondary cytoreduction--thoughts on the pro side. Gynecol Oncol 1993 Oct; 51(1):127-30.

Cromer DW. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy. Surg Gynecol Obstet 1990;170(4):69.

Davidson NG, Khanna S, Kirwan P, Bircumshaw D. Advanced ovarian cancer: long-term results following chemotherapy and second-look laparotomy. Gynecol Oncol 1990 Dec;39(3):295-9.

Deligdisch L, Kerner H, Cohen CJ, Dargent D, Gil J. Morphometric differentiation between responsive tumor cells and mesothelial hyperplasia in second-look operations for ovarian cancer. Hum Pathol 1993 Feb;24(2):143-7.

Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE, Stanhope CR, Everson LK, Laurie JA, Ebbert LP, Malkasian GD, et al. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989 Oct 4;81(19):1500-4.

Elg SA, Yu Y, Carson LF, Adcock LL, Twiggs LB, Prem KA, Ramakrishnan S. Serum levels of macrophage colony-stimulating factor in patients with ovarian cancer undergoing second-look laparotomy. Am J Obstet Gynecol 1992 Jan; 166(1 Pt 1):134-7.

Friedman JB, Weiss NS. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med 1990 Apr 12;322(15):1079-82.

Gallion HH, Hunter JE, van Nagell JR, Averette HE, Cain JM, Copeland LJ, Higgins RV, Husseinzadeh N, Nahhas WA, Partridge EE, et al. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. Gynecol Oncol 1992 Jul; 46(1):29-32.

Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards CL, Rutledge FN. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985 Mar 1;55(5):1129-35.

Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative second-look laparotomy. Gynecol Oncol 1990 Feb;36(2):172-5.

Goldberg GL, Scheiner J, Friedman A, O'Hanlan KA, Davidson SA, Runowicz CD. Lymph node sampling in patients with epithelial ovarian carcinoma. Gynecol Oncol 1992 Nov;47(2):143-5.

Granowska M, Mather SJ, Britton KE. Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. Int J Rad Appl Instrum [B] 1991;18(4):413-24.

Granowska M, Mather SJ, Jobling T, Naeem M, Burchell J, Taylor-Papadimitriou J, Shepherd J, Britton KE. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int J Biol Markers 1990 Apr-Jun; 5(2):89-96.

Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS, Keeney GL, Roche PC. Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival. Gynecol Oncol 1992 Nov; 47(2):191-5.

Hoskins JH, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989 Sep;34(3):365-71.

Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993 Feb 15; 71(4 Suppl):1534-40.

Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.

Jager W, Feistel H, Paterok EM, Ronay G, Tulusan AH, Wolf F, Lang N. Resection guided by antibodies (REGAJ): a diagnostic procedure during second-look operation in ovarian cancer patients. Br J Cancer Suppl 1990 Jul;10:18-20.

Kamura T, Tsukamoto N, Saito T, Kaku T, Matsuyama T, Nakano H. Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma. Int J Gynaecol Obstet 1990 Oct;33(2):141-7.

Krag DN, Ford P, Smith L, Taylor M, Schneider PD, Bushberg JT, Goodnight JE. Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody. Arch Surg 1993 Jul;128(7):819-23.

Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Andersen J. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989 Jul; 34(1):88-93.

Kudo R, Takashina T, Ito E, Mizuuchi H, Sagae S, Moriwaka O, Tamagawa A. Peritoneal washing cytology at second-look laparotomy in cisplatin-treated ovarian cancer patients. Acta Cytol 1990 Jul-Aug;34(4):545-8.

Lastoria S, Panza N, Esposito G, Vergara E, Castelli L, Caraco C, Battista C, Pacilio G, Salvatore M. Management of patients with ovarian cancer using monoclonal antibodies. Biomed Pharmacother 1992; 46(10):453-63.

Liu L, Hong W, Hou Y, Yao Z, Wu A, Wang X. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125. Chin Med Sci J 1991 Jun;6(2):96-9.

Lund B, Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990 Oct;76(4):617-22.

Makar AP, Kristensen GB, Bormer OP, Trope CG. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992 Jun;45(3):323-8.

Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 1992 Jan 15;69(2):502-10.

Morgan MA, Noumoff JS, King S, Mikuta JJ. A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial. Obstet Gynecol 1992 Dec;80(6):944-8.

Mottolese M, Salzano M, Vincenzoni C, Benevolo M, Bigotti A, Iacovelli A, Lombardi A, Atlante G, Natali PG. The use of a panel of monoclonal antibodies can lower false-negative diagnoses of peritoneal washings in ovarian tumors. Cancer 1991 Oct 15;68(8):1803-7.

Nishimura H, Hamaguchi K, Miyahara K, Tazaki T, Tateno N, Yakushiji M. The current therapeutic approaches to advanced ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12): 1691-6.

Ojeda-Gonzalez MB, Alvarez-Lopez I, Alonso-Munoz MC, Badia-Serra J, Delgado-Latre E, de Andres-Basauri L, Lopez-Lopez JJ. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look. Oncology 1991;48(1):7-12.

Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991 Jul;9(7):1138-50.

Papazefkos V, Michalas S, Papantoniou V, Datseris J, Athanasiadis P, Akrivos T, Leonti A, Xygakis A, Aravantinos D. Comparative study of RIS with the 131I-OC 125 F(ab')2 Mab and CT scan prior to second look operation for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1990 Dec;37(3):271-7.

Patsner B, Orr JW Jr, Mann WJ Jr, Taylor PT, Partridge E, Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990 Jun;37(3):319-22.

Patsner B, Orr JW Jr, Mann WJ Jr, Taylor PT, Partridge E, Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990 Sep;38(3):373-6.

Pectasides D, Kayianni H, Facou A, Bobotas N, Barbounis V, Zis J, Athanassiou A. Correlation of abdominal computed tomography scanning and second-look operation findings in ovarian cancer patients. Am J Clin Oncol 1991 Dec;14(6):457-62.

Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, DeGeest K, Mortel R. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990 Jan;36(1):43-7.

Podratz KC, Kinney WK. Second-look operation in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl): 1551-8.

Podratz KC, Malkasian GD Jr, Hilton JF, Harris EA, Gaffey TA. Second-look laparotomy in ovarian cancer: evaluation of pathologic variables. Am J Obstet Gynecol 1985 May 15;52(2):230-8.

Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS, Lee RA, Stanhope CR, Williams TJ. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988 Mar;29(3):274-82.

Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988 Sep;31(1):9-24.

Potter ME. Secondary cytoreduction in ovarian cancer: pro or con? Gynecol Oncol 1993 Oct;51(1):131-5.

Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr, Shingleton HM. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 1992 Jan;44(1):3-9. Comment in: Gynecol Oncol 1992 Nov;47(2):275.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G, Lucarelli C. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Redman CW, Blackledge G, Lawton FG, Varma R, Luesley DM, Chan KK. Early second surgery in ovarian cancer--improving the potential for cure or another unnecessary operation? Eur J Surg Oncol 1990 Oct;16(5):426-9.

Redman CW, Chapman SE, Chan SY, Buxton EJ, Blackledge G, Luesley DM. Out-patient peritoneal lavage cytology in the detection of residual epithelial ovarian cancer. Cytopathology 1991; 2(6):291-8.

Rose PG, Reale FR, Fisher A, Hunter RE. Appendectomy in primary and secondary staging operations for ovarian malignancy. Obstet Gynecol 1991 Jan;77(1):116-8.

Rubin SC. Second-look laparotomy in ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 175-85.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):851-65.

Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL Jr. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991 Aug;42(2): 137-41.

Scambia G, Panici PB, Baiocchi G, Gallo A, Laurelli G, Iacobelli S, Mancuso S. Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. Cancer 1991 Dec 15;68(12):2582-5.

Second-look surgery for ovarian carcinoma. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 100--November 1991. Int J Gynaecol Obstet 1992 Sep;39(1):61-2.

Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993 Mar;11(3):434-9.

Soeters RP, Bloch B, Dehaeck K, Levin W. The influence of initial residual disease on the outcome of second-look laparotomy in patients with carcinoma of the ovary. Eur J Gynaecol Oncol 1992;13(3):223-7.

Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 1991 Jun;41(3):239-44. Comment in: Gynecol Oncol 1992 Jul;46(1):138.

Tomas C, Kauppila A. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma. Gynecol Oncol 1992 Jun;45(3): 279-83.

Torretta L, Balestreri D, Fasola M, Schinko E, Scorbati E, Tateo S. Diagnostic alternatives to second look in ovarian cancer. Eur J Gynaecol Oncol 1990; 11(2):145-8.

Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst 1992 Mar 18; 84(6):407-14.

Comment in: J Natl Cancer Inst 1992 Mar 18;84(6):376-8.

Tuxen MK, Lund B, Hansen OP, Hansen M. Second-look laparotomy in the management of patients after radical surgery for ovarian cancer. Ann Oncol 1993 Feb;4(2):169-71.

van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992 Feb;40(1-2): 36-51.

van Kranenburg DL, van Kroonenburgh MJ, Trimbos JB, Fleuren GJ, Pauwels EK. Imaging of ovarian cancer with radiolabelled monoclonal antibodies. Arch Gynecol Obstet 1990;247(3):107-16.

Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992 Feb;79(2): 168-72. Comment in: Obstet Gynecol 1992 Jul; 80(1):155-6.

Vergote IB. Surgery for gynecologic malignancies. Curr Opin Oncol 1993 Sep;5(5):877-84.

Vergote IB, Onsrud M, Bormer OP, Sert BM, Moen M. CA125 in peritoneal fluid of ovarian cancer patients. Gynecol Oncol 1992 Feb;44(2):161-5.

Wangensteen OH, Lewis FJ, Tongen LA. The "second-look" in cancer surgery: a patient with colic cancer and involved lymph nodes negative on the "sixth - look." J Lancet 1951 Aug;51(8):303-7.

Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B, Tripcony L, Free KE. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays. Cancer 1993 Jan 15;71(2):430-8.

Williams L. The role of secondary cytoreductive surgery in epithelial ovarian malignancies. Oncology (Huntingt) 1992 Aug;6(8):25-32; discussion 37-9. Comment in: Oncology (Huntingt) 1993 Feb;7(2):21.

Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet 1990 Mar;170(3):276-81.

Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol 1993 Aug; 11(8):1506-10.

FOLLOW-UP AFTER PRIMARY SURGERY

Follow-Up of the Asymptomatic Patient

Beattie GJ, Sturgeon C, Fisken J, Roulston JE. The effect of surgery on the serum concentration of CA125 in epithelial ovarian cancer. Ann Clin Biochem 1993 Jul;30(Pt 4):402-3.

Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T, Merlini L, Parodi S, Bentivoglio G, Ventrella W, et al. CA-125 monitoring in the management of ovarian cancer. Anticancer Res 1990 Sep-Oct;10(5A):1353-9.

Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 1991 Aug;165(2):360-7.

Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992 Oct;47(1):87-92.

Buller RE, Manetta A, Bloss JD, DiSaia PJ, Berman ML. Does intraperitoneal CA-125 reflect disease status? Gynecol Oncol 1991 Jan;40(1):66-9.

Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, Harmer CL, Blake PR, Chilvers CE. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991 Feb 2; 302(6771):259-62. Comment in: BMJ 1991 Mar 30; 302(6779):790.

Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, Mariani G, Bianchi R. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992 Feb;44(2):155-60.

Fisken J, Leonard RC, Badley A, Jonrup I, Aspinall L, Sturgeon C, Roulston JE. Serological monitoring of epithelial ovarian cancer. Dis Markers 1991 May-Aug;9(3-4):175-90.

Gerli M, Palumbo R, Angelini A, Gerli S, Brunelli E, Pupita P, Bonaca S, Spagnolo W. Immunoscintigraphy in the follow up of patients with ovarian cancer. Eur J Gynaecol Oncol 1990; 11(3):203-4.

Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993 Aug;50(2):202-7.

Hising C, Anjegard IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol 1991 Apr;14(2): 111-4.

Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol 1992 Aug;46(2):191-8.

Jimenez-Vicioso A, Torres M, Jimenez-Heffernan A, Grana MD, Latre JM, Llamas JM, Carreras JL, Mateo A. Immunoscintigraphy with 131I or 111In labelled OC 125 F(ab')2 fragments in patients with ovarian carcinoma. Int J Biol Markers 1990 Oct-Dec;5(4):159-65.

Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi Y, Tomoda Y. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer. Obstet Gynecol 1990 Sep;76(3 Pt 1):417-21.

Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology--a review. Eur J Obstet Gynecol Reprod Biol 1993 Apr;49(1-2):115-24.

Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasmussen K. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990 May;37(2): 279-83.

Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993 Apr; 49(1):3-7. Comment in: Gynecol Oncol 1993 Apr; 49(1):1-2.

Markowska J, Kojczynski Z, Szewierski Z, Manys G. CA 125 in monitoring chemotherapy of the patients with ovarian cancer. Eur J Gynaecol Oncol 1990; 11(3):209-14.

Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a marker of ovarian cancer. Eur J Gynaecol Oncol 1992;13(4):360-5.

Maughan TS, Haylock B, Hayward M, Facey P, Evans WD, Shelley MD, Fish RG, Adams M. OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment. Clin Oncol (R Coll Radiol) 1990 Jul;2(4):199-205.

Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission. Cancer 1992 Oct 1; 70(7):1956-9.

Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 1992 Aug;46(2):222-5.

Ngan HY, Wong LC, Chan SY, Ma HK. Role of CA125 and abdominal pelvic computerized axial tomogram in the monitoring of chemotherapy treatment of ovarian cancer. Cancer Invest 1990; 8(5):467-70.

Nishimura H, Tashiro M, Hamaguchi K, Kiyozuka Y, Ide H, Tateno N, Miyoshi T, Yakushiji M. Significance of the serum CA125 level in recurrent ovarian cancer. Asia Oceania J Obstet Gynaecol 1992 Mar;18(1):37-43.

Oncoscint for detection of disseminated colorectal and ovarian cancer. Med Lett Drugs Ther 1993 Jun 11; 35(898):52-3.

Patsner B. Is there a role for CT scanning to monitor therapy of optimally debulked patients with advanced ovarian epithelial cancer? Int J Gynecol Cancer 1994;4(1):19-21.

Peltier P, Dutin JP, Chatal JF, Fumoleau P, Bourguet P, Liehn JC, Vuillez JP, Herry JY, Loboguerrero A. Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay). Ann Oncol 1993 Apr;4(4): 307-11.

Peltier P, Wiharto K, Dutin JP, Chatal JF, Bourguet P, Liehn JC, Vuillez JP, Herry JY, Loboguerrero A. Correlative imaging study in the diagnosis of ovarian cancer recurrences. The INSERM Research Network (Nantes, Rennes, Reims, Villejuif, Saclay, France). Eur J Nucl Med 1992;19(12):1006-10.

Perkins AC, Powell MC, Wastie ML, Scott IV, Hitchcock A, Worthington BS, Symonds EM. A prospective evaluation of OC125 and magnetic resonance imaging in patients with ovarian carcinoma. Eur J Nucl Med 1990;16(4-6):311-6.

Pirtoli L, Risso G, Inaudi P, Landoni F, Pepi F, Bindi M, Tucci E, D'Antona N, Mangioni C. A role for tumor markers in therapeutic decisions after chemotherapy induction of objective remission in stage III epithelial ovarian neoplasms. Int J Biol Markers 1991 Apr-Jun;6(2):107-14.

Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, Schima W, Poelzleitner D, Reinthaller A, Koelbl H, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 1993 Jul-Aug;17(4):626-32.

Prayer L, Stiglbauer R, Kramer J, Wimberger D, Poelzleitner D, Schima W, Kainz C, Koelbl H, Haugen I, Imhof H. Superparamagnetic particles as oral contrast medium in magnetic resonance imaging of patients with treated ovarian cancer--comparison with plain MRI. Br J Radiol 1993 May; 66(785):415-9.

Prosser ES, Pomeroy M, Barker F, Carroll K, Davis M, Duffy J, Duffy G, Fennelly JJ, O'Kennedy R. The relationship between 111In-labelled immunoscintigraphy and serum CA-125 levels in ovarian carcinoma patients postchemotherapy. Biochem Soc Trans 1992 Feb;20(1):54S.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G, Lucarelli C. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rustin GJ. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary. Dis Markers 1991 May-Aug;9(3-4):153-8.

Sevelda P, Rosen A, Denison U, Barrada M, Spona J, Salzer H. Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels? Gynecol Oncol 1991 Nov;43(2):154-8.

van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992 Feb;40(1-2): 36-51.

van der Burg ME, Lammes FB, Verweij J. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 1993 Apr;176(4):310-4.

van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990 Jul; 1(4):301-2.

van Kranenburg DL, van Kroonenburgh MJ, Trimbos JB, Fleuren GJ, Pauwels EK. Imaging of ovarian cancer with radiolabelled monoclonal antibodies. Arch Gynecol Obstet 1990;247(3):107-16.

Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumour Biol 1992;13(3): 168-74.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol 1992;13(2):205-8.

Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B, Tripcony L, Free KE. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays. Cancer 1993 Jan 15;71(2):430-8.

Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl 1992;155:85-93.

Wojcik EM, Selvaggi SM, Johnson SC, Martier SS, Ager JW. Factors influencing fine-needle aspiration cytology in the management of recurrent gynecologic malignancies. Gynecol Oncol 1992 Sep;46(3):281-6.

Surgery for the Symptomatic Patient

Adelson MD, Kasowitz MH. Percutaneous endoscopic drainage gastrostomy in the treatment of gastrointestinal obstruction from intraperitoneal malignancy. Obstet Gynecol 1993 Mar;81(3): 467-71.

Allum WH, Ambrose NS, Fielding JW, Chan KK. Selective salvage surgery in gastrointestinal and gynaecological cancer. Ann R Coll Surg Engl 1990 Jan;72(1):2-5.

Ball HG 3d. Secondary surgery for epithelial ovarian cancer. Curr Opin Obstet Gynecol 1990 Feb;2(1): 57-63.

Barnhill D, Doering D, Remmenga S, Bosscher J, Nash J, Park R. Intestinal surgery performed on gynecologic cancer patients. Gynecol Oncol 1991 Jan;40(1):38-41.

Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige JE. A new approach to the management of malignant ascites; a permanently implanted abdominal drain. Eur J Surg Oncol 1990 Feb; 16(1):47-53.

Brown CL, Lewis JL Jr. Palliative surgery in ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 217-28.

Burke TW, Morris M. Secondary cytoreductive operations. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 301-12.

Chevinsky AH, Minton JP. Ablation of recurrent and metastatic intraabdominal tumor with the CO2 laser. Lasers Surg Med 1990;10(1):5-11.

Clarke-Pearson DL, Rodriguez GC, Boente M. Palliative surgery for epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 351-73.

Donato D, Angelides A, Irani H, Penalver M, Averette H. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol Oncol 1992 Jan;44(1): 40-7.

Gilly FN, Carry PY, Brachet A, Sayag AC, Panteix G, Salle B, Bienvenu J, Banssillon V, Burgard G, Manchon M, Rochette A, Braillon G. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother 1992;9(4):177-81.

Herman LL, Hoskins WJ, Shike M. Percutaneous endoscopic gastrostomy for decompression of the stomach and small bowel. Gastrointest Endosc 1992 May-Jun;38(3):314-8.

Hogan WM, Boente MP. The role of surgery in the management of recurrent gynecologic cancer. Semin Oncol 1993 Oct;20(5):462-72.

Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993 Feb 15; 71(4 Suppl):1534-40.

Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.

Isaacs JH. Cytoreductive surgery for nonresectable ovarian cancer. In: Economou SG, Witt TR, Deziel DJ, et al., eds. Adjuncts to cancer surgery. Philadelphia: Lea and Febiger; 1991. p. 334-8.

Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992 Oct 15; 70(8):2129-36.

Lee MJ, Saini S, Brink JA, Morrison MC, Hahn PF, Mueller PR. Malignant small bowel obstruction and ascites: not a contraindication to percutaneous gastrostomy. Clin Radiol 1991 Nov;44(5):332-4.

LeRoux PD, Berger MS, Elliott JP, Tamimi HK. Cerebral metastases from ovarian carcinoma. Cancer 1991 Apr 15;67(8):2194-9.

Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989 Sep;34(3):334-8.

Paganelli AM, Leone V, Malagutti V, Vescovo M, Sallusto A. Intestinal surgery in patients with ovarian carcinoma. Eur J Gynaecol Oncol 1990; 11(2):157-60.

Potter ME. Secondary cytoreduction in ovarian cancer: pro or con? Gynecol Oncol 1993 Oct;51(1):131-5.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):851-65.

Rubin SC, Benjamin I, Hoskins WJ, Pierce VK, Lewis JL Jr. Intestinal surgery in gynecologic oncology. Gynecol Oncol 1989 Jul;34(1):30-3.

Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989 Jul; 34(1):16-9.

Rubin SC, Hoskins WJ, Hakes TB, Markman M: Cain JM, Lewis JL Jr. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988 Nov;159(5): 1094-8.

Rubin SC, Lewis JL Jr. Tumor antigens in ovarian malignancy. Clin Obstet Gynecol 1986 Sep; 29(3):693-704.

Sun A, Lian L, Tang M. Surgical treatment for recurrent ovarian malignancies. Proc Chin Acad Med Sci Peking Union Med Coll 1990;5(4):219-22.

Taal BG, Steinmetz R, Den Hartog Jager FC. Rectosigmoid obstruction caused by ovarian cancer. Clin Radiol 1990 Mar;41(3):170-4.

van der Burg ME, van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Buyse M, Pecorelli S. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC): an EORTC Gynecological Cancer Cooperative Group (GCCG) Study [abstract]. Program Proc Am Soc Clin Oncol 1993 Mar;12:258.

van Ooijen B, van der Burg ME, Planting AS, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 1993 May;176(5):469-74.

Williams L. The role of secondary cytoreductive surgery in epithelial ovarian malignancies. Oncology (Huntingt) 1992 Aug;6(8):25-32; discussion 37-9. Comment in: Oncology (Huntingt) 1993 Feb;7(2):21.

Williams LL. Secondary cytoreduction of ovarian malignancies. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 187-203.

Salvage Chemotherapy

Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993 Oct;11(10):1957-68.

Alberts DS, Mason-Liddil N, Stock-Novack D, O'Toole RV, Abbott TM, Salmon SE. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study. Am J Clin Oncol 1992 Apr; 15(2):146-9.

Altretamine for ovarian cancer. Med Lett Drugs Ther 1991 Aug 9;33(850):76-7.

Asbury RF, Blessing JA, Look KY, Clarke-Pearson D, Homesley HD. A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer. Am J Clin Oncol 1993 Dec;16(6):529-31.

Baker TR, Piver MS, Hempling RE. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma. Eur J Gynaecol Oncol 1993;14(1):18-22.

Beddoe AM, Dottino PR, Cohen CJ. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma. Mt Sinai J Med 1993 Sep;60(4):311-6.

Benedetti Panici P, Greggi S, Scambia G, Salerno MG, Baiocchi G, Cento R, Mancuso S. Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma. Oncology 1992;49(3):183-7.

Benedetti Panici P, Scambia G, Greggi S, Salerno G, Cento R, Mancuso S. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy. Oncology 1990;47(4):296-8.

Bezwoda WR, Golombick T, Dansey R, Keeping J. Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro. Eur J Cancer 1991;27(11):1423-9.

Bruzzone M, Campora E, Merlini L, Giudici S, Bottero G, Iskra L, Donadio M, Ferrari I, Ragni N. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer. J Chemother 1991 Oct; 3(5):332-4.

Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP, Chevallier B, Kerbrat P, de Forni M, Lhomme C, Roche H, et al. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1993;29A(3):350-4.

Chiara S, Campora E, Merlini L, Simoni C, Iskra L, Odicino F, Ragni N, Conto PF, Rosso R. Recurrent ovarian carcinoma: Salvage treatment with platinum in patients responding to first-line platinum-based regimens (3). Eur J Cancer 1993;29A(4):652.

Covens A, O'Connell G, Rusthoven J, Mazurka J. Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer. Eur J Gynaecol Oncol 1992;13(2):125-30.

Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB, Morrow CP. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991;42(3):193-6.

de Graeff A, van Hoef ME, Tjia P, Heintz AP, Neijt JP. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin. Ann Oncol 1991 Oct;2(9):691-2.

De Vriese G, Bonte J. Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers. Eur J Gynaecol Oncol 1993;14(3):187-91.

De Vriese G, Bonte J. Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers. J Gynaecol Endocrinol 1991-92; 7-8(1-4): 5-9.

Delaloye JF, Tran L, Leyvraz S, Bauer J, De Grandi P. Intraperitoneal carboplatin in advanced ovarian carcinoma. Gynakol Geburtshilfliche Rundsch 1993; 33(1):25-30.

Dittrich C, Baur M, Vavra N, Hudec M, Fazeny B, Barrada M, Salzer H, Sevelda P. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients. Ann Oncol 1993 Sep;4(8): 697-9.

Du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall P, Pfisterer J, Baukneckt T. Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. J Cancer Res Clin Oncol 1994; 120(3):173-8.

Dufour P, Maloisel F, Bergerat JP, Barats JC, Dellenbach P, Renaud R, Ritter P, Herbrecht R, Wendling C, Audhuy B, et al. Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. Bull Cancer (Paris) 1991;78(3):273-80.

Eckhardt S, Hernadi Z, Thurzo L, Telekes A, Sopkova B, Mechl Z, Pawlicki M, Kerpel-Fronius S. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. Oncology 1990; 47(4):289-95.

Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41(3):401-49.

Frasci G, Pacelli R, Scala S, Facchini G, Rinaldi L, Tinessa V, Bianco AR, Iaffaioli RV. Intraperitoneal mitoxantrone via temporary catheter in patients with ovarian cancer: Toxicity and feasibility evaluation. Adv Ther 1990;7(3):124-35.

Frasci G, Tortoriello A, Facchini G, Conforti S, Cardone A, Persico G, Mastrantonio P, Iaffaioli RV. Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. Gynecol Oncol 1993 Jul; 50(1):60-7.

Fromm GL, Freedman RS, Fritsche HA, Atkinson EN, Scott W. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 1991 Nov 1;68(9):1885-9.

Gallion HH, Liu PY, Alberts DE, O'Toole RV, O'Sullivan J, Mills G, Smith HO, Hynes HE. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 1992 Aug; 46(2):230-2.

Gore ME, Fryatt I, Wiltshaw I, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Obstet Gynecol Surv 1990;45(8):553-4.

Greco FA. Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 1993; 19 Suppl C:35-45.

Green MD, Speyer JL, Wernz JC, Colombo N, Beller U, Muggia FM, Beckman EM. Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. Invest New Drugs 1990 Aug;8(3):333-6.

Hamilton TC, Ozols RF, Dabrow MB. Multidrug resistance to alkylating agents and platinum compounds: state of our knowledge. Oncology (Huntingt) 1990 Mar;4(3):101-6; discussion 106, 109.

Hamilton TC, Schilder RJ, Onishi Y, Ozols RF. Mechanisms of resistance to the cytotoxicity of classic alkylating agents and platinum-containing drugs. In: Nagourney RA and Sheikh KM, eds. Clinical management of the drug-resistant cancer patient: new options in clinical oncology. Long Beach (CA): Memorial Medical Center Foundation Press; 1991. p. 49-59.

Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. Gynecol Oncol 1990 Mar; 36(3):369-70.

Hansen LA, Hughes TE. Altretamine. DICP 1991 Feb; 25(2):146-52.

Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991 Jul 15;68(2):269-71.

Hauge MD, Long HJ, Hartmann LC, Edmonson JH, Webb MJ, Su J. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest New Drugs 1992 Nov; 10(4):299-301.

Hendrick AM, Harris AL, Cantwell BM. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann Oncol 1991 Jan; 2(1): 71-2.

Hirono M, Yoshihara T, Hayashi Y, Suzuki M, Majima H. Multi-drug chemotherapy for patients with peritonitis carcinomatosa associated with ascites. J Jpn Soc Cancer Ther 1990;25(3):672-8.

Hoskins PJ, McMurtrie E, Swenerton KD. A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin. Am J Clin Oncol 1990 Oct;13(5):416-9.

Judson IR, Calvert AH, Gore ME, Balmanno K, Gumbrell LA, Perren T, Wiltshaw E. Phase II trial of trimelamol in refractory ovarian cancer. Br J Cancer 1991 Feb;63(2):311-3.

Kaye SB. Chemotherapy for ovarian cancer. Eur J Cancer 1993;29A(4):632-5.

Kaye SB, Wanders J, Clavel M, Verweij J, Piccart MJ, Smyth JF, Ten Bokkel Huinink WW, Wagener DJ, Judson IR, Cavalli F. Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. Ann Oncol 1992 May; 3(5):406-8.

Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991 Apr;9(4):649-57.

Kirmani S, McVey L, Loo D, Howell SB. A phase I clinical trial of intraperitoneal thiotepa for refractory ovarian cancer. Gynecol Oncol 1990 Mar;36(3):331-4.

Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, O'Dwyer PJ. Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma. Gynecol Oncol 1991 Dec;43(3):242-6.

Leopold KA, Oleson JR, Clarke-Pearson D, Soper J, Berchuck A, Samulski TV, Page RL, Blivin J, Tomberlin JK, Dewhirst MW. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1993; 27(5):1245-51.

Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmons D, Carmichael J, Harris AL. A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992 Apr; 65(4):621-3.

Long HJ 3d, Laurie JA, Wieand HS, Edmonson JH, Levitt R, Krook JE, Abu-Ghazaleh S. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. Cancer 1991 Aug 15;68(4):730-2.

Look KY, Blessing JA, Muss HB, DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1992 Dec;15(6):494-6.

Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, De Lena M. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993 Oct;11(10):1952-6.

Louvet C, de Gramont A, Demuynck B, Varette C, Beerblock K, Bennamoun M, Krulik M. Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study. Ann Oncol 1992 Sep;3(8):657-8.

Malfetano J, Beecham JB, Bundy BN, Hatch KD. A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study. Am J Clin Oncol 1993 Apr;16(2): 149-51.

Malfetano JH, Blessing JA, Adelson MD. A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1991 Aug;14(4):349-51.

Malfetano JH, Blessing JA, Jacobs AJ. A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993 Feb;16(1):47-9.

Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson JE, Schein P. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine). Cancer Treat Rev 1991 Mar;18 Suppl A:23-9.

Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson JE, Schein P. Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol 1990 Jan; 36(1):93-6.

Markman M. Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone? Eur J Cancer 1993;29A(9):1225-6. Comment on: Eur J Cancer 1993;29A(9):1242-8.

Markman M. Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery? Gynecol Oncol 1993 Oct;51(1):86-9.

Markman M, Alberts D, Rubin S, Hakes T, Lewis JL Jr, Reichman B, Jones W, Curtin J, Barakat R, Brodar F, et al. Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. Gynecol Oncol 1993 Feb; 48(2):185-8.

Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992 Apr;45(1): 3-8. Comment in: Gynecol Oncol 1992 Apr;45(1): 1-2.

Markman M, Blessing JA, Major F, Manetta A. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Gynecol Oncol 1993 Aug; 50(2):191-5.

Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. J Cancer Res Clin Oncol 1993;119(4):234-6.

Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 1990 Jan;8(1):146-50.

Markman M, Hakes T, Reichman B, Barakat R, Curtin J, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W. Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this new drug in the management of platinum-refractory disease? Semin Oncol 1992 Dec; 19(6 Suppl 14):25-7.

Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992; 119(1):55-7.

Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Yordan EL Jr, Eriksson J, Lewis JL Jr. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 1991 Feb;9(2):204-10. Comment in: J Clin Oncol 1991 Feb;9(2):197-9.

Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. J Clin Oncol 1991 Jun;9(6):978-82.

Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992 Feb;10(2):243-8.

Markman M, Hakes T, Reichman B, Rubin S, Curtin J, Barakat R, Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment. Gynecol Oncol 1993 May; 49(2):185-9.

Markman M, Iannotti N, Hakes T, Reichman B, Rubin S, Jones W, Hoskins W, Lewis JL Jr. A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2. Reg Cancer Treat 1990; 3(1):44-6.

Markman M, Reichman B, Hakes T, Curtin J, Barakat R, Rubin S, Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy. J Cancer Res Clin Oncol 1992;118(5):391-4.

Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 1992 Sep; 10(9):1479-84.

Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat R, Curtin J, Almadrones L, Hoskins W. Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1992 Dec;47(3):353-7.

Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat R, Curtin J, Almadrones L, Hoskins W. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993 May;49(2):172-6.

Markman M, Reichman B, Hakes T, Rubin S, Lewis JL Jr, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol 1993 Jul;50(1):100-4.

Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 Mar;9(3):389-93.

Markman M, Rothman R, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W. Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma. Gynecol Oncol 1991 Jun;41(3): 217-9.

Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'Incalci M, Cavalli F, Mangioni C. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993 Jun;4(6):517-9.

McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. Semin Oncol 1991 Jun;18(3): 255-69.

McGuire WP 3d, Blessing JA, Berek JS, Munoz A. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. Invest New Drugs 1990 May;8(2):191-4.

Menczer J, Ben-Baruch G, Rizel S, Brenner H. Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study. Eur J Gynaecol Oncol 1992;13(4):316-8.

Menczer J, Ben-Baruch G, Rizel S, Brenner H. Extraperitoneal metastases after intraperitoneal chemotherapy of ovarian cancer patients with a negative second-look laparotomy. Int J Gynecol Cancer 1993;3(6):359-62.

Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1992 Apr; 15(2):125-8.

Moore DH, Fowler WC Jr, Jones CP, Crumpler LS. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol 1991 Sep;165(3):573-6.

Moore DH, Valea F, Crumpler LS, Fowler WC Jr. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 1993 Oct;51(1):109-12.

Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J, Curtin J, Morrow CP. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol 1993 Aug;50(2):232-8.

Murphy D, Lind MJ, Prendiville J, Renninson J, Smith DR, Thompson G, Ranson M, Crowther D. Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. Eur J Cancer 1992;28A(4-5):870-2.

Muss HB, Blessing JA, Baker VV, Barnhill DR, Adelson MD. Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990 Aug;13(4):299-301.

Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 1990 Jun;8(6):1036-41.

Nash JD, Young RC. Gynecologic malignancies. Cancer Chemother Biol Response Modif 1991;12: 549-69.

Neijt JP. Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 1992 Jan;3(1): 17-27.

Nicoletto MO, Fiorentino MV, Vinante O, Prosperi A, Tredese F, Tumolo S, Cima GP, Monfardini S. Experience with intraperitoneal alpha-2a interferon. Oncology 1992;49(6):467-73.

Nicoletto MO, Padrini R, Ferrazzi E, Nascimben O, Visona E, Tumolo S, Palumbo M, Costa L, Vinante O, Monfardini S, et al. Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. Eur J Cancer 1993;29A(9):1242-8. Comment in: Eur J Cancer 1993;29A(9):1225-6.

Nieminen U, Kauppila A, Gronroos M, Kuoppala T, Vayrynen M. Placebo-controlled study on the efficacy of the pyrimido-pyrimidine derivative RA 233 in ovarian cancer. Gynecol Oncol 1990 Feb; 36(2):226-31.

O'Brien ME, Hardy J, Tan S, Walling J, Peters B, Hatty S, Wiltshaw E. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 1992;30(3): 245-8.

O'Dwyer PJ, LaCreta F, Hogan M, Rosenblum N, O'Dwyer JL, Comis RL. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. J Clin Pharmacol 1991 Mar;31(3):253-8.

Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S. Clinical experience in gynecological cancer management. d). Ovarian tumors--1) Epithelial: report from the Gynaecological Institutes of Padua University (1963-1990). Eur J Gynaecol Oncol 1992;13(1):17-33.

Ozols RF. Advances in the chemotherapy of gynecologic malignancies. Hematol Oncol 1992 Jan-Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the treatment of ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990; 6(6):328-38.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment of ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.

Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991 Jun;18(3):222-32.

Panici PB, Scambia G, Greggi S, Salerno G, Cento R, Mancuso S. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy. Oncology 1990;47(4):296-8.

Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990 Mar;36(3): 306-11.

Ploin DY, Tranchand B, Guastalla JP, Rebattu P, Chauvin F, Clavel M, Ardiet C. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28A(8-9):1311-5. Comment in: Eur J Cancer 1992; 28A(8-9):1302-4.

Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr, Shingleton HM. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 1992 Jan;44(1):3-9. Comment in: Gynecol Oncol 1992 Nov;47(2):275.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 1992;28A(4-5):864-6.

Reed E, Jacob J, Ozols RF, Young RC, Allegra C. 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecol Oncol 1992 Sep;46(3):326-9.

Reichman B. Second-line intravenous chemotherapy for refractory ovarian cancer. In: Rubin RC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 313-24.

Reichman B, Markman M, Hakes T, Rubin S, Jones W, Curtin J, Barakat R, Almadrones L, Lewis JL Jr, Hoskins W. Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma. Gynecol Oncol 1993 Jul;50(1): 30-3.

Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study. Anticancer Res 1991 Jul-Aug;11(4):1641-3.

Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V, Donadio G, Odicino F, Ragni N, Conte PF, et al. Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol 1990 Nov;39(2):146-9.

Rosso R, Alama A, Repetto L, Conte PF. Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer. Cancer Chemother Pharmacol 1990; 26 Suppl:S43-4.

Schein PS, Scheffler B, McCulloch W. The role of hexamethylmelamine in the management of ovarian cancer. Cancer Treat Rev 1991 Mar;18 Suppl A: 67-75.

Scotto V, Sbiroli C. Weekly cis-platinum as third line chemotherapy in advanced ovarian carcinoma. Phase II study. Eur J Gynaecol Oncol 1991;12(1): 51-3.

Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F. Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur J Cancer 1990 Feb; 26(2):137-8.

Sherman AI, Rosenberg R, Fink D. Use of intraperitoneal chemotherapy for treatment of ovarian cancer. Eur J Gynaecol Oncol 1992;13(4): 295-305.

Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D, Knudsen C, Tuttle RL. A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Invest New Drugs 1992 Jul;10(2): 107-12.

Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, Green M, Porges R, Muggia FM, Canetta R, et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990 Aug;8(8):1335-41.

Speyer JL, Sorich J. Intraperitoneal carboplatin: rationale and experience. Semin Oncol 1992 Feb; 19(1 Suppl 2):107-13.

Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol 1993 Oct;51(1):104-8.

Sutton GP, Blessing JA, Adelson MD, Hanjani P. Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Invest New Drugs 1990 Nov;8(4):377-9.

Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W. Gynecologic Oncology Group studies with ifosfamide. Semin Oncol 1992 Dec; 19(6 Suppl 12):31-4.

Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. Cancer Chemother Pharmacol 1990;26 Suppl:S55-8.

Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD. Gynecologic Oncology Group experience with ifosfamide. Semin Oncol 1990 Apr;17(2 Suppl 4):6-10.

Tarraza HM Jr, Boyce CR, Smith WG, Jones MA. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol 1993 Sep; 50(3):287-90.

Taylor CW, Alberts DS, Peng YM, McCloskey TM, Matzner M, Roe DJ, Plezia PM, Grindey GB, Hamilton M, Seitz D. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. J Natl Cancer Inst 1992 Dec 2;84(23): 1798-802.

ten Tije BJ, Wils J. Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma. Oncology 1992;49(6):442-4.

Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993 Feb 15;71(4 Suppl):1559-64.

Thigpen T, Lambuth BW, Vance RB. Ifosfamide in the management of gynecologic cancers. Semin Oncol 1990 Apr;17(2 Suppl 4):11-8.

Thompson P, Wilson P, Osborne R, Slevin M, Wiltshaw F, Blake P, Harper P, Coleman R, Williams C, Sweetenham J, et al. The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study. Br J Cancer 1991 Nov;64(5):973-4.

Triptorelin pamoate. Phase III Drug Profiles 1993; 3(3):1-8.

Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharmacol 1990; 26 Suppl:S45-7.

van der Burg ME, Hoff AM, van Lent M, Rodenburg CJ, van Putten WL, Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991;27(3):248-50.

van der Gaast A, Splinter TA. Teniposide (VM-26) in ovarian cancer: a review. Semin Oncol 1992 Apr; 19(2 Suppl 6):95-7.

van Oosterom AT, ten Bokkel Huinink WW, van der Burg ME, Vermorken JB, Willemse PH, Neijt JP. Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer. Eur J Cancer 1991; 27(6):747-9.

Venesmaa P, Ylikorkala O. Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. Br J Cancer 1991 Jan; 63(1):84-6.

Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992 Dec;47(3):282-6. Comment in: Gynecol Oncol 1992 Dec;47(3): 279-81.

Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet Gynecol Scand 1993;72(8):682-4.

Weiss G, Green S, Alberts DS, Thigpen JT, Hines HE, Hanson K, Pierce HI, Baker LH, Goodwin JW. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer 1991;27(2): 135-8.

Wharton JT. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer. Cancer Treat Rev 1991 Mar; 18 Suppl A:15-21.

Whelan JS, van Dam PA, Shepherd JH, Slevin ML. The treatment of microscopic residual ovarian cancer with intraperitoneal interferon: a clinical and flow cytometric study. Br J Obstet Gynaecol 1992 Jul;99(7):615-7.

Willemse PH, de Vries EG, Mulder NH, Aalders JG, Bouma J, Sleijfer DT. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 1990 Mar;26(3): 353-8.

Willemse PH, Gietema JA, Mulder NH, de Vries EG, Meijer S, Bouma J, Birkhofer M, Rastogi RB, Sleijfer DT. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer 1993; 29A(3):359-62.

Willemse PH, Sleijfer DT, de Vries EG, Boonstra H, Bouma J, Mulder NH. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer. Eur J Cancer 1992;28(2-3):479-81.

Willemse PH, v.d. Burg ME, v.d. Gaast A, Neijt JP, ten Bokkel Huinink WW, Aalders JG, de Vries EG. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother Pharmacol 1990; 26 Suppl:S51-4.

Williams CJ. Implications of an overview of chemotherapy in advanced ovarian carcinoma. Br J Cancer 1992;66(2):225-6.

Williams CJ. A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma. Cancer Chemother Pharmacol 1990;25(4):304-5.

Williams LL, Fudge M, Burnett LS, Jones HW 3d. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Am J Clin Oncol 1992 Aug;15(4):331-6.

Zanaboni F, Scarfone G, Presti M, Maggi R, Borello C, Bolis G. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 1991 Oct;43(1):24-8.

Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D, Dormont D. Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer. Gynecol Oncol 1990 Feb;36(2): 271-6.

Quality of Life Considerations

August DA, Thorn D, Fisher RL, Welchek CM. Home parenteral nutrition for patients with inoperable malignant bowel obstruction. JPEN J Parenter Enteral Nutr 1991 May-Jun;15(3):323-7. Comment in: JPEN J Parenter Enteral Nutr 1992 Mar-Apr; 16(2):190-1.

Cain JM. Quality of life considerations in the therapy of epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 451-64.

Cassem EH. Appropriate treatment limits in advanced cancer. In: Billings JA. Outpatient management of advanced cancer: symptom control, support, and hospice-in-the-home. Philadelphia: Lippincott; 1985. p. 139-51.

Cella DF, Jacobsen PB, Lesko LM. Research methods in psychooncology. In: Holland JC; Rowland JH, eds. Handbook of psychooncology: psychological care of the patient with cancer. New York: Oxford; 1989. p. 737-49.

Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989 Jul;7(7):959-68.

Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med 1980 Jul 17;303(3):130-5.

Lamb MA. Psychosexual issues: the woman with gynecologic cancer. Semin Oncol Nurs 1990 Aug; 6(3):237-43.

Lew S. A tribute to Gayle. Can Oncol Nurs J 1993 Aug;3(3):156.

MacDonald N. Oncology and palliative care: the case for co-ordination. Cancer Treat Rev 1993; 19 Suppl A:29-41.

Makar AP, Trope CG. Gynecologic malignancy and surgery: from quantity to quality of life. Curr Opin Obstet Gynecol 1992 Jun;4(3):419-29.

Mann SC, Andrews PA, Howell SB. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991 Jul 30; 48(6):866-72.

Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol 1993;11(10):2043-9.

Ovesen L, Hannibal J, Mortensen EL. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 1993; 19(2):159-67.

Payne SA. Coping with palliative chemotherapy. J Adv Nurs 1990 Jun;15(6):652-8.

Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992 Dec;35(12):1505-9.

Pickard-Holley S. Fatigue in cancer patients. A descriptive study. Cancer Nurs 1991 Feb;14(1): 13-9.

Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988 Jul;148(7):1586-91.

Roberts CS, Rossetti K, Cone D, Cavanagh D. Psychosocial impact of gynecologic cancer: a descriptive study. J Psychosoc Oncol 1992; 10(1):99-109.

Schonwetter RS, Teasdale TA, Storey P, Luchi RJ. Estimation of survival time in terminal cancer patients: an impedance to hospice admissions? Hosp J 1990;6(4):65-79.

Smith EM, Redman R, Burns TL, Sagert KM. Perceptions of social support among patients with recently diagnosed breast, endometrial, and ovarian cancer: An exploratory study. J Psychosoc Oncol 1985 Fall;3(3):65-81.

Sneed NV, Edlund B, Dias JK. Adjustment of gynecological and breast cancer patients to the cancer diagnosis: comparisons with males and females having other cancer sites. Health Care Women Int 1992 Jan-Mar;13(1):11-22.

Stjernsward J. WHO cancer pain relief programme. Cancer Surv 1988;7(1):195-208.

NEW DIRECTIONS FOR RESEARCH

Abbate I, Correale M, Gargano G, Tedone T, Izzi G, Catino A, Musci MD, Dragone D, Cramarossa A. Tumor necrosis factor and soluble interleukin-2 receptor: two immunological biomarkers in female neoplasms. Eur J Gynaecol Oncol 1992; 13(1 Suppl):92-6.

Adelson MD. Future directions in the surgical management of ovarian carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 465-83.

Alama A, Merlo F, Chiara S, Muttini MP, Guido T, Nicolo G, Conte PF, Ragni N. Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma. Eur J Cancer 1992;28A(6-7):1079-80.

Antman KH, Souhami RL. High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary. Ann Oncol 1993;4 Suppl 1:29-44.

Ariad S, Bezwoda WR. High-dose chemotherapy: Therapeutic potential in the age of growth factor support. Isr J Med Sci 1992;28(6):377-85.

Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A, Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993 Sep;69(3):312-21.

Baker V. Oncogenes in gynecologic malignancy. Curr Opin Obstet Gynecol 1992 Feb;4(1):75-80.

Balkwill FR. Tumour necrosis factor and cancer. Prog Growth Factor Res 1992;4(2):121-37.

Barletta C, Lazzaro D, Prosperi Porta R, Testa U, Grignani F, Ragusa RM, Leone R, Patella A, Carenza L, Peschle C. C-MYB activation and the pathogenesis of ovarian cancer. Eur J Gynaecol Oncol 1992;13(1):53-9.

Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer 1993 Feb 15; 71(4 Suppl):1597-601.

Beattie GJ, Roulston JE, Eccles DM, Richardson JM, Fisken J, Leonard RC. Alpha-fucosidase as a marker of genetic deletion in ovarian carcinoma. Ann Clin Biochem 1993 Mar;30(Pt 2):207-8.

Becker JL, Prewett TL, Spaulding GF, Goodwin TJ. Three-dimensional growth and differentiation of ovarian tumor cell line in high aspect rotating-wall vessel: morphologic and embryologic considerations. J Cell Biochem 1993 Mar;51(3): 283-9.

Bell DA. Flow cytometry of ovarian neoplasms. Curr Top Pathol 1992;85:337-56.

Benchekroun MN, Parker R, Reed E, Sinha BK. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha. Biochem Biophys Res Commun 1993 Aug 31;195(1):294-300.

Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC Jr, Bacus SS. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 1992 Jan;44(1): 61-5.

Berchuck A, Kohler MF, Bast RC Jr. Oncogenes in ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):813-27.

Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Jr. Growth regulation and transformation of ovarian epithelium. Cancer 1993 Jan 15;71(2 Suppl):545-51.

Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC Jr. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 1992 Feb; 166(2):676-84.

Berek JS. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur J Cancer 1992; 28A(4-5):719-21.

Berns EM, Klijn JG, Henzen-Logmans SC, Rodenburg CJ, van der Burg ME, Foekens JA. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer 1992 Sep 9;52(2):218-24.

Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 1992 Apr;45(1):32-9.

Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO, Jacob J, Christian M, Reed E. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor. Anticancer Drugs 1993 Apr; 4(2):141-8.

Biesma B, Willemse PH, Mulder NH, Sleijfer DT, Gietema JA, Mull R, Limburg PC, Bouma J, Vellenga E, de Vries EG. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992 Sep 1;80(5):1141-8.

Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA damage recognition proteins in human tumour extracts. Br J Cancer 1993 Apr; 67(4):742-8.

Blaakaer J, Hogdall CK, Hording U, Bennett P, Toftager-Larsen K, Daugaard S, Bock J. Hormonal factors and prognosis in epithelial ovarian cancer: A multivariate analysis. Eur J Obstet Gynecol Reprod Biol 1993;51(1):21-7.

Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC Jr. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 1992 Dec;167(6):1877-82.

Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr, Berchuck A. The biology of ovarian cancer. Curr Opin Oncol 1993 Sep;5(5):900-7.

Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl 1992;7:78-81.

Bonetti A, Howell SB, McClay E, Kirmani S, Goel R, Plaxe S, Braly P, Kim S. High-dose biweekly intraperitoneal cisplatin: An effective way to increase cisplatin dose intensity. Gynecol Oncol 1993;49(3):318-24.

Bookman MA. Biologic therapy in the management of refractory ovarian cancer. Gynecol Oncol 1993 Oct;51(1):113-26.

Bookman MA, Berek JS. Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):941-65.

Borresen AL. Oncogenesis in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:25-30.

Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993 Nov;24(11):1175-9.

Bose CK, Mukherjea M. Alpha-fetoprotein in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1993;100(12):1149-50.

Braly PS, Klevecz RR. Flow cytometric evaluation of ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl): 1621-8.

Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993 Oct 21;55(4):678-84.

Buijs WC, Massuger LF, Claessens RA, Kenemans P, Corstens FH. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. J Nucl Med 1992 Jun;33(6): 1113-20.

Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992;19(6):663-9.

Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992 May;16(5):500-7.

Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993 Aug 15;53(16): 3830-8.

Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993 Jan;24(1): 90-5.

Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992 Jan 1;52(1):181-6.

Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992 Feb 1;50(3): 373-81.

Chen G, Zeller WJ. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines. Cancer Lett 1992 Oct 30; 67(1):27-33.

Chen JT, Hasumi K, Masubuchi K. Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer--a preliminary trial. Biotherapy 1992;5(4):275-80.

Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992 Oct 1;89(19):9267-71.

Chien CH, Chow SN. Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol 1993 Sep;12(7):623-7.

Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 1993 Jul;92(1):431-40.

Cimoli G, Valenti M, Venturini M, Conte P, Russo P. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells. Anticancer Res 1992 Sep-Oct;12(5):1411-4.

Colombo N, Peccatori F, Paganin C, Bini S, Brandely M, Mangioni C, Mantovani A, Allavena P. Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 1992 Apr 22;51(1): 42-6.

Crown J, Wassherheit C, Hakes T, Fennelly D, Reich L, Moore M, Schneider J, Curtin J, Rubin SC, Reichman B, Moore M, Yao TJ, Gilewski T, Gulati S, Markman M, Norton L. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst 1992;84(24):1935-6.

Cuijpers VM, Boerman OC, Salet van de Pol MR, Vooijs GP, Poels LG, Ramaekers FC. Immunocytochemical detection of ovarian carcinoma cells in serous effusions. Acta Cytol 1993 May-Jun;37(3):272-9.

Daoud SS, Sakata MK. In vitro interaction of liposomal valinomycin and platinum analogs: cytotoxic and cytokinetic effects. Anticancer Drugs 1993 Aug; 4(4):479-86.

de Gramont A, Demuynck B, Louvet C, Gonzalez-Canali G, Varette C, Pigne A, Marpeau L, Herbulot P, Lagadec B, Cady J, et al. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. Am J Clin Oncol 1992 Feb;15(1):7-11.

de Gramont A, Demuynck B, Varette C, Louvet C, Pigne A, Marpeau L, Lagadec B, Cady J, Couturier JY, Delfau S, et al. Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1992;28(1):53-8.

Deisseroth AB, Kavanagh JJ, Hanania EG, Fu S, Kornblau SM, Estey E, Talpaz M, Kantarjian HM, Claxton DF, Reading CL, Dixon DA, Anderson RW, Lopez-Berestein G, Holmes FA, Logothetis CJ, Andreeff M, Benedict W. Gene therapy: Chemoprotection, immunoenhancement, and modification of tumor cells. Cancer Bull 1993; 45(2):139-45.

DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM, Glatstein E. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993 Feb 15;25(3):445-57.

Dempke WC, Shellard SA, Hosking LK, Fichtinger-Schepman AM, Hill BT. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis 1992 Jul;13(7):1209-15.

Dempke WC, Whelan RD, Hill BT. Expression of resistance to etoposide and vincristine in vitro and in vivo after X-irradiation of ovarian tumor cells. Anticancer Drugs 1992 Aug;3(4):395-9.

Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D, Long S. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients. Cancer 1993 Sep 15;72(6):2007-15.

Devine PL, McGuckin MA, Ward BG. Circulating mucins as tumor markers in ovarian cancer (review). Anticancer Res 1992 May-Jun;12(3): 709-17.

Di Re F, Bohm S, Oriana S, Spatti GB, Pirovano C, Tedeschi M, Zunino F. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993 Jan; 4(1):55-61.

Dittrich C, Sevelda P, Baur M, Marth C, Hudec M, Vavra N, Grunt T, Fazeny B, Salzer H. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer 1993 May 15;71(10):3082-90.

Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RC. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992 Jan;65(1):40-4.

Elg SA, Carson LF, Fowler JM, Twiggs LB, Moradi MM, Ramakrishnan S. Ascites levels of haptoglobin in patients with ovarian cancer. Cancer 1993 Jun 15;71(12):3938-41.

Elsasser-Beile U, von Kleist S, Sauther W, Gallati H, Monting JS. Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Br J Cancer 1993 Jul;68(1):32-6.

Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schulz KD. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992; 155:31-8.

Erba E, Sen S, Lorico A, D'Incalci M. Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur J Cancer 1992;28(1):66-71.

Fady C, Gardner AM, Gera JF, Lichtenstein A. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells. Cancer Res 1992 Feb 15; 52(4):764-9.

Ferrandina G, Scambia G, Benedetti Panici P, Bonanno G, De Vincenzo R, Rumi C, Bussa S, Genuardi M, Spica Romano V, Mancuso S. Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. Mol Cell Endocrinol 1992 Feb;83(2-3):183-93.

Ferrandina G, Scambia G, Benedetti Panici P, Ranelletti FO, De Vincenzo R, Piantelli M, Distefano M, Capelli A, Mancuso S. Type II estrogen-binding sites in human ovarian cancer: correlation with estrogen, progesterone, and epidermal growth factor receptor. Gynecol Oncol 1993 Apr;49(1):67-72.

Fisken J, Roulston JE, Sturgeon C, Badley RA, Jonrup I, Aspinall L, Leonard RC. The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. Br J Cancer 1993 May;67(5):1065-70.

Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies. Acta Cytol 1993 Jul-Aug; 37(4):439-47.

Francis P, Markman M, Hakes T, Reichman B, Rubin S, Jones W, Lewis JL Jr, Curtin J, Barakat R, Phillips M, et al. Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicity. J Cancer Res Clin Oncol 1993;119(6):360-2.

Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD. Novel immunologic strategies in ovarian carcinoma. Am J Obstet Gynecol 1992 Nov;167(5):1470-8.

Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M, Scanlon KJ. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul 1992;32:195-209.

Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992 Dec;75(6):1497-502.

Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993 Feb; 142(2):557-67.

Garzetti GG, Cignitti M, Ciavattini A, Fabris N, Romanini C. Natural killer cell activity and progression-free survival in ovarian cancer. Gynecol Obstet Invest 1993;35(2):118-20.

Garzetti GG, Possati L, Ciavattini A, Recanatini E, Cignitti M, Valensise H, Romanini C. Immunobiologic integration for therapeutic approach in ovarian carcinoma. Eur J Gynaecol Oncol 1992; 13(6):514-21.

Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993 Mar;83(3):433-41.

Gatanaga M, Grosen EA, Burger RA, Granger GA, Gatanaga T. Release of soluble TNF/LT receptors from a human ovarian tumor cell line (PA-1) by stimulation with cytokines in vitro. Lymphokine Cytokine Res 1993 Aug;12(4):249-53.

Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992 Apr 1; 89(7):3070-4.

Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4): 829-41.

Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. Cancer 1993 Jan 15; 71(2 Suppl):530-6.

Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992 Apr 15; 84(8):592-601. Comment in: J Natl Cancer Inst 1992 Apr 15;84(8):556-8.

Goldberg BB, Liu JB, Merton DA, Feld RI, Miller LS, Cohn HE, Barbot D, Gillum DR, Vernick JJ, Winkel CA. Sonographically guided laparoscopy and mediastinoscopy using miniature catheter-based transducers. J Ultrasound Med 1993 Jan;12(1): 49-54.

Gordon JD, Polan ML. The use of GnRH agonists in breast and gynecologic cancers. Semin Reprod Endocrinol 1993;11(2):187-94.

Gorn AH, Lin HY, Yamin M, Auron PE, Flannery MR, Tapp DR, Manning CA, Lodish HF, Krane SM, Goldring SR. Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 1992 Nov;90(5):1726-35.

Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992 Sep; 4(5):385-90.

Green JA, Robertson LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 1993 Aug;68(2): 235-9.

Grosen EA, Granger GA, Gatanaga M, Ininns EK, Hwang C, DiSaia P, Berman M, Manetta A, Emma D, Gatanaga T. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol Oncol 1993 Jul;50(1):68-77.

Grunt TW, Oeller H, Somay C, Dittrich E, Fazeny B, Mannhalter C, Dittrich C. Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1. J Cell Physiol 1993 Aug;156(2):358-66.

Grunt TW, Somay C, Ellinger A, Pavelka M, Dittrich E, Dittrich C. The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7). J Cell Physiol 1992 Apr;151(1):13-22.

Grunt TW, Somay C, Oeller H, Dittrich E, Dittrich C. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci 1992 Oct;103(Pt 2):501-9.

Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH, Poirier MC. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev 1993 May-Jun; 2(3):229-34.

Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993 Nov 1; 53(21):5225-32.

Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C, Grunt TW. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer 1993;68(3): 530-6.

Harlozinska A, Bar JK, Cislo M, Richter R, Rabczynski J. Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms. Anal Cell Pathol 1992 Jan;4(1):1-12.

Harlozinska A, Bar JK, Jothy S, Sedlaczek P, Slesak B, Richter R. Carcinoembryonic antigen isotypes in tissue sections and loose cyst fluid cells of ovarian neoplasms. Tumour Biol 1993;14(1):1-8.

Harlozinska A, Bar JK, Richter R, Cislo M. Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma. Acta Cytol 1992 Nov-Dec;36(6):869-74.

Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. Eur J Cancer 1993;29A(7):1000-2.

Hawkins MJ. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles Oncology (Huntingt) 1992 Dec;6(12):17-23; discussion 27-30. Published erratum appears in Oncology (Huntingt) 1993 Mar;7(3):105.

Hayward IP, Hurst T, Parsons PG, Khoo SK. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas. Int J Cell Cloning 1992 May;10(3):182-9.

Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993 Nov 18;329(21):1539-42.

Helle M, Helin H, Ashorn P, Putkinen EL, Krohn K, Wahlstrom T. The expression of CEA, CA 19-9 and HMFG antigens in ovarian clear-cell and endometrioid carcinomas. Pathol Res Pract 1992 Feb;188(1-2):74-7.

Helm CW, Shrestha K, Thomas S, Shingleton HM, Miller DM. A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol 1993 Jun;49(3):339-43.

Hengstler JG, Fuchs J, Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res 1992 Oct 15;52(20):5622-6.

Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993 Oct 1;53(19):4550-4.

Henzen-Logmans SC, van der Burg ME, Foekens JA, Berns PM, Brussee R, Fieret JH, Klijn JG, Chadha S, Rodenburg CJ. Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. J Cancer Res Clin Oncol 1992;118(4):303-7.

Hereiz HA, Bayoumi FA. Evaluation of diagnosis of ovarian malignancy using immunohistochemical technique. J Egypt Public Health Assoc 1992; 67(5-6):697-707.

Hightower RD, Sevin BU, Perras J, Nguyen H, Angioli R, Untch M, Averette H. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines. Cancer Invest 1993;11(3):276-82.

Hightower RD, Sevin BU, Perras JP, Untch M, Angioli R, Ramos R, Averette H. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay. Gynecol Oncol 1992 Nov; 47(2):186-90.

Hill BT, Shellard SA, Hosking LK, Dempke WC, Fichtinger-Schepman AM, Tone T, Scanlon KJ, Whelan RD. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res 1992 Jun 1;52(11): 3110-8.

Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii K, Kudoh K, Nagata I. Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine. Int J Cancer 1993 Sep 30;55(3):521-7.

Hirte HW, Clark DA, Mazurka J, O'Connell G, Rusthoven J. A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecol Oncol 1992 Mar;44(3): 223-6.

Hirte HW, Clark DA, O'Connell G, Rusthoven J, Mazurka J. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 1992 Jun;142(1):207-16.

Hoffman AG, Burghardt RC, Tilley R, Auersperg N. An in vitro model of ovarian epithelial carcinogenesis: changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 1993 Jul 9;54(5):828-38.

Hogdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 1993 Oct 15;72(8):2415-22.

Hornby AE, Pan J, Auersperg N. Intermediate filaments in rat ovarian surface epithelial cells: changes with neoplastic progression in culture. Biochem Cell Biol 1992 Jan;70(1):16-25.

Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 1992 Mar;239(3): 143-6.

Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak H, Klein M, Leodolter S, Medl M, Mullauer-Ertl S, Preiser J, et al. HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. Eur J Cancer 1993; 29A(11):1593-7.

Hsieh-Ma ST, Eaton AM, Shi T, Ring DB. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. Cancer Res 1992 Dec 15;52(24):6832-9.

Huettner PC, Carney WP, Naber SP, DeLellis RA, Membrino W, Wolfe HJ. Neu oncogene expression in ovarian tumors: a quantitative study. Mod Pathol 1992 May;5(3):250-6.

Huettner PC, Weinberg DS, Lage JM. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 1992 Sep;141(3):699-706.

Hughes PM, Zammit-Maempel I, Murphy D. Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer. Br J Radiol 1992;65(772): 295-7.

Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 1992 Jan 10;61(2):95-103.

Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993 Jul 1;178(1):361-6.

Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993 Oct 1;53(19):4595-602.

Ikarashi H, Aoki Y, Fujita K, Kodama S, Tanaka K. Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer. Jpn J Cancer Res 1992 Dec;83(12):1359-65.

Imaishi K. Intraperitoneal transplantation of ascitic cancer cells from a 7,12-dimethylbenz[a]anthracene (DMBA)-induced ovarian cancer. Kurume Med J 1992;39(3):195-201.

Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993 Oct 1;151(1):225-34.

Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993 Oct 1;151(7):3693-703.

Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor Wharton J, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 1993 Apr;37(4):413-24.

Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS. Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer Immunol Immunother 1992; 35(2):83-91.

Ishii K, Kikuchi Y, Hirata J, Tode T, Kita T, Nagata I, Tsuru S, Rokutanda M. Antitumor effect of PSK in nude mice with human ovarian carcinoma cells and its combined effect with cis-diammine-dichloroplatinum (II). Cancer J 1993;6(2):87-90.

Ishii S, Naito M, Tsuruo T. Expression behavior of 85-kDa membrane protein in adriamycin-resistant tumor cells and the inhibition of human tumor growth in athymic mice by MRK-20 monoclonal antibody against the protein. Jpn J Cancer Res 1993 Jul;84(7):776-82.

Islam MQ, Kopf I, Levan A, Granberg S, Friberg LG, Levan G. Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. Cancer Genet Cytogenet 1993 Jan;65(1):35-46.

Isonishi S, Jekunen AP, Hom DK, Eastman A, Edelstein PS, Thiebaut FB, Christen RD, Howell SB. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. J Clin Invest 1992 Oct;90(4):1436-42.

Ito K, Sasano H, Ozawa N, Sato S, Silverberg SG, Yajima A. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma. Int J Gynecol Pathol 1992 Oct;11(4):253-7.

James RD, Wilkinson PM, Belli F, Welch R, Cowan R. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol 1992;87 Suppl 1:12-5.

Jekunen A, Vick J, Sanga R, Chan TC, Howell SB. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res 1992 Jul 1;52(13):3566-71.

Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993 Jan 15;71(2 Suppl):644-9.

Jones M, Siracky J, Kelland LR, Harrap KR. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer 1993 Jan;67(1):24-9.

Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC Jr, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1993 Jun;99(6):736-40.

Jozan S, Guerrin M, Mazars P, Dutaur M, Monsarrat B, Cheutin F, Bugat R, Martel P, Valette A. Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Int J Cancer 1992 Nov 11;52(5):766-70.

Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol 1992 Mar;44(3):245-53.

Kamada M, Mori T, Sakamoto Y, Daitoh T, Furumoto H, Irahara M, Aono T, Mori T. Heterophile antigens in serous cystadenocarcinoma of the human ovary. Asia Oceania J Obstet Gynaecol 1992 Dec; 18(4):387-95.

Karlan BY, Chamorro T, Fowler JM, Muderspach LI, Greenberg S, Lagasse LD. Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies. Int J Gynecol Cancer 1993;3(5):304-10.

Kavanagh JJ, Kudelka AP. Systemic therapy for gynecologic cancer. Curr Opin Oncol 1993 Sep; 5(5):891-9.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993 Jun 1;53(11):2581-6.

Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol 1992; 30(1):43-50.

Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 1992 Jul 15;52(14):3857-64.

Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992 Feb 15;52(4):822-8.

Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC Jr, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992 Jul;40(7):1047-51.

Kido Y, Khokhar AR, Siddik ZH. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs 1993 Apr; 4(2):251-8.

Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallager HS, Edwards CL, Hajek RA, Jones LA. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res 1993 Nov 1;53(21):5188-92.

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993 Aug 1;72(3):804-8.

Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992 Sep; 83(9):978-84.

Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res 1993 Jul-Aug;13(4):891-6.

Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T, Nagata I. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells. Gynecol Oncol 1993 Jun;49(3):365-72.

Kikuchi Y, Kita T, Miyauchi M, Hirata J, Sasa H, Nagata I, Fukushima M. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 1992;118(6):453-7.

Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 1993 May;11(5):891-8.

Kimura E, Enns RE, Thiebaut F, Howell SB. Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line. Cancer Chemother Pharmacol 1993;32(4):279-85.

Kimura E, Howell SB. Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line. Cancer Chemother Pharmacol 1993;32(6):419-24.

King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol 1992 Jan;140(1):23-31.

Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 1993 Jun;84(6):633-40.

Kobayashi H, Ohi H, Fujii T, Terao T. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers. Br J Cancer 1993 Feb;67(2):237-43.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992 Jul 1;52(13):3610-4.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao T. Characterization and clinical evaluation of tumor-associated antigen CA54/61 identified by monoclonal antibodies MA54 and MA61 in epithelial ovarian cancer. Gynecol Oncol 1992 Dec;47(3):328-36.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao T. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer. Gynecol Oncol 1993 Apr;49(1): 80-5.

Kobayashi H, Sakahara H, Saga T, Hosono M, Shirato M, Kanda H, Ishibashi K, Watanabe T, Endo K, Ishiwata I, et al. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol Immunother 1993 Aug;37(3):143-9.

Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992 Jan;10(1):95-101.

Kobayashi H, Terao T, Kawashima Y. Sialyl Tn as a prognostic marker in epithelial ovarian cancer. Br J Cancer 1992;66(5):984-5.

Kobayashi H, Tsuruchi N, Sugihara K, Kaku T, Saito T, Kamura T, Tsukamoto N, Nakano H, Taniguchi S. Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors. Gynecol Oncol 71993 Mar;48(3):308-13.

Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 1992;28A(8-9):1432-7.

Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993 May;81(5 Pt 1):643-50.

Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993 Sep 15; 85(18):1513-9.

Kohn E. Aging issues in invasion and metastasis. Fertile ground for investigation. Cancer 1993 Jan 15;71(2 Suppl):552-7.

Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 1992 Jun 1;52(11): 3208-12.

Kommoss F, Bauknecht T, Birmelin G, Kohler M, Tesch H, Pfleiderer A. Oncogene and growth factor expression in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:19-24.

Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992 Dec;47(3):317-22.

Kotylo PK, Michael H, Fineberg N, Sutton G, Roth LM. Flow cytometric analysis of DNA content and RAS P21 oncoprotein expression in ovarian neoplasms. Int J Gynecol Pathol 1992;11(1):30-7.

Krag DN, Haseman MK, Ford P, Smith L, Taylor MH, Schneider P, Goodnight JE. Gamma probe location of 111indium-labeled B72.3: an extension of immunoscintigraphy. J Surg Oncol 1992 Dec; 51(4):226-30.

Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993 Jun 1;90(11):4961-5.

Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993 Aug 1;53(15):3468-71.

Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage. Cancer 1992 Jun 1;69(11):2668-75.

Lai CH, Hsueh S, Lin CY, Huang MY, You GB, Chang HC, Pao CC. Human papillomavirus in benign and malignant ovarian and endometrial tissues. Int J Gynecol Pathol 1992 Jul;11(3):210-5.

Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting V, Bramley T, Hillier S, Hawkins RA, Tesdale AL, Smyth JF, et al. Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 1993 Sep 30; 55(3):459-64.

Lee CY, Chen KW, Sheu FS, Tsang A, Chao KC, Ng HT. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunol Immunother 1992;35(1):19-26.

Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim DJ, Park JG. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines. Korean J Intern Med 1992 Jul;7(2):111-7.

Lee SM, Harris M, Rennison J, McGown A, Bromley M, Elder RH, Rafferty JA, Crowther D, Margison GP. Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours. Eur J Cancer 1993;29A(9):1306-12.

Leu JG, Jech KS, Wheeler NC, Chen BX, ERlanger BF. Immunoassay of taxol and taxol-like compounds in plant extracts. Life Sci 1993; 53(12):PL183-7.

Leung BS, Stout LE, Shaskan EG, Thompson RM. Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells. Cancer Lett 1992 Sep 14; 66(1):77-81.

Levin L. Dose intensity in the treatment of ovarian carcinoma. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 251-60.

Lewis AD, Duran GE, Lau DH, Sikic BI. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys 1992;22(4):821-4.

Li BY, Mohanraj D, Olson MC, Moradi M, Twiggs L, Carson LF, Ramakrishnan S. Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res 1992 Apr 15;52(8):2248-52.

Li S, Han H, Resnik E, Carcangiu ML, Schwartz PE, Yang-Feng TL. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993 Oct;51(1):21-5.

Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC Jr. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 1993 Nov;92(5):2440-7.

Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC Jr. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 1993 Aug;207(2):332-9.

Locatelli MC, D'Antona A, Labianca R, Vinci M, Tedeschi M, Carcione R, Corbo A, Venturino P, Luporini G. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 1993 Feb 28;79(1):37-9.

Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 1992 Dec;66(6):1109-15.

Look KY, Sutton GP, Natsumeda Y, Eble JN, Stehman FB, Ehrlich CE, Olah E, Prajda N, Bosze P, Eckhardt S, et al. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas. Gynecol Oncol 1992 Oct;47(1):66-70.

Louie KG, Hamilton TC, Shoemaker RH, Young RC, Ozols RF. Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. Invest New Drugs 1992 Jul;10(2):73-8.

Lucci JA 3d, Manetta A, Cappuccini F, Ininns EK, Dett CA, DiSaia P, Yamamoto RS, Berman ML, Soopikian J, Granger GA. Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patients. Gynecol Oncol 1992 May;45(2): 129-35.

Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations. Cancer 1993;72(11 Suppl):3502-14.

Luqmani YA, Ryall G, Shousha S, Coombes RC. An immunohistochemical survey of pS2 expression in human epithelial cancers. Int J Cancer 1992 Jan 21; 50(2):302-4.

MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 1992 May;11(4):292-305.

Maeda O, Terasawa M, Ishikawa T, Oguchi H, Mizuno K, Kawai M, Kikkawa F, Tumoda Y, Hidaka H. A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells. Cancer Res 1993 May 1;53(9): 2051-6.

Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 1992 Sep;46(3):292-7.

Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates. Cancer 1993 Dec 1; 72(11 Suppl):3453-62.

Maher VE, Drukman SJ, Kinders RJ, Hunter RE, Jennings J, Brigham C, Stevens S, Griffin TW. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody. J Immunother 1992 Jan;11(1):56-66.

Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992 Sep;167(3): 729-35.

Malik ST, East N, Boraschi D, Balkwill FR. Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor. Br J Cancer 1992 May;65(5):661-6.

Malmstrom H. Prevention of complications of subcutaneous peritoneal access devices in intraperitoneal chemotherapy of ovarian carcinoma. Eur J Gynaecol Oncol 1993;14(4):323-30.

Malmstrom H, Rasmussen S, Simonsen E. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer. Gynecol Oncol 1993 May;49(2):166-71.

Maneschi F, Geraci P, Barreca PV, Palisi F, Adragna F, Napoli M. Estradiol, progesterone, 17-hydroxyprogesterone, androstenedione and CA125 in patients with ovarian carcinoma. Gynecol Endocrinol 1992 Mar;6(1):25-30.

Manetta A, Emma D, Fuchtner C, Gamboa-Vujicic G, Paredes P, Lucci J, Gatanaga T, Granger G. Effect of recombinant human tumor necrosis factor alpha and dequalinium chloride on human ovarian cancer cell lines in vitro. Int J Oncol 1993;3(1):127-33.

Manetta A, Emma D, Gamboa G, Liao S, Berman M, DiSaia P. Failure to enhance the in vivo killing of human ovarian carcinoma by sequential treatment with dequalinium chloride and tumor necrosis factor. Gynecol Oncol 1993 Jul;50(1):38-44.

Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retel J, Pinedo HM, Lankelma J. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. Eur J Cancer 1992; 28A(8-9):1447-52.

Markman M. Current status of intraperitoneal therapy for ovarian cancer. Curr Opin Obstet Gynecol 1993 Feb;5(1):99-104.

Markman M. Intraperitoneal chemotherapy. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 317-25.

Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 1993 Feb;14(1):15-28.

Markman M, Jones W, Lewis JL Jr, Rubin S, Hakes T, Reichman B, Barakat R, Curtin J, Almadrones L, Hoskins W. Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. J Cancer Res Clin Oncol 1992;118(2):163-5.

Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S, Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. J Cancer Res Clin Oncol 1992;118(3):235-7.

Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JL Jr, Barakat R, Rubin S, Mychalczak B, Saigo P, et al. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1565-70.

Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, Daxenbichler G. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer 1992 Jan 2; 50(1):64-8.

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F, Ullrich A, Daxenbichler G. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. Int J Cancer 1992 Sep 9;52(2):311-6.

Marth C, Muller-Holzner E, Gaugg I, Daxenbichler G, Dapunt O. Modulation of ovarian carcinoma OV632 antigen by interferons. Oncology 1992;49(1):53-7.

Marth C, Zeimet AG, Bock G, Daxenbichler G. Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. Eur J Cancer 1992;28A(12):2002-6.

Martignone S, Pellegrini R, Villa E, Tandon NN, Mastroianni A, Tagliabue E, Menard S, Colnaghi MI. Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis 1992 Nov;10(6):379-86.

Martin AR, Kotylo PK, Kennedy JC, Fineberg NS, Roth LM. Flow cytometric DNA analysis of ovarian Brenner tumors and transitional cell carcinomas. Int J Gynecol Pathol 1992 Jul; 11(3):188-96.

Martinez-Maza O, Berek JS. Immunotherapy of ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 301-16.

Massuger LF, Thomas CM, Segers MF, Corstens FH, Verheijen RH, Kenemans P, Poels LG. Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer. J Nucl Med 1992 Nov;33(11): 1958-63.

Mazzoni A, Trave F. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells. Oncol Res 1993;5(2):75-82.

McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 1993 Dec 2;55(6):1018-22.

McClay EF, Goel R, Andrews P, Gorelick S, Kirmani S, Kim S, Braly P, Plaxe S, Hoff S, Alcaraz J, et al. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Br J Cancer 1993 Oct;68(4):783-8.

McClay EF, Howell SB. Intraperitoneal therapy in the management of patients with ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4): 915-26.

McGuire WP. Experimental agents (nonbiological) in ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 287-300.

McGuire WP. Ovarian cancer. Experimental chemotherapy. Hematol Oncol Clin North Am 1992 Aug;6(4):927-40.

McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993 Jun 15;71(12):3942-6.

Melioli G, Ferrari I, Casartelli G, Ragni N. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes. Gynecol Oncol 1993 Mar;48(3): 301-7.

Micelli G, Lozupone A, Quaranta M, Donadeo A, Coviello M, Lorusso V. Determination of intraperitoneal mitoxantrone in the serum of cancer patients using a high performance liquid chromatograph coupled to an Advanced Automated Sample Processor (AASP). Biomed Chromatogr 1992 Jul-Aug;6(4):168-71.

Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici C, Mattei E, Mancuso S, Delpino A. Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. Int J Biol Markers 1992 Apr-Jun;7(2):114-8.

Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici C, Mattei E, Mancuso S, Delpino A. Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. Int J Biol Markers 1992 Jan-Mar;7(1):47-51.

Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993 May 1;53(9):2128-32.

Miotti S, Alberti S, Facheris P, Mantovani L, Fornaro M, Stella M, Menard S, Canevari S, Colnaghi MI. Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells. Int J Cancer 1992 May 28; 51(3):499-505.

Mirshahi SS, Vasse M, Soria C, Moreau JF, Taupin JL, Mirshahi M, Pujade-Lauraine E, Bernadou A, Soria J. Incubation of monocytes with adriamycin increases secretion of hepatocyte stimulating factor for fibrinogen biosynthesis. Blood Coagul Fibrinolysis 1993 Feb;4(1):149-52.

Misawa T, Kikkawa F, Oguchi H, Morikawa Y, Kawai M, Maeda O, Iwata M, Kano T, Furuhashi Y, Tomada Y. Accumulation of cis-diamminedichloroplatinum (II) and its analogues in sensitive and resistant human ovarian carcinoma cells. Oncology 1992;49(3):173-9.

Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine) platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 1992 Nov 15;52(22): 6188-93.

Mistry P, Loh SY, Kelland LR, Harrap KR. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 1993 Nov 11;55(5):848-56.

Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993 Jan;12(1):59-63.

Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993 Aug 1;72(3): 809-18.

Mobus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, Pollow K, Knapstein PG, Kreienberg R. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 1992 Aug 19;52(1):76-84.

Mochizuki H, Sato I, Nagoya K, Furusako S, Yamauchi T, Masuko H, Sato H, Morishita H, Yajima M, Sasaki H, et al. An immunoenzymometric assay for a CA125-like antigen, CA602. J Clin Lab Anal 1992;6(2):84-90.

Mogensen O, Mogensen B. Measurement of CA 125 by an automated microparticle enzyme immunoassay; comparison with a manual enzyme immunoassay. Scand J Clin Lab Invest 1992 Oct;52(6):507-12.

Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992 Sep 15;52(18): 5119-22.

Molthoff CF, Pinedo HM, Schluper HM, Boven E. Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int J Cancer 1992 Feb 1;50(3):474-80.

Molthoff CF, Pinedo HM, Schluper HM, Nijman HW, Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br J Cancer 1992 May;65(5):677-83.

Molthoff CF, Pinedo HM, Schluper HM, Rutgers DH, Boven E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int J Cancer 1992 Apr 22;51(1):108-15.

Monti E, Mimnaugh EG, Sinha BK. Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). Biochem Pharmacol 1993 May 25;45(10):2099-107.

Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993 Oct 15;72(8): 2433-40.

Morimitsu Y, Yano H, Kojiro M. Morphologic characteristics, proliferation, and tumor marker expression of two human ovarian carcinoma cell lines in three-dimensional culture. Gynecol Oncol 1993 Feb;48(2):155-64.

Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP, Curtin J, Schlaerth J. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol 1992 Feb;3(2):149-54.

Murphy D, McGown AT, Bromley M, Tsuruo T, Crowther D, Fox BW. P-glycoprotein expression in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. J Obstet Gynecol 1992; 12(4):269-73.

Murphy D, McGown AT, Hall A, Cattan A, Crowther D, Fox BW. Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 1992 Nov;66(5):937-42.

Mutch DG, Herzog TJ, Chen CA, Collins JL. The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. Gynecol Oncol 1992 Oct;47(1):28-33.

Mutch DG, Powell CB, Kao MS, Collins JL. Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha. Cancer Res 1992 Feb 15; 52(4):866-72.

Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 1992;29(3):195-200.

Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N, Kanzaki H, Ito Y, Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992 Oct;83(10):1030-6.

Nakopoulou L, Janinis J, Panagos G, Comin G, Davaris P. The immunohistochemical expression of proliferating cell nuclear antigen (PCNA/cyclin) in malignant and benign epithelial ovarian neoplasms and correlation with prognosis. Eur J Cancer 1993; 29A(11):1599-601.

Nassander UK, Steerenberg PA, Poppe H, Storm G, Poels LG, De Jong WH, Crommelin DJ. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res 1992 Feb 1;52(3):646-53.

Naumann RW, Alvarez RD, Partridge EE, Kilgore LC, Austin JM. The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients. Gynecol Oncol 1993 Sep; 50(3):291-3.

Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993 May;91(5): 2194-206.

Neungton N, Moongkarndi P, Laohathai K, Neungton S, Juntrachotiwit P. Immuno-histological characterization of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. Asian Pac J Allergy Immunol 1992 Dec;10(2):129-34.

Neven P, Iles RK, Lee CL, Hudson CN, Shepherd JH, Chard T. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders. Cancer 1993 Jun 15;71(12):4124-30.

Nguyen HN, Averette HE, Wyble L, Sevin BU, Donato D, Penalver M. Preliminary experience with a modified Tenckhoff catheter for intraperitoneal chemotherapy. J Surg Oncol 1993 Apr;52(4): 237-40.

Nguyen HN, Sevin BU, Averette HE, Perras J, Ramos R, Donato D, Ochiai K, Penalver M. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 1993;11(3):264-75.

Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M, Giavazzi R. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol 1993 Feb;4(2):151-5.

Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 1992 Jan 15; 52(2):328-33.

O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George SL, Berchuck A, Soper J, Fowler W, et al. Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol 1992 Jun; 45(3):299-302.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 1992 Oct 15;70(8):2137-42.

Orengo G, Noviello E, Cimoli G, Pagnan G, Parodi S, Venturini M, Conte P, Schenone F, Conzi G, Russo P. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. Jpn J Cancer Res 1992 Nov;83(11):1132-6.

Owens OJ, Mutch F. Immunocytochemical staining of ovarian tumours with Ov632. Cytopathology 1992;3(3):161-6.

Owens OJ, Stewart C, Leake RE, McNicol AM. A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer. Anticancer Res 1992 Sep-Oct;12(5):1455-8.

Owens OJ, Taggart C, Wilson R, Walker JJ, McKillop JH, Kennedy JH. Interleukin-2 receptor and ovarian cancer. Br J Cancer 1993 Aug;68(2):364-7.

Ozols RF. Advances in the chemotherapy of gynecologic malignancies. Hematol Oncol 1992 Jan-Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the treatment of ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment of ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.

Ozols RF, O'Dwyer PJ, Hamilton TC. Clinical reversal of drug resistance in ovarian cancer. Gynecol Oncol 1993 Oct;51(1):90-6.

Ozols RF, O'Dwyer PJ, Hamilton TC. Drug resistance in ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 261-76.

Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi AG, et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992;19(5):322-9.

Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993 Mar 12;53(5):863-71.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Cancer Res 1993 Jan 15;53(2):242-7.

Pearson JW, Fogler WE, Volker K, Riggs CW, Gruys E, Groves ES, Wiltrout RH, Longo DL. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors. J Natl Cancer Inst 1993 Jun 2;85(11): 907-12.

Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993 Nov;92(5):2160-7.

Pejovic T, Himmelmann A, Heim S, Mandahl N, Floderus UM, Furgyik S, Elmfors B, Helm G, Willen H, Mitelman F. Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer 1992 Feb;65(2):282-6.

Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 1993 Mar;12(3):961-71.

Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993 Nov 15;151(10):5472-80.

Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993 Nov 15;151(10):5481-91.

Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ. T-cell recognition of ovarian cancer. Surgery 1993 Aug;114(2):227-34.

Perez RP, Godwin AK, Handel LM, Hamilton TC. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 1993;29A(3):395-9.

Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC, Godwin AK. Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res 1993 Aug 15;53(16):3771-5.

Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1571-80.

Perez RP, Handel LM, Hamilton TC. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. Gynecol Oncol 1992 Jul;46(1):82-7.

Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 1992;29(6):430-4.

Perkins AC, Symonds IM, Pimm MV, Price MR, Wastie ML, Symonds EM. Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl Med Commun 1993 Jul;14(7):578-86.

Perras JP, Ramos R, Sevin BU. Demonstration of an S phase population of cells without DNA synthesis generated by cisplatin and pentoxifylline. Cytometry 1993;14(4):441-8.

Peterson CM, Reed R, Jolles CJ, Jones KP, Straight RC, Poulson AM. Photodynamic therapy of human ovarian epithelial carcinoma, OVCAR-3, heterotransplanted in the nude mouse. Am J Obstet Gynecol 1992 Dec;167(6):1852-5.

Pettersen EO, Larsen RO, Dornish JM, Borretzen B, Juul ME, Aastveit TE, Nesland JM, Rofstad EK, Oftebro R. Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H). Br J Cancer 1993 Apr; 67(4):650-6.

Pico JL, Ibrahim A, Castagna L, Bourhis JH, Chazard M, Maraninchi D, Droz JP. Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology 1993 Nov;50 Suppl 2:47-52.

Pirovano C, Balzarini A, Bohm S, Oriana S, Spatti GB, Zunino F. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Tumori 1992 Aug 31;78(4):253-7.

Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A 1992 Aug 15;89(16):7708-12.

Plante M, Wong GY, Nisselbaum JS, Almadrones L, Hoskins WJ, Rubin SC. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer. Obstet Gynecol 1993 Jun; 81(6):989-92.

Platsoucas CD, Freedman RS. Tumor-infiltrating lymphocytes in gene therapy. Cancer Bull 1993;45(2):118-24.

Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 1993 Apr;67(4):728-33.

Poirier MC, Shamkhani H, Reed E, Tarone RE, Gupta-Burt S. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues. Prog Clin Biol Res 1992;374:197-212.

Poplin E, Smith H, Behrens B, Redman B, Flaherty L, Neidhart J, Alberts D. SWOG 8825: melphalan GM-CSF: a phase I study. Gynecol Oncol 1992 Jan;44(1):66-70.

Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992 Jan;140(1):145-53.

Powell CB, Horuchi T, Kao MS, Collins JL. Interferon alfa activates a lytic mechanism in ovarian and cervical carcinoma cells. Am J Obstet Gynecol 1993 Sep;169(3):661-7.

Powell CB, Manning K, Collins JL. Interferon-alpha (IFN alpha) induces a cytolytic mechanism in ovarian carcinoma cells through a protein kinase C-dependent pathway. Gynecol Oncol 1993 Aug; 50(2):208-14.

Powell DE, Puls L, van Nagell J Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum Pathol 1992 Aug;23(8):846-7. Comment in: Hum Pathol 1992 Aug;23(8):845 and Hum Pathol 1993 May;24(5):562-3.

Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993 Aug;68(2):418-24.

Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER, Kacinski BM. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 1993 Feb;168(2): 520-7.

Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi Ricotti GB, Bottiroli G. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo. Anticancer Res 1992 Nov-Dec;12(6B): 2093-9.

Provencher DM, Finstad CL, Saigo PE, Rubin SC, Hoskins WJ, Federici MG, Stockert E, Lloyd KO, Lewis JL Jr. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993 Jul;50(1):78-83.

Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EK, Lijnen HR, Burtin P. The plasminogen-activation system in ovarian tumors. Int J Cancer 1993 Aug 19;55(1):27-31.

Pupa SM, Bazzini P, Menard S, Colnaghi MI. Network of idiotypic and anti-idiotypic antibodies related to the ovarian carcinoma-associated folate binding protein. Anticancer Res 1992 Sep-Oct;12(5): 1565-70.

Qian H, Feng J, Cui H, Gao B, Qi G, Fu T, Wei P, Fu Z. Clinical evaluation of radioimmunoimaging with 131I-C0C183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection. Gynecol Oncol 1992 Nov;47(2):216-22.

Qian HN, Li WJ. Target therapy of ovarian carcinoma by monoclonal antibodies bearing chemical drugs entrapped in liposomes. Chin Med J (Engl) 1993 May;106(5):343-7.

Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Redmond A, Moran E, Clynes M. Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A. Eur J Cancer 1993;29A(8):1078-81.

Ridderheim M, Mahlck CG, Selstam G, Stendahl U, Backstrom T. Steroid production in different parts of malignant and benign ovarian tumors in vitro. Cancer Res 1993 May 15;53(10 Suppl):2309-12.

Risteli L, Risteli J, Puistola U, Tomas C, Zhu GG, Kauppila A. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review. Acta Obstet Gynecol Scand Suppl 1992;155:99-103.

Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC Jr. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 1993 Jan; 168(1 Pt 1):228-32.

Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, Hanak H, Vavra N, Salzer H, Leodolter S, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer 1993 May;67(5): 1122-5.

Rotmensch J, Atcher RW, Schwartz JL, Grdina DJ. Analysis of ascites from patients with ovarian carcinoma by cell flow cytometry. Gynecol Oncol 1992 Jan;44(1):10-2.

Rowlands C, Krishnan V, Wang X, Santostefano M, Safe S, Miller WR, Langdon S. Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines. Cancer Res 1993 Apr 15;53(8):1802-7.

Rubin SC. Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer 1993 Feb 15;71(4 Suppl):1602-12.

Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993 Jan;168(1 Pt 1):162-9.

Rubin SC, Kairemo KJ, Brownell AL, Daghighian F, Federici MG, Pentlow KS, Finn RD, Lambrecht RM, Hoskins WJ, Lewis JL Jr, et al. High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies. Gynecol Oncol 1993 Jan; 48(1):61-7.

Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd KO, Larson SM, Hoskins WJ. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol 1993 Oct;51(1):61-6.

Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993 Jun 1;53(11): 2457-9.

Russo P, Parodi S, Billi G, Oliva C, Venturini M, Noviello E, Conte P. Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines. Jpn J Cancer Res 1992 Jul;83(7):684-7.

Rusthoven JJ, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal A, Lu HX, Onetto N, Swenerton K, Jeffrey J. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J Natl Cancer Inst 1993 May 19;85(10):823-5.

Ryuko K, Iwanari O, Kitao M, Moriwaki S. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas. Gynecol Oncol 1993 May;49(2):215-24.

Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers. Cancer 1992 May 1;69(9): 2368-78.

Safrit JT, Berek JS, Bonavida B. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecol Oncol 1993 Feb;48(2):214-20.

Sasano H, Garrett CT. Oncogenes in gynecological tumors. Curr Top Pathol 1992;85:357-72.

Sasano H, Nagura H, Silverberg SG. Immunolocalization of c-myc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Hum Pathol 1992 May;23(5):491-5.

Sass GL, Mohler JD, Walsh RC, Kalfayan LJ, Searles LL. Structure and expression of hybrid dysgenesis-induced alleles of the ovarian tumor (otu) gene in Drosophila melanogaster. Genetics 1993 Feb; 133(2):253-63.

Saunders DE, Christensen C, Lawrence WD, Malviya VK, Malone JM, Williams JR, Deppe G. Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol 1992 Feb;44(2):131-6.

Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, Malone JM, Deppe G. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993 Apr;4(2):201-8.

Savino L, Baldini B, Susini T, Pulli F, Antignani L, Massi GB. GnRH analogs in gynecological oncology: a review. J Chemother 1992 Oct;4(5): 312-20.

Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992 Apr; 10(4):529-35.

Scambia G, Catozzi L, Panici PB, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A, Mancuso S. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol 1993 Jan;168(1 Pt 1):71-8.

Scambia G, Panici PB, Pierelli L, Baiocchi G, Rumi C, Menichella G, Foddai ML, Serafini R, Arno E, Bonanno G, et al. Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur J Cancer 1993;29A(11):1518-22.

Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, De Vincenzo R, Bonanno G, Ferrandina G, Isola G, Mancuso S. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer 1992;28A(11): 1885-9.

Scheim DE, Lin JY. Glucose effects in an ovarian cancer protocol of exceptional activity. Med Hypotheses 1993 Apr;40(4):235-44.

Schilder RJ, Ozols RF. New therapies for ovarian cancer. Cancer Invest 1992;10(4):307-15.

Schisselbauer JC, Hogan WM, Buetow KH, Tew KD. Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. Pharmacogenetics 1992 Apr;2(2):63-72.

Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993 Feb 15;53(4):799-805.

Schneider-Gadicke E, Humm JL, Lau CC, Macklis RM, Bastert G, Knapp RC. Analysis of cytotoxicity of 131I-labelled OC125 F(ab')2 on human epithelial ovarian cancer cell lines. Radiother Oncol 1992 Mar;23(3):150-9.

Schwartz PE, Chambers JT. Hormone therapy in ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 339-48.

See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992 Apr 1; 84(7):510-5.

Segna RA, Dottino PR, Jennings TS, Cohen CJ. Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: assessment of acute postoperative morbidity. Gynecol Oncol 1993 Feb;48(2):227-31.

Sehy DW, Shao LE, Rideout D, Yu J. Sensitivity of committed hematopoietic progenitor cells in vitro (BFU-E, CFU-E, CFU-GM) and two human carcinoma cell lines toward rhodamine-123 and phosphonium salt II-41. Leuk Res 1993 Mar; 17(3):247-53.

Seidman JD, Frisman DM, Norris HJ. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 1992 Dec 15;70(12):2857-60.

Sekiya S, Nunoyama T, Shirasawa H, Kimura H, Kawata M, Iijima N, Sugimoto Y, Tsuruo T, Takamizawa H. Expression of a human multidrug resistance gene in human ovarian carcinoma cell lines. Arch Gynecol Obstet 1992;251(2):79-86.

Sevin BU, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1613-20.

Sheid B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992 Feb 29; 62(2):153-8.

Sheldon K, Baumal R, Marks A. Targeting of [111In]biocytin to cultured ovarian adenocarcinoma cells using covalent monoclonal antibody-streptavidin conjugates. Int J Rad Appl Instrum [A] 1992 Nov;43(11):1399-402.

Sheridan E, Hancock BW, Goyns MH. High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage. Cancer Lett 1993 Jan 15;68(1):83-9.

Shiozawa T, Tsukahara Y, Ishii K, Ota H, Nakayama J, Katsuyama T. Histochemical demonstration of gastrointestinal mucins in ovarian mucinous cystadenoma. Acta Pathol Jpn 1992 Feb;42(2): 104-10.

Shiraishi Y, Yamamoto K, Soma H. Characteristic mucinous ovarian cancer antigen is expressed in malignantly transformed Bloom's syndrome cells. Cancer Res 1993 Jul 15;53(14):3427-32.

Shpall EJ, Stemmer SM, Bearman SI, Bast RC Jr, Peters WP, Ross M, Jones RB. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p. 327-38.

Shpall EJ, Stemmer SM, Bearman SI, Jones RB. Role of autotransplantation in treatment of other solid tumors. Hematol Oncol Clin North Am 1993;7(3): 663-86.

Sikut R, Veromann S, Piirsoo A, Mikelsaar AV, Saar H, Reintam MA. Ovarian carcinomas express a sperm acrosomal antigen, defined by monoclonal antibody 9H8. Tumour Biol 1992;13(4):217-25.

Silvestrini R, Daidone MG, Valentinis B, Ferraris C, Di Re E, Raspagliesi F, Landoni F, Scarfone G, Bolis G. Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer 1992;28(2-3):386-90. Comment in: Eur J Cancer 1992;29A(1):169-70.

Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992 Nov 11;52(5):813-7.

Skrincosky DM, Allen HJ, Bernacki RJ. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoproteins. Cancer Res 1993 Jun 1;53(11): 2667-75. Published erratum appears in Cancer Res 1993 Aug 1;53(15):3652.

Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992; 10(3):221-7.

Smith LH, Yin A, Glasky MS, Tyler N, Robles M, Foster CA, Bieber M, Teng NN. Human monoclonal antibody recognizing an antigen associated with ovarian and other adenocarcinomas. Am J Obstet Gynecol 1992 Feb;166(2):634-45.

Spitzer G, Velasquez W, Dunphy FR, Spencer V. Autologous bone marrow transplantation in solid tumors. Curr Opin Oncol 1992 Apr;4(2):272-8.

Strang P, Stendahl U, Tribukait B. Prognostic significance of S-phase fraction as measured by

DNA flow cytometry in gynecologic malignancies. Ann N Y Acad Sci 1993 Mar 20;677:354-63.

Stromberg K, Collins TJ 4th, Gordon AW, Jackson CL, Johnson GR. Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res 1992 Jan 15;52(2):341-7. Published erratum appears in Cancer Res 1992 Mar 1;52(5):1382.

Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993 Mar 15;71(6): 2027-30.

Surwit EA, Childers JM, Krag DN, Katterhagen JG, Gallion HH, Waggoner S, Mann WJ Jr. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 1993 Mar;48(3): 285-92. Comment in: Gynecol Oncol 1993 Mar; 48(3):283-4.

Tagliabue G, Citti L, Massazza G, Damia G, Giavazzi R, D'Incalci M. Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts. Anticancer Res 1992 Nov-Dec; 12(6B):2123-5.

Taniguchi N, Ishikawa M, Kawaguchi T, Fujii J, Suzuki K, Nakata T. Expression of Mn-superoxide dismutase in carcinogenesis. Tohoku J Exp Med 1992 Oct;168(2):105-11.

Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992 Mar 12;50(5): 828-33.

Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993 Jul 1;53(13):3103-8.

Tenti P, Aguzzi A, Riva C, Usellini L, Zappatore R, Bara J, Samloff IM, Solcia E. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 1992 Apr 15;69(8):2131-42.

Tepler I, Cannistra SA, Frei E 3d, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993 Aug;11(8):1583-91.

Teyssier JR, Couillin P, Benard J, Ravisse N, Ulrich E, Cornillet P. A multidrug-resistant ovarian carcinoma cell line with a malignant suppressed phenotype is a CD44 gene expression defective mutant. Cancer Genet Cytogenet 1992 May;60(1): 14-9.

Thierry AR, Dritschilo A, Rahman A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun 1992 Sep 16;187(2):1098-105.

Thompson MA, Adelson MD. Aging and development of ovarian epithelial carcinoma: the relevance of changes in ovarian stromal androgen production. Adv Exp Med Biol 1993;330:155-65.

Thompson S, Dargan E, Turner GA. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 1992 Sep 14;66(1):43-8.

Tibben JG, Massuger LF, Claessens RA, Schijf CP, Pak KY, Strijk SP, Kenemans P, Corstens FH. Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer. Nucl Med Commun 1992 Dec; 13(12):885-93.

Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992 Apr 15; 52(8):2257-60.

Trope C, Makar A, Kaern J. DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review. Acta Obstet Gynecol Scand Suppl 1992; 155:95-7.

Untch M, Sevin BU, Perras JP, Angioli R, Baibl A, Nguyen HN, Hightower RD, Averette HE. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro. Gynecol Oncol 1992 Nov;47(2):172-8.

Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993 Dec 15; 72(12):3671-5.

Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P, Russo P. Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 1993;29A(8): 1157-61.

van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit VT, Kuppen PJ, van Ravenswaay Claasen HH, Cornelisse CJ, Schrier PI. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 1993 Feb 20;53(4):613-20.

van der Burg MEL, Henzen-Logmans SC, Foekens JA, Berns EMJJ, Rodenburg CJ, Van Putten WLJ, Klijn JGM. The prognostic value of epidermal growth factor receptor, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: A pilot study. Eur J Cancer 1993;29A(14):1951-7.

van der Zee AG, van Ommen B, Meijer C, Hollema H, van Bladeren PJ, de Vries EG. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 1992 Nov;66(5):930-6.

Van Niekerk CC, Ramaekers FC, Hanselaar AG, Aldeweireldt J, Poels LG. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993 Jan; 142(1):157-77.

van't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, Schrier PI. Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene 1993 Oct;8(10):2673-81.

Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet Gynecol Scand 1993;72(8):682-4.

Wagner UA, Oehr PF, Reinsberg J, Schmidt SC, Schlebusch HW, Schultes B, Werner A, Prietl G, Krebs D. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Ther 1992;3(1-2):81-9.

Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T, Nonogaki H, Mori T, Fujii S. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows Arch A Pathol Anat Histopathol 1992; 421(5):393-400.

Wasserman L, Aviram R, Levavi H, Ovadia J, Shneyuor Y, Frisch A, Blau O, Beery E, Novogrodsky A, Nordenberg J. A cell line with unusual characteristics from an ovarian carcinoma patient: modulation of sensitivity to antitumour drugs. Eur J Cancer 1992;28(1):22-7.

Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 1993 Apr;49(1):8-15.

Whittington R, Faulds D. Interleukin-2: A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46(3):446-514.

Williams CJ. Implications of an overview of chemotherapy in advanced ovarian carcinoma. Br J Cancer 1992;66(2):225-6.

Wimalasena J, Dostal R, Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 1992 Sep;46(3):345-50.

Woynarowska B, Wikiel H, Sharma M, Carpenter N, Fleet GW, Bernacki RJ. Inhibition of human ovarian carcinoma cell- and hexosaminidase- mediated degradation of extracellular matrix by sugar analogs. Anticancer Res 1992 Jan-Feb;12(1): 161-6.

Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC Jr. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993 Apr 15;53(8): 1939-44.

Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol 1992 Mar;166(3):997-1007.

Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Canevari S, Colnaghi MI, Segal DM. Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. Int J Clin Lab Res 1992;22(1):17-20.

Xing PX, Prenzoska J, McKenzie IF. Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies. Mol Immunol 1992 May;29(5):641-50.

Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992 Aug 1; 52(15):4196-9.

Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M, Shimizu T. ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol 1992 Jul;46(1):45-50.

Yang FE, Brown RS, Koral KF, Clavo AC, Jackson GA, Wahl RL. Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts. Cancer Immunol Immunother 1992;35(6):365-72.

Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993 Feb 15;53(4):891-8.

Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993 Aug 4;85(15):1225-30.

Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992 Sep;12(9):3689-98.

Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 1993 Sep 15; 53(18):4138-42.

Zhou L, Leung BS. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim Biophys Acta 1992 Dec 10;1180(2):130-6.

Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res 1993 Oct 15; 53(20):5028-32.

Zhu GG, Stenback F, Risteli L, Risteli J, Kauppila A. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study. Cancer 1993 Sep 1;72(5):1679-84.

Zinkewich-Peotti K, Andrews PA. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992 Apr 1;52(7):1902-6.

Zoumpourlis V, Kerr DJ, Spandidos DA. Differential interaction of cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. Anticancer Drugs 1993 Feb;4(1):77-83.

MONOGRAPHS

Al-Azzawi, F. A. Specific human antibodies against cancer raised by lymphocyte transformation with Epstein-Barr virus [dissertation]. Glasgow (UK): University of Strathclyde; 1988. 239 p. Available from: University Microfilms International, Ann Arbor, MI; AADD-97065.

Alvarez, V. Psychosexual adjustment of ovarian cancer patients and their spouses [dissertation]. Los Angeles: Univ. of California; 1987. 243 p. Available from: University Microfilms International, Ann Arbor, MI: AAD87-19920.

Barber, Hugh R. K. Ovarian carcinoma: etiology, diagnosis, and treatment. 3rd ed. New York: Springer-Verlag; 1993. 362 p.

Blackledge, George; Jordan, Joseph A.; Shingleton, Hugh M., eds. Textbook of gynecologic oncology. London: Saunders; 1991. 504 p.

Burghardt, E., ed. Surgical gynecologic oncology. Stuttgart: G. Thieme Verlag; 1993. 729 p.

Campbell, V. C. The biologic effects of HER-2/neu proto-oncogene overexpression [dissertation]. Los Angeles: University of California; 1992. 126 p. Available from: University Microfilms International, Ann Arbor, MI; AAD92-06689.

Coppleson, Malcolm, ed. Gynecologic oncology: fundamental principles and clinical practice. 2nd ed. Edinburgh: Churchill Livingstone; 1992. 2 vol.

Deligdisch, Liane; Altchek, Albert; Cohen, Carmel J. Atlas of ovarian tumors. New York: Igaku-Shoin; 1994.

DiSaia, Philip J.; Creasman, William T. Clinical gynecologic oncology. 4th ed. St. Louis: Mosby Year Book; 1993. 743 p.

Fleischer, Arthur C., ed. Early detection of ovarian carcinoma with transvaginal sonography: potentials and limitations. New York: Raven Press; 1993. 206 p.

Gallup, Donald G.; Talledo, O. Eduardo, eds. Surgical atlas of gynecologic oncology. Philadelphia : W.B. Saunders; c1994.

Giancotti, F. R. Isolation of an antigen from ascites-derived immune complexes and the production and characterization of an ovarian cancer-associated monoclonal antibody [dissertation]. New York: Columbia Univ.; 1989. 190 p. Available from: University Microfilms International, Ann Arbor, MI; AAD89-19149.

Greer, Benjamin E.; Berek, Jonathan S., eds. Gynecologic oncology: treatment rationale and techniques. New York: Elsevier; c1991. 320 p.

Haapasalo, H. K. Prognostic factors in ovarian carcinoma: a clinicopathologic study with special reference to mitotic counts, nuclear morphometry and DNA cytometry [dissertation]. Kuopio (Finland): Kuopion Yliopisto; 1990. 158 p.

Hagen, B. Thio-TEPA: pharmacokinetics and pharmacodynamics in ovarian cancer patients, and experimental studies of serum protein binding and metabolism [dissertation]. Trondheim (Norway): Univ. of Trondheim; 1991. 92 p.

Herbst, Arthur L., et al. Comprehensive gynecology. 2nd ed. St. Louis: Mosby Year Book; 1992. 1333 p.

Hernandez, Enrique; Rosenshein, Neil B. Manual of gynecologic oncology. New York: Churchill Livingstone; 1989. 184 p.

Hoffman, A. G. An in vitro model of ovarian epithelial carcinogenesis [dissertation]. College Station (TX): Texas A & M University; 1992. 165 p. Available from: University Microfilms International, Ann Arbor, MI: AAD93-15073.

Holcombe, J. K. Social support, perception of illness, and self-esteem of women with gynecologic cancer [dissertation]. Birmingham (AL): Univ. of Alabama; 1985. 152 p. Available from: University Microfilms International, Ann Arbor, MI: AAD86-09028.

Hoskins, William J.; Perez, Carlos A.; Young, Robert C., eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott; 1992. 924 p.

Howell, S. B, ed. Platinum and other metal coordination compounds in cancer chemotherapy. 6th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; 1991 Jan 23-26; San Diego. New York: Plenum Press; 1991. 545 p.

Knapp, Robert C.; Berkowitz, Ross Stuart, eds. Gynecologic oncology. 2nd ed. New York: McGraw-Hill, Health Professions Division; c1993. 500 p.

Kullander, Stig; Bertelsen, Kamma; Kauppila, Antti, et al., eds. Ovarian cancer: a prevailing challenge. Proceedings of a Nordic symposium. 1991 May 10-11; Stenungsund, Sweden. Goteborg: Scandinavian Association of Obstetricians and Gynecologists; Oslo: [distributor] Scandinavian University Press; 1992. 111 p. (Acta obstetricia et gynecologica Scandinavica. Supplementum; 155).

Kurjak, Asim, ed. Ultrasound and the ovary. Carnforth (Lancs. UK): Parthenon Pub. Group; 1994. (Progress in obstetric and gynecological sonography; 1).

Lambert, Hannah E.; Blake, Peter R. Gynaecological oncology. Oxford: Oxford University Press; 1992. 230 p.

Lawton, F. An assessment of the clinical role of urinary polyamine measurement in epithelial ovarian cancer [dissertation]. Manchester (UK): Victoria Univ. of Manchester; 1987. 224 p. Available from: University Microfilms International, Ann Arbor, MI: AADD-92362.

Lowe, D. G.; Fox, H., eds. Advances in gynaecological pathology. Edinburgh: Churchill Livingstone; 1992. 383 p.

Maguire, Robert T.; Van Nostrand, Douglas, eds. Diagnosis of colorectal and ovarian carcinoma: application of immunoscintigraphic technology. New York: Marcel Dekker; 1992. 237 p. (Targeted diagnosis and therapy; 6).

Mancuso, Salvatore, ed. Achievements in gynecology, 1989-90. Basel: Karger; 1991. 185 p. (Contributions to gynecology and obstetrics; 18).

Markman, Maurie; Hoskins, William J., eds. Cancer of the ovary. New York: Raven Press; 1993. 442 p.

Milatovich, A. Cytogenic studies of ovarian and endometrial malignancies [dissertation]. Bloomington (IN): Indiana Univ.; 1990. 237 p. Available from: University Microfilms International, Ann Arbor, MI: AAD91-07317.

Monaghan, John M. Complications in the surgical management of gynaecological and obstetrical malignancy. London: Bailliere Tindall; 1989. 170 p.

Morrow, C. Paul; Curtin, John P.; Townsend, Duane E. Synopsis of gynecologic oncology. 4th ed. New York: Churchill Livingstone; 1993. 558 p.

Pejovic, T. Cytogenetic analysis of ovarian tumors [dissertation]. Lund (Sweden): Lunds Univ.; 1991. 141 p.

Phipps, Jeffrey H. Laparoscopic hysterectomy and oophorectomy: a practical manual and colour atlas. Edinburgh: Churchill Livingstone; 1993. 78 p.

Piver, M. Steven, ed. Manual of gynecologic oncology and gynecology. Boston: Little, Brown; 1989. 401 p.

Pocinki, Karen McCrory. Cancer of the ovary: research report. [Bethesda (MD)]: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health; [1989]. 18 p. (NIH publication; no. 89-3014).

Powell, Martin C.; Worthington, B. S.; Symonds, E. M. Magnetic resonance imaging in obstetrics and gynaecology. Oxford: Butterworth-Heinemann; 1993.

Rothenberg, Mace, ed. Gynecologic oncology: controversies and new developments. Boston:

Kluwer Academic; 1994. (Cancer treatment and research; CTAR 70).

Rubin, Stephen C.; Sutton, Gregory P., eds. Ovarian cancer. New York: McGraw-Hill, Health Professions Division; 1993. 498 p.

Sasano, Nobuaki, ed. Gynecological tumors: recent progress in diagnostic pathology. Berlin: Springer-Verlag; c1992. 378 p. (Current topics in pathology; 85).

Scully, Robert E., et al. Histological typing of female genital tract tumours. 2nd ed. Berlin: Springer-Verlag; 1994.

Sharp, F.; Mason, W. Peter; Creasman, William T., eds. Ovarian cancer 2: biology, diagnosis and management. The result of the 3rd Helene Harris Memorial Trust Biennial International Forum on Ovarian Cancer; 1991 Apr 16-20; Charleston, SC. New York: Chapman & Hall Medical; 1992. 453 p.

Sharp, F.; Mason, W. Peter; Leake, R. E., eds. Ovarian cancer: biological and therapeutic challenges. Based on the proceedings of the 2nd Helene Harris Memorial Trust Biennial International Forum on Ovarian Cancer; [1989]; Graz (Austria). London: Chapman and Hall Medical; c1990. 480 p.

Sheldon, K. M. Immunoscintigraphy of ovarian carcinoma using indium-111-labelled monoclonal antibodies [dissertation]. Toronto: Univ. of Toronto; 1991. 139 p. Available from: University Microfilms International, Ann Arbor, MI: AADNN-69169.

Shepherd, John H.; Monaghan, John M., eds. Clinical gynaecological oncology. 2nd ed. Oxford: Blackwell Scientific Publications; 1990. 479 p.

Teoh, Eng-Soon; Ratnam, S. S.; Macnaughton, Malcolm C., eds. Gynaecological cancer. Proceedings of the 13th World Congress of Gynaecology and Obstetrics; 1991 Sep; Singapore. Carnforth (Lanc., UK): Parthenon Pub. Group; 1993. 235 p. (Current status of gynaecology and obstetrics series; 3).

Tholander, B. Tumor markers for ovarian carcinoma: diagnostic and prognostic studies with emphasis on the CA-125 antigen [dissertation]. Uppsalla (Sweden): Uppsalla Universitet; 1992. 55 p.

Thorvinger, B. Diagnostic and interventional radiology in gynecologic neoplasms [dissertation]. Lund (Sweden): Lunds University; 1990. 46 p.

Tourigny, S. C. Remission or death: the social-psychology of stress and coping in epithelial ovarian carcinoma patients [dissertation]. Storrs (CT): Univ. of Connecticut; 1988. 738 p. Available from University Microfilms International, Ann Arbor, MI: AAD89-16139.

Uyttenbroeck, Frans. Function and sense of radical surgery in gynaecological and mammary cancerology in a period of biological evolution: controversies and pitfalls. Leuven (Belgium): Peeters; 1990. 660 p.

Zeller, Kathleen R. Screening for gynecologic malignancy: what every internist should know. [Dallas]: University of Texas Southwestern Medical Center at Dallas; [1992]. 35 p.

c

AUDIOVISUALS

Advances in surgery for gynecologic cancer [videorecording]. University of Texas Medical School at Houston. [Houston (TX): UT/TV]; c1991. 1 videocassette: 60 min., sound, color, 1/2 in. (OB/GYN grand rounds). Credits: Mitchell Morris, presenter.

Cancers that threaten women [videorecording]. Princeton (NJ): Films for the Humanities; c1992. 1 videocassette: 19 min., sound, color, 1/2 in. Credits: Herbert Hyman.

Current concepts in ovarian cancer [videorecording]. [Houston (TX): UT/TV]; c1990. 1 videocassette: 53 min., sound, color, 1/2 in. Credits: Charles Levenback, presenter.

Gynecologic tumors [slide]. New York: Gower Medical Pub.; c1991. 80 slides : color. with black & white. Accompanied by: 1 guide, 38 p. (Slide atlas of diagnostic oncology; 5). Credits: Karen J. Krag.

Is there life after menopause [videorecording]. University of California, San Diego School of Medicine Office of Learning Resources-Television. [Berkeley (CA)]: UC Regents; c1990. 1 videocassette: 32 min., sound, color with black & white, 1/2 in. (Ob/gyn ultrasound; tape 17). Credits: Barbara B. Gosink.

Ovarian cancer 1991 [videorecording]. Marshfield Clinic; St. Joseph's Hospital; Marshfield Medical Research Foundation. Marshfield (WI): Marshfield Regional Video Network; [1991]. 1 videocassette: 35 min.: sound, color, 1/2 in. Credits: Dale M. Larson.

Radiation therapy in carcinoma of the ovary: indications, technical considerations, and results [sound recording]. American Society for Therapeutic Radiology and Oncology. Chicago: Teach'em; [1989]. 2 sound cassettes: analog. Recorded at ASTRO's 31st annual meeting.

Screening for epithelial ovarian cancer [videorecording]. Bast, Robert C., Jr. Secaucus (NJ): Network for Continuing Medical Education; 1992. 1 videocassette: 12 min., sound, color, 1/2 in. (NCME telecourse; no. 624). Issued with: Neurological emergencies in head trauma; Anesthetic infusion assisted by the programmable calculator.

Screening for ovarian cancer [videorecording]. [Houston (TX)]: UT-TV; c1991. 1 videocassette: 60 min., sound, color with black & white, 1/2 in. (OB/GYN grand rounds). Credits: Rajat Goswamy, presenter.

Surgery for staging and treatment of early ovarian carcinoma [videorecording]. Buschbaum, Herbert J.; Davis & Geck, Inc ., Medical Device Division. [Wayne (NJ)]: American Cyanamid; c1990. 1 videocassette: 22 min., sound, color, 1/2 in. Credits: James H. Nelson, co-author and narrator.

Transvaginal color Doppler scanning techniques [videorecording]. Nashville (TN): Vanderbilt University Medical Center; c1990. 1 videocassette: sound, color with black & white, 1/2 in. (Advances in color Doppler sonography). Credits: Patricia C. Freeman. From a course given by the Dept. of Radiological Sciences, Vanderbilt University, School of Medicine, Nashville, TN, Nov. 1-3, 1990.

Transvaginal color Doppler sonography: current and potential clinical applications [videorecording]. Health Video Dynamics, Inc. Nashville (TN): Vanderbilt University Medical Center; c1990. 1 videocassette: sound, color with black & white, 1/2 in. (Advances in color Doppler sonography). Credits: Arthur C. Fleischer. From a course given by the Dept. of Radiology and Radiological Sciences, Vanderbilt University, School of Medicine, Nashville, Tenn., Nov. 1-3, 1990.

Transvaginal ultrasonography for ovarian and e[n]dometrial cancer [videorecording]. [Houston (TX)]: UT/TV-Houston; c1992. 1 videocassette: 61 min., sound, color, 1/2 in. (OB/GYN grand rounds / University of Texas Medical School at Houston). Credits: Arthur Fleisher, presenter.